Compounds for modulating s1p1 activity and methods of using the same

ABSTRACT

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S 1 P 1  receptor and methods of using the same.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Non-Provisional applicationSer. No. 16/613,152, filed Nov. 13, 2019, which is a National PhaseEntry of International Patent Application No. PCT/US2018/03689, filedJun. 12, 2018, which claims priority to U.S. Provisional Application No.62/519,575, filed Jun. 14, 2017, each of which is hereby incorporated byreference in its entirety.

FIELD

Embodiments disclosed herein are directed, in part, to compounds, orpharmaceutically acceptable salts thereof, for modulating S1P1 receptoractivity and/or methods for treating and/or preventing pain, such asneuropathic pain, chemotherapy induced neuropathic pain (CINP),chemotherapy induced peripheral neuropathy (CIPN), or treating cancer orinhibiting tumor growth, and the like as described herein.

BACKGROUND

Pain is still a prevalent and pervasive problem, especially neuropathicpain, which has few good treatments or preventive therapeutics. This isespecially true in conditions such chemotherapy induced neuropathic pain(CINP) and chemotherapy induced peripheral neuropathy (CIPN). Thus,there is a need for new compounds and compositions for treating and/orpreventing such conditions. The compounds and compositions describedherein fulfill these needs as well as others.

SUMMARY OF EMBODIMENTS

In some embodiments, compounds, or pharmaceutically acceptable saltsthereof, are provided that, in part, modulate the activity of the S1P1receptor. The compounds can have, for example, a formula as describedherein. In some embodiments, the compound is selected from a compounddescribed herein. In some embodiments, methods of treating theconditions described herein are provided. In some embodiments, thecondition is CIPN, CINP, pain, neuropathy, and the like. In someembodiments, the condition is cancer and the like.

In some embodiments, the compound is a compound having a formula ofFormula I or Formula II:

or a pharmaceutically acceptable salt thereof, wherein AA, B₁, B₂, B₃,B₄, D₁, V, R₃₀, and R₃₁ are as provided for herein and, for example, canbe selected from the respective groups of chemical moieties describedherein. Also provided are processes for preparing these compounds.

In some embodiments, also provided are pharmaceutical compositionscomprising one or more compounds as described herein, which can alsocomprise a pharmaceutically acceptable carrier.

In some embodiments, the compounds described herein can be provided inany form, such as a solid or solution (e.g., aqueous solution), such asis described herein. The compounds described herein, for example, can beobtained and employed in lyophilized form alone or with suitableadditives.

Also provided are methods for treating and/or preventing pain such asneuropathic pain, chemotherapy induced neuropathic pain (CINP),chemotherapy induced peripheral neuropathy (CIPN), or treating cancer orinhibiting tumor growth, and the like as described herein. In someembodiments, the methods comprise administering a one or more compoundsdescribed herein to a subject or subjects.

DESCRIPTION OF EMBODIMENTS

Unless defined otherwise, all technical and scientific terms have thesame meaning as is commonly understood by one of ordinary skill in theart to which the embodiments disclosed belong.

As used herein, the terms “a” or “an” means that “at least one” or “oneor more” unless the context clearly indicates otherwise.

As used herein, the term “about” means that the numerical value isapproximate and small variations would not significantly affect thepractice of the disclosed embodiments. Where a numerical limitation isused, unless indicated otherwise by the context, “about” means thenumerical value can vary by +10% and remain within the scope of thedisclosed embodiments.

As used herein, the term “acylamino” means an amino group substituted byan acyl group (e.g., —O—C(═O)—H or —O—C(═O)-alkyl). An example of anacylamino is —NHC(═O)H or —NHC(═O)CH₃. The term “lower acylamino” refersto an amino group substituted by a lower acyl group (e.g., —O—C(═O)—H or—O—C(═O)—C₁₋₆alkyl). An example of a lower acylamino is —NHC(═O)H or—NHC(═O)CH₃.

As used herein, the term “alkenyl” means a straight or branched alkylgroup having one or more double carbon-carbon bonds and 2-20 carbonatoms, including, but not limited to, ethenyl, 1-propenyl, 2-propenyl,2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. In someembodiments, the alkenyl chain is from 2 to 10 carbon atoms in length,from 2 to 8 carbon atoms in length, from 2 to 6 carbon atoms in length,or from 2 to 4 carbon atoms in length.

The terms “alkoxy”, “phenyloxy”, “benzoxy” and “pyrimidinyloxy” refer toan alkyl group, phenyl group, benzyl group, or pyrimidinyl group,respectively, each optionally substituted, that is bonded through anoxygen atom. For example, the term “alkoxy” means a straight or branched—O-alkyl group of 1 to 20 carbon atoms, including, but not limited to,methoxy, ethoxy, n-propoxy, isopropoxy, t-butoxy, and the like. In someembodiments, the alkoxy chain is from 1 to 10 carbon atoms in length,from 1 to 8 carbon atoms in length, from 1 to 6 carbon atoms in length,from 1 to 4 carbon atoms in length, from 2 to 10 carbon atoms in length,from 2 to 8 carbon atoms in length, from 2 to 6 carbon atoms in length,or from 2 to 4 carbon atoms in length.

As used herein, the term “alkyl” means a saturated hydrocarbon groupwhich is straight-chained or branched. An alkyl group can contain from 1to 20, from 2 to 20, from 1 to 10, from 2 to 10, from 1 to 8, from 2 to8, from 1 to 6, from 2 to 6, from 1 to 4, from 2 to 4, from 1 to 3, or 2or 3 carbon atoms. Examples of alkyl groups include, but are not limitedto, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl),butyl (e.g., n-butyl, t-butyl, isobutyl), pentyl (e.g., n-pentyl,isopentyl, neopentyl), hexyl, isohexyl, heptyl, 4,4-dimethylpentyl,octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl,2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,3-methyl-1-butyl, 2-methyl-3-butyl, 2-methyl-1-pentyl,2,2-dimethyl-1-propyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, and thelike.

As used herein, the term “allylamino” means an amino group substitutedby an alkyl group having from 1 to 6 carbon atoms. An example of analkylamino is —NHCH₂CH₃.

As used herein, the term “alkylene” or “alkylenyl” means a divalentalkyl linking group. An example of an alkylene (or alkylenyl) ismethylene or methylenyl (—CH₂—).

As used herein, the term “alkylthio” means an —S-alkyl group having from1 to 6 carbon atoms. An example of an alkylthio group is —SCH₂CH₃.

As used herein, the term “alkynyl” means a straight or branched alkylgroup having one or more triple carbon-carbon bonds and 2-20 carbonatoms, including, but not limited to, acetylene, 1-propylene,2-propylene, and the like. In some embodiments, the alkynyl chain is 2to 10 carbon atoms in length, from 2 to 8 carbon atoms in length, from 2to 6 carbon atoms in length, or from 2 to 4 carbon atoms in length.

As used herein, the term “amidino” means —C(═NH)NH₂.

As used herein, the term “amino” means —NH₂.

As used herein, the term “aminoalkoxy” means an alkoxy group substitutedby an amino group. An example of an aminoalkoxy is —OCH₂CH₂NH₂.

As used herein, the term “aminoalkyl” means an alkyl group substitutedby an amino group.

An example of an aminoalkyl is —CH₂CH₂NH₂.

As used herein, the term “aminosulfonyl” means —S(═O)₂NH₂.

As used herein, the term “aminoalkylthio” means an alkylthio groupsubstituted by an amino group. An example of an aminoalkylthio is—SCH₂CH₂NH₂.

As used herein, the term “amphiphilic” means a three-dimensionalstructure having discrete hydrophobic and hydrophilic regions. Anamphiphilic compound suitably has the presence of both hydrophobic andhydrophilic elements.

As used herein, the term “animal” includes, but is not limited to,humans and non-human vertebrates such as wild, domestic, and farmanimals.

As used herein, the term “antagonize” or “antagonizing” means reducingor completely eliminating an effect, such as an activity of the S₁P₁receptor.

As used herein, the phrase “anti-receptor effective amount” of acompound can be measured by the anti-receptor effectiveness of thecompound. In some embodiments, an anti-receptor effective amountinhibits an activity of the receptor by at least 10%, by at least 20%,by at least 30%, by at least 40%, by at least 50%, by at least 60%, byat least 70%, by at least 80%, by at least 90%, or by at least 95%. Insome embodiments, an “anti-receptor effective amount” is also a“therapeutically effective amount” whereby the compound reduces oreliminates at least one effect of a S₁P₁ receptor.

In some embodiments, the effect is the beta-arrestin effect. In someembodiments, the effect is the G-protein mediated effect.

As used herein, the term “aryl” means a monocyclic, bicyclic, orpolycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons.In some embodiments, aryl groups have from 6 to 20 carbon atoms or from6 to 10 carbon atoms. Examples of aryl groups include, but are notlimited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl,indenyl, tetrahydronaphthyl, and the like. Examples of aryl groupsinclude, but are not limited to:

As used herein, the term “arylalkyl” means a C₁₋₆alkyl substituted byaryl.

As used herein, the term “arylamino” means an amino group substituted byan aryl group. An example of an arylamino is —NH(phenyl).

As used herein, the term “arylene” means an aryl linking group, i.e., anaryl group that links one group to another group in a molecule.

As used herein, the term “cancer” means a spectrum of pathologicalsymptoms associated with the initiation or progression, as well asmetastasis, of malignant tumors.

As used herein, the term “carbamoyl” means —C(═O)—NH₂.

As used herein, the term “carbocycle” means a 5- or 6-membered,saturated or unsaturated cyclic ring, optionally containing O, S, or Natoms as part of the ring. Examples of carbocycles include, but are notlimited to, cyclopentyl, cyclohexyl, cyclopenta-1,3-diene, phenyl, andany of the heterocycles recited above.

As used herein, the term “carrier” means a diluent, adjuvant, orexcipient with which a compound is administered. Pharmaceutical carrierscan be liquids, such as water and oils, including those of petroleum,animal, vegetable or synthetic origin, such as peanut oil, soybean oil,mineral oil, sesame oil and the like. The pharmaceutical carriers canalso be saline, gum acacia, gelatin, starch paste, talc, keratin,colloidal silica, urea, and the like. In addition, auxiliary,stabilizing, thickening, lubricating and coloring agents can be used.

As used herein, the term, “compound” means all stereoisomers, tautomers,and isotopes of the compounds described herein.

As used herein, the terms “comprising” (and any form of comprising, suchas “comprise”, “comprises”, and “comprised”), “having” (and any form ofhaving, such as “have” and “has”), “including” (and any form ofincluding, such as “includes” and “include”), or “containing” (and anyform of containing, such as “contains” and “contain”), are inclusive oropen-ended and do not exclude additional, unrecited elements or methodsteps.

As used herein, the term “contacting” means bringing together of twoelements in an in vitro system or an in vivo system. For example,“contacting” a S₁P₁ receptor compound with a S₁P₁ receptor with anindividual or patient or cell includes the administration of thecompound to an individual or patient, such as a human, as well as, forexample, introducing a compound into a sample containing a cellular orpurified preparation containing the S₁P₁ receptor.

As used herein, the term “cyano” means —CN.

As used herein, the term “cycloalkyl” means non-aromatic cyclichydrocarbons including cyclized alkyl, alkenyl, and alkynyl groups thatcontain up to 20 ring-forming carbon atoms.

Cycloalkyl groups can include mono- or polycyclic ring systems such asfused ring systems, bridged ring systems, and spiro ring systems. Insome embodiments, polycyclic ring systems include 2, 3, or 4 fusedrings. A cycloalkyl group can contain from 3 to 15, from 3 to 10, from 3to 8, from 3 to 6, from 4 to 6, from 3 to 5, or 5 or 6 ring-formingcarbon atoms. Ring-forming carbon atoms of a cycloalkyl group can beoptionally substituted by oxo or sulfido. Examples of cycloalkyl groupsinclude, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclopentenyl,cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl,norcarnyl, adamantyl, and the like. Also included in the definition ofcycloalkyl are moieties that have one or more aromatic rings fused(having a bond in common with) to the cycloalkyl ring, for example,benzo or thienyl derivatives of pentane, pentene, hexane, and the like(e.g., 2,3-dihydro-1H-indene-1-yl, or 1H-inden-2(3H)-one-1-yl).

As used herein, the term “cycloalkylalkyl” means a C₁₋₆alkyl substitutedby cycloalkyl.

As used herein, the term “dialkylamino” means an amino group substitutedby two alkyl groups, each having from 1 to 6 carbon atoms.

As used herein, the term “diazamino” means —N(NH₂)₂.

As used herein, the term “facially amphiphilic” or “facialamphiphilicity” means compounds with polar (hydrophilic) and nonpolar(hydrophobic) side chains that adopt conformation(s) leading tosegregation of polar and nonpolar side chains to opposite faces orseparate regions of the structure or molecule.

As used herein, the term “guanidino” means —NH(═NH)NH₂.

As used herein, the term “halo” means halogen groups including, but notlimited to fluoro, chloro, bromo, and iodo.

As used herein, the term “haloalkoxy” means an —O-haloalkyl group. Anexample of an haloalkoxy group is OCF₃.

As used herein, the term “haloalkyl” means a C₁₋₆alkyl group having oneor more halogen substituents. Examples of haloalkyl groups include, butare not limited to, CF₃, C₂F₅, CH₂F, CHF₂, CCl₃, CHCl₂, CH₂CF₃, and thelike.

As used herein, the term “heteroaryl” means an aromatic heterocyclehaving up to 20 ring-forming atoms (e.g., C) and having at least oneheteroatom ring member (ring-forming atom) such as sulfur, oxygen, ornitrogen. In some embodiments, the heteroaryl group has at least one ormore heteroatom ring-forming atoms, each of which are, independently,sulfur, oxygen, or nitrogen. In some embodiments, the heteroaryl grouphas from 3 to 20 ring-forming atoms, from 3 to 10 ring-forming atoms,from 3 to 6 ring-forming atoms, or from 3 to 5 ring-forming atoms. Insome embodiments, the heteroaryl group contains 2 to 14 carbon atoms,from 2 to 7 carbon atoms, or 5 or 6 carbon atoms. In some embodiments,the heteroaryl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 or2 heteroatoms. Heteroaryl groups include monocyclic and polycyclic(e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroarylgroups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl,pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl,imidazolyl, thiazolyl, indolyl (such as indol-3-yl), pyrroyl, oxazolyl,benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl,triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl,benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyranyl,oxadiazolyl, isoxazolyl, triazolyl, thianthrenyl, pyrazolyl,indolizinyl, isoindolyl, isobenzofuranyl, benzoxazolyl, xanthenyl,2H-pyrrolyl, pyrrolyl, 3H-indolyl, 4H-quinolizinyl, phthalazinyl,naphthyridinyl, quinazolinyl, phenanthridinyl, acridinyl, perimidinyl,phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl,furanyl, phenoxazinyl groups, and the like. Suitable heteroaryl groupsinclude 1,2,3-triazole, 1,2,4-triazole, 5-amino-1,2,4-triazole,imidazole, oxazole, isoxazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole,3-amino-1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, pyridine,and 2-aminopyridine.

As used herein, the term “heteroarylalkyl” means a C₁₋₆alkyl groupsubstituted by a heteroaryl group.

As used herein, the term “heteroarylamino” means an amino groupsubstituted by a heteroaryl group. An example of a heteroarylamino is—NH-(2-pyridyl).

As used herein, the term “heteroarylene” means a heteroaryl linkinggroup, i.e., a heteroaryl group that links one group to another group ina molecule.

As used herein, the term “heterocycle” or “heterocyclic ring” means a 5-to 7-membered mono- or bicyclic or 7- to 10-membered bicyclicheterocyclic ring system any ring of which may be saturated orunsaturated, and which consists of carbon atoms and from one to threeheteroatoms chosen from N, O and S, and wherein the N and S heteroatomsmay optionally be oxidized, and the N heteroatom may optionally bequaternized, and including any bicyclic group in which any of theabove-defined heterocyclic rings is fused to a benzene ring.Particularly useful are rings containing one oxygen or sulfur, one tothree nitrogen atoms, or one oxygen or sulfur combined with one or twonitrogen atoms. The heterocyclic ring may be attached at any heteroatomor carbon atom which results in the creation of a stable structure.Examples of heterocyclic groups include, but are not limited to,piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl,2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl,pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl,imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl,oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl,thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl,quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl,benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl,thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide,thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same asmorpholinyl.

As used herein, the term “heterocycloalkyl” means non-aromaticheterocycles having up to 20 ring-forming atoms including cyclizedalkyl, alkenyl, and alkynyl groups, where one or more of thering-forming carbon atoms is replaced by a heteroatom such as an O, N,or S atom. Hetercycloalkyl groups can be mono or polycyclic (e.g.,fused, bridged, or spiro systems). In some embodiments, theheterocycloalkyl group has from 1 to 20 carbon atoms, or from 3 to 20carbon atoms. In some embodiments, the heterocycloalkyl group contains 3to 14 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 or 6ring-forming atoms. In some embodiments, the heterocycloalkyl group has1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 or 2 heteroatoms. In someembodiments, the heterocycloalkyl group contains 0 to 3 double bonds. Insome embodiments, the heterocycloalkyl group contains 0 to 2 triplebonds. Examples of heterocycloalkyl groups include, but are not limitedto, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl,tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole,benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl,oxazolidinyl, isothiazolidinyl, pyrazolidinyl, thiazolidinyl,imidazolidinyl, pyrrolidin-2-one-3-yl, and the like. In addition,ring-forming carbon atoms and heteroatoms of a heterocycloalkyl groupcan be optionally substituted by oxo or sulfido. For example, aring-forming S atom can be substituted by 1 or 2 oxo (form a S(O) orS(O)₂). For another example, a ring-forming C atom can be substituted byoxo (form carbonyl). Also included in the definition of heterocycloalkylare moieties that have one or more aromatic rings fused (having a bondin common with) to the nonaromatic heterocyclic ring including, but notlimited to, pyridinyl, thiophenyl, phthalimidyl, naphthalimidyl, andbenzo derivatives of heterocycles such as indolene, isoindolene,4,5,6,7-tetrahydrothieno[2,3-c]pyridine-5-yl,5,6-dihydrothieno[2,3-c]pyridin-7(4H)-one-5-yl, isoindolin-1-one-3-yl,and 3,4-dihydroisoquinolin-1(2H)-one-3yl groups. Ring-forming carbonatoms and heteroatoms of the heterocycloalkyl group can be optionallysubstituted by oxo or sulfido.

As used herein, the term “heterocycloalkylalkyl” refers to a C₁₋₆alkylsubstituted by heterocycloalkyl.

As used herein, the term “hydoxy” or “hydroxyl” means an —OH group.

As used herein, the term “hydroxyalkyl” or “hydroxylalkyl” means analkyl group substituted by a hydroxyl group. Examples of a hydroxylalkylinclude, but are not limited to, —CH₂OH and —CH₂CH₂OH.

As used herein, the term “individual” or “patient,” usedinterchangeably, means any animal, including mammals, such as mice,rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses,or primates, such as humans.

As used herein, the phrase “inhibiting activity,” such as enzymatic orreceptor activity means reducing by any measurable amount the activityof an enzyme or receptor, such as the S₁P₁ receptor.

As used herein, the phrase “in need thereof” means that the animal ormammal has been identified as having a need for the particular method ortreatment. In some embodiments, the identification can be by any meansof diagnosis. In any of the methods and treatments described herein, theanimal or mammal can be in need thereof. In some embodiments, the animalor mammal is in an environment or will be traveling to an environment inwhich a particular disease, disorder, or condition is prevalent.

As used herein, the phrase “in situ gellable” means embracing not onlyliquids of low viscosity that form gels upon contact with the eye orwith lacrimal fluid in the exterior of the eye, but also more viscousliquids such as semi-fluid and thixotropic gels that exhibitsubstantially increased viscosity or gel stiffness upon administrationto the eye.

As used herein, the phrase “integer from X to Y” means any integer thatincludes the endpoints. For example, the phrase “integer from X to Y”means 1, 2, 3, 4, or 5.

As used herein, the term “isolated” means that the compounds describedherein are separated from other components of either (a) a naturalsource, such as a plant or cell, or (b) a synthetic organic chemicalreaction mixture, such as by conventional techniques.

As used herein, the term “mammal” means a rodent (i.e., a mouse, a rat,or a guinea pig), a monkey, a cat, a dog, a cow, a horse, a pig, or ahuman. In some embodiments, the mammal is a human.

As used herein, the term “N-alkyl” refers to a alkyl chain that issubstituted with an amine group. Non-limiting examples, include, but arenot limited to

and the like. The alkyl chain can be linear, branched, cyclic, or anycombination thereof. In some embodiments, the alkyl comprises 1-10, 1-9,1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 carbons.

As used herein, the term “nitro” means —NO₂.

As used herein, the term “n-membered”, where n is an integer, typicallydescribes the number of ring-forming atoms in a moiety, where the numberof ring-forming atoms is n. For example, pyridine is an example of a6-membered heteroaryl ring and thiophene is an example of a 5-memberedheteroaryl ring.

As used herein, the phrase “ophthalmically acceptable” means having nopersistent detrimental effect on the treated eye or the functioningthereof, or on the general health of the subject being treated. However,it will be recognized that transient effects such as minor irritation ora “stinging” sensation are common with topical ophthalmic administrationof drugs and the existence of such transient effects is not inconsistentwith the composition, formulation, or ingredient (e.g., excipient) inquestion being “ophthalmically acceptable” as herein defined.

As used herein, the phrase “optionally substituted” means thatsubstitution is optional and therefore includes both unsubstituted andsubstituted atoms and moieties. A “substituted” atom or moiety indicatesthat any hydrogen on the designated atom or moiety can be replaced witha selection from the indicated substituent groups, provided that thenormal valency of the designated atom or moiety is not exceeded, andthat the substitution results in a stable compound. For example, if amethyl group is optionally substituted, then 3 hydrogen atoms on thecarbon atom can be replaced with substituent groups.

As used herein, the phrase “pharmaceutically acceptable” means thosecompounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith tissues of humans and animals. In some embodiments,“pharmaceutically acceptable” means approved by a regulatory agency ofthe Federal or a state government or listed in the U.S. Pharmacopeia orother generally recognized pharmacopeia for use in animals, and moreparticularly in humans.

In some embodiments, the salt of a compound described herein is apharmaceutically acceptable salt thereof. As used herein, the phrase“pharmaceutically acceptable salt(s),” includes, but is not limited to,salts of acidic or basic groups. Compounds that are basic in nature arecapable of forming a wide variety of salts with various inorganic andorganic acids. Acids that may be used to prepare pharmaceuticallyacceptable acid addition salts of such basic compounds are those thatform non-toxic acid addition salts, i.e., salts containingpharmacologically acceptable anions including, but not limited to,sulfuric, thiosulfuric, citric, maleic, acetic, oxalic, hydrochloride,hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, bisulfite,phosphate, acid phosphate, isonicotinate, borate, acetate, lactate,salicylate, citrate, acid citrate, tartrate, oleate, tannate,pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate,fumarate, gluconate, glucaronate, saccharate, formate, benzoate,glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate,p-toluenesulfonate, bicarbonate, malonate, mesylate, esylate,napsydisylate, tosylate, besylate, orthophoshate, trifluoroacetate, andpamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts.Compounds that include an amino moiety may form pharmaceuticallyacceptable salts with various amino acids, in addition to the acidsmentioned above. Compounds that are acidic in nature are capable offorming base salts with various pharmacologically acceptable cations.Examples of such salts include, but are not limited to, alkali metal oralkaline earth metal salts and, particularly, calcium, magnesium,ammonium, sodium, lithium, zinc, potassium, and iron salts. The presentembodiments also include quaternary ammonium salts of the compoundsdescribed herein, where the compounds have one or more tertiary aminemoiety.

As used herein, the term “phenyl” means —C₆H₅. A phenyl group can beunsubstituted or substituted with one, two, or three suitablesubstituents.

As used herein, the term “prodrug” means a derivative of a known directacting drug, which derivative has enhanced delivery characteristics andtherapeutic value as compared to the drug, and is transformed into theactive drug by an enzymatic or chemical process.

As used herein, the term “purified” means that when isolated, theisolate contains at least 90%, at least 95%, at least 98%, or at least99% of a compound described herein by weight of the isolate.

As used herein, the phrase “quaternary ammonium salts” means derivativesof the disclosed compounds with one or more tertiary amine moietieswherein at least one of the tertiary amine moieties in the parentcompound is modified by converting the tertiary amine moiety to aquaternary ammonium cation via alkylation (and the cations are balancedby anions such as Cl⁻, CH₃COO⁻, and CF₃COO⁻), for example methylation orethylation.

As used herein, the term “semicarbazone” means ═NNHC(═O)NH₂.

As used herein, the phrase “solubilizing agent” means agents that resultin formation of a micellar solution or a true solution of the drug.

As used herein, the term “solution/suspension” means a liquidcomposition wherein a first portion of the active agent is present insolution and a second portion of the active agent is present inparticulate form, in suspension in a liquid matrix.

As used herein, the phrase “substantially isolated” means a compoundthat is at least partially or substantially separated from theenvironment in which it is formed or detected.

As used herein, the phrase “suitable substituent” or “substituent” meansa group that does not nullify the synthetic or pharmaceutical utility ofthe compounds described herein or the intermediates useful for preparingthem. Examples of suitable substituents include, but are not limited to:C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynyl, C₅-C₆aryl, C₁-C₆alkoxy,C₃-C₅heteroaryl, C₃-C₆cycloalkyl, C₅-C₆aryloxy, —CN, —OH, oxo, halo,haloalkyl, —NO₂, —CO₂H, —NH₂, —NH(C₁-C₈alkyl), —N(C₁-C₈alkyl)₂,—NH(C₆aryl), —N(C₅-C₆aryl)₂, —CHO, —CO(C₁-C₆alkyl), —CO((C₅-C₆)aryl),—CO₂((C₁-C₆)alkyl), and —C₀₂((C₅-C₆)aryl). One of skill in art canreadily choose a suitable substituent based on the stability andpharmacological and synthetic activity of the compounds describedherein.

As used herein, the phrase “therapeutically effective amount” means theamount of active compound or pharmaceutical agent that elicits thebiological or medicinal response that is being sought in a tissue,system, animal, individual or human by a researcher, veterinarian,medical doctor or other clinician. The therapeutic effect is dependentupon the disorder being treated or the biological effect desired. Assuch, the therapeutic effect can be a decrease in the severity ofsymptoms associated with the disorder and/or inhibition (partial orcomplete) of progression of the disorder, or improved treatment,healing, prevention or elimination of a disorder, or side-effects. Theamount needed to elicit the therapeutic response can be determined basedon the age, health, size and sex of the subject. Optimal amounts canalso be determined based on monitoring of the subject's response totreatment.

As used herein, the terms “treat,” “treated,” or “treating” mean boththerapeutic treatment and prophylactic measures wherein the object is toslow down (lessen) an undesired physiological condition, disorder ordisease, or obtain beneficial or desired clinical results. Beneficial ordesired clinical results include, but are not limited to, alleviation ofsymptoms; diminishment of extent of condition, disorder or disease;stabilized (i.e., not worsening) state of condition, disorder ordisease; delay in onset or slowing of condition, disorder or diseaseprogression; amelioration of the condition, disorder or disease state orremission (whether partial or total), whether detectable orundetectable; an amelioration of at least one measurable physicalparameter, not necessarily discernible by the patient; or enhancement orimprovement of condition, disorder or disease. Treatment includeseliciting a clinically significant response without excessive levels ofside effects. Treatment also includes prolonging survival as compared toexpected survival if not receiving treatment. Thus, “treatment of pain”or “treating pain” means an activity that alleviates or ameliorates anyof the primary phenomena or secondary symptoms associated with the painor other condition described herein.

As used herein, the term “ureido” means —NHC(═O)—NH₂.

At various places in the present specification, substituents ofcompounds may be disclosed in groups or in ranges. It is specificallyintended that embodiments include each and every individualsubcombination of the members of such groups and ranges. For example,the term “C₁₋₆alkyl” is specifically intended to individually disclosemethyl, ethyl, propyl, C₄alkyl, C₅alkyl, and C₆alkyl.

For compounds in which a variable appears more than once, each variablecan be a different moiety selected from the Markush group defining thevariable. For example, where a structure is described having two Rgroups that are simultaneously present on the same compound, the two Rgroups can represent different moieties selected from the Markush groupsdefined for R. In another example, when an optionally multiplesubstituent is designated in the form, for example,

then it is understood that substituent R can occur s number of times onthe ring, and R can be a different moiety at each occurrence. In theabove example, where the variable T¹ is defined to include hydrogens,such as when T¹ is CH₂, NH, etc., any H can be replaced with asubstituent.

It is further appreciated that certain features described herein, whichare, for clarity, described in the context of separate embodiments, canalso be provided in combination in a single embodiment. Conversely,various features which are, for brevity, described in the context of asingle embodiment, can also be provided separately or in any suitablesubcombination.

It is understood that the present embodiments encompass the use, whereapplicable, of stereoisomers, diastereomers and optical stereoisomers ofthe compounds, as well as mixtures thereof. Additionally, it isunderstood that stereoisomers, diastereomers, and optical stereoisomersof the compounds, and mixtures thereof, are within the scope of theembodiments. By way of non-limiting example, the mixture may be aracemate or the mixture may comprise unequal proportions of oneparticular stereoisomer over the other. Additionally, the compounds canbe provided as a substantially pure stereoisomers, diastereomers andoptical stereoisomers (such as epimers).

The compounds described herein can be asymmetric (e.g., having one ormore stereocenters). All stereoisomers, such as enantiomers anddiastereomers, are intended to be included within the scope of theembodiments unless otherwise indicated. Compounds that containasymmetrically substituted carbon atoms can be isolated in opticallyactive or racemic forms. Methods of preparation of optically activeforms from optically active starting materials are known in the art,such as by resolution of racemic mixtures or by stereoselectivesynthesis. Many geometric isomers of olefins, C═N double bonds, and thelike can also be present in the compounds described herein, and all suchstable isomers are provided herein. Cis and trans geometric isomers ofthe compounds are also included within the present embodiments and canbe isolated as a mixture of isomers or as separated isomeric forms.Where a compound capable of stereoisomerism or geometric isomerism isdesignated in its structure or name without reference to specific R/S orcis/trans configurations, it is intended that all such isomers arecontemplated.

In some embodiments, the composition comprises a compound, or apharmaceutically acceptable salt thereof, that is at least 90%, at least95%, at least 98%, or at least 99%, or 100% enantiomeric pure, whichmeans that the ratio of one enantiomer to the other in the compositionis at least 90:1 at least 95:1, at least 98:1, or at least 99:1, or iscompletely in the form of one enantiomer over the other.

Resolution of racemic mixtures of compounds can be carried out by any ofnumerous methods known in the art, including, for example, chiral HPLC,fractional recrystallization using a chiral resolving acid which is anoptically active, salt-forming organic acid. Suitable resolving agentsfor fractional recrystallization methods include, but are not limitedto, optically active acids, such as the D and L forms of tartaric acid,diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malicacid, lactic acid, and the various optically active camphorsulfonicacids such as 0-camphorsulfonic acid. Other resolving agents suitablefor fractional crystallization methods include, but are not limited to,stereoisomerically pure forms of α-methylbenzylamine (e.g., S and Rforms, or diastereomerically pure forms), 2-phenylglycinol,norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine,1,2-diaminocyclohexane, and the like. Resolution of racemic mixtures canalso be carried out by elution on a column packed with an opticallyactive resolving agent (e.g., dinitrobenzoylphenylglycine). Suitableelution solvent compositions can be determined by one skilled in theart.

Compounds may also include tautomeric forms. Tautomeric forms resultfrom the swapping of a single bond with an adjacent double bond togetherwith the concomitant migration of a proton. Tautomeric forms includeprototropic tautomers which are isomeric protonation states having thesame empirical formula and total charge. Examples of prototropictautomers include, but are not limited to, ketone-enol pairs,amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs,enamine-imine pairs, and annular forms where a proton can occupy two ormore positions of a heterocyclic system including, but not limited to,1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be inequilibrium or sterically locked into one form by appropriatesubstitution.

Compounds also include hydrates and solvates, as well as anhydrous andnon-solvated forms.

Compounds can also include all isotopes of atoms occurring in theintermediates or final compounds. Isotopes include those atoms havingthe same atomic number but different mass numbers. For example, isotopesof hydrogen include tritium and deuterium.

In some embodiments, the compounds, or salts thereof, are substantiallyisolated. Partial separation can include, for example, a compositionenriched in the compound. Substantial separation can includecompositions containing at least about 50%, at least about 60%, at leastabout 70%, at least about 80%, at least about 90%, at least about 95%,at least about 97%, or at least about 99% by weight of the compound, orsalt thereof. Methods for isolating compounds and their salts areroutine in the art.

Although the disclosed compounds are suitable, other functional groupscan be incorporated into the compound with an expectation of similarresults. In particular, thioamides and thioesters are anticipated tohave very similar properties. The distance between aromatic rings canimpact the geometrical pattern of the compound and this distance can bealtered by incorporating aliphatic chains of varying length, which canbe optionally substituted or can comprise an amino acid, a dicarboxylicacid or a diamine. The distance between and the relative orientation ofmonomers within the compounds can also be altered by replacing the amidebond with a surrogate having additional atoms. Thus, replacing acarbonyl group with a dicarbonyl alters the distance between themonomers and the propensity of dicarbonyl unit to adopt ananti-arrangement of the two carbonyl moiety and alter the periodicity ofthe compound. Pyromellitic anhydride represents still anotheralternative to simple amide linkages which can alter the conformationand physical properties of the compound. Modern methods of solid phaseorganic chemistry (E. Atherton and R. C. Sheppard, Solid Phase PeptideSynthesis A Practical Approach IRL Press Oxford 1989) now allow thesynthesis of homodisperse compounds with molecular weights approaching5,000 Daltons. Other substitution patterns are equally effective.

The compounds also include derivatives referred to as prodrugs.

Compounds containing an amine function can also form N-oxides. Areference herein to a compound that contains an amine function alsoincludes the N-oxide. Where a compound contains several amine functions,one or more than one nitrogen atom can be oxidized to form an N-oxide.Examples of N-oxides include N-oxides of a tertiary amine or a nitrogenatom of a nitrogen-containing heterocycle. N-Oxides can be formed bytreatment of the corresponding amine with an oxidizing agent such ashydrogen peroxide or a per-acid (e.g., a peroxycarboxylic acid) (see,Advanced Organic Chemistry, by Jerry March, 4th Edition, WileyInterscience).

Embodiments of various compounds and salts thereof are provided. Where avariable is not specifically recited, the variable can be any optiondescribed herein, except as otherwise noted or dictated by context.

In some embodiments, the compound is as described in the appendedexemplary, non-limiting claims, or a pharmaceutically acceptable saltthereof.

In some embodiments, compounds having Formula I or Formula II, or apharmaceutically acceptable salt thereof, are provided:

wherein:

AA is

W is O, S, or NR1;

X is O, S, or NR₄;

V is O, S, or NR₃₂;

Z is CHR₄₂ or NR₄₃;

n is 0, 1, 2, 3, or 4;

Y₁ and Y₂ are independently O, S, NR₅, C═O, C═S or C═NR₆;

Y₃ is O, S, CH₂, or NR₃₄;

m is 0, 1, 2, or 3;

A₁ is O, S, NR₇, C═O, or C═S;

A₂ and A₃ are independently CR₂₉ or N;

B₁ is an optionally substituted aryl or heteroaryl group, a carbocycle,or

B₂, B₃, and B₄ are independently CR₃₈ or N;

D₁ is H, OH, NH₂, NO₂, cycle, optionally substituted aryl group,branched or unbranched alkyl alcohol, halo, branched or unbranchedalkyl, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, oralkylsulfanyl;

R₂ and R₃, are independently H, optionally substituted C₁-C₆ alkyl,optionally substituted C₁-C₆ hydroxyalkyl, optionally substituted C₁-C₆alkoxy, optionally substituted cycloalkyl, or optionally substitutedcycloheteroalkyl; or R₂ and R₃ are together optionally substitutedcycloalkyl, or optionally substituted cycloheteroalkyl;

R₁, R₄, R₅, R₆, R₇, R₂₉, R₃₁, R₃₂, R₃₃, R₃₄, R₃₈, and R₄₃ areindependently H, OH, NH₂, optionally substituted C₁-C₆ alkyl, optionallysubstituted C₁-C₆ hydroxyalkyl, optionally substituted C₁-C₆ alkoxy,optionally substituted cycloalkyl, or optionally substitutedcycloheteroalkyl.

R₃₀ is independently H, CN, CF₃, optionally substituted C₁-C₆ alkyl,optionally substituted C₁-C₆ hydroxyalkyl, optionally substituted C₁-C₆alkoxy, optionally substituted cycloalkyl, or optionally substitutedcycloheteroalkyl; or optionally substituted haloalkyl;

R₄₂ is independently Br, C₁, F, optionally substituted C₁-C₆ alkyl,optionally substituted C₁-C₆ hydroxyalkyl, optionally substituted C₁-C₆alkoxy, optionally substituted cycloalkyl, or optionally substitutedcycloheteroalkyl;

In some embodiments of compounds of Formula I or Formula II, D₁ and B₁are:

wherein:

Z₁ and Z₂ are independently N or CR₃₉;

Z₃ is O, S, or NR₂₇;

R₂₇ and R₃₉ are independently H, optionally substituted C₁-C₆ alkyl,optionally substituted C₁-C₆ hydroxyalkyl, optionally substituted C₁-C₆alkoxy, optionally substituted cycloalkyl, or optionally substitutedcycloheteroalkyl.

In some embodiments, one of Z₁ and Z₂ is N. In some embodiments, both Z₁and Z₂ are N. In some embodiments, Z₃ is O.

In some embodiments of compounds, or a pharmaceutically acceptable saltthereof, of Formula I or Formula II, D₁ and B₁ have a formula of:

wherein:

Z₄ is O, S, or NR₂₈;

Z₅ is N or CH;

R₁₉, and R₂₀ are each independently H, OH, NH₂, NO₂, cycle, aryl,branched or unbranched alkyl alcohol, halo, branched or unbranchedalkyl, amide, cyano, alkoxy, alkylthio, haloalkyl, aklylsulfonyl,nitrite, or alkylsulfanyl; or two of R₁₉, and R₂₀ together form an arylor cycle that is attached to one or more of the atoms of B₁.

R₂₈ is H, optionally substituted C₁-C₆ alkyl, optionally substitutedC₁-C₆ hydroxyalkyl, optionally substituted C₁-C₆ alkoxy, optionallysubstituted cycloalkyl, or optionally substituted cycloheteroalkyl.

In some embodiments, Z₅ is N. In some embodiments, Z₄ is 0. In someembodiments, Z₅ is N and Z₄ is O.

In some embodiments of compounds of Formula I or Formula II, D₁ is

wherein R₂₁, R₂₂, and R₂₃ are each independently H, OH, NH₂, NO₂, cycle,aryl, branched or unbranched alkyl alcohol, halo, branched or unbranchedalkyl, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, oralkylsulfanyl; or two of R₂₁, R₂₂, and R₂₃ together form an aryl orcycle that is attached to one or more of the atoms of D₁.

In some embodiments, one of R₂₁, R₂₂, and R₂₃ is H. In some embodiments,two of R₂₁, R₂₂, and R₂₃ are H. In some embodiments, R₂₃ is Me, OH, NH₂,C₁, NHSO₂Me, SO₂NH₂, NH(CO)Me, or (CO)NH₂. In some embodiments, R₂₁ andR₂₂ are H and R₂₃ is Me, OH, NH₂, C₁, NHSO₂Me, SO₂NH₂, NH(CO)Me, or(CO)NH₂.

In some embodiments of compounds of Formula I or Formula II, D₁ isoptionally substituted aryl or optionally substituted hetero aryl.

In some embodiments of compounds of Formula I or Formula II, D₁ is

wherein R₂₄, R₂₅, and R₂₆ are each independently H, OH, NH₂, NO₂, cycle(e.g. carbocycle or heterocyle), aryl, branched or unbranched alkylalcohol, halo, branched or unbranched alkyl, amide, cyano, alkoxy,haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; or two of R₂₄, R₂₅,and R₂₆ together form an aryl or cycle that is attached to one or moreof the atoms of D₁.

In some embodiments, one of R₂₄, R₂₅, and R₂₆ is H. In some embodiments,two of R₂₄, R₂₅, and R₂₆ are H. In some embodiments, R₂₆ is H, Me, OH,CF₃, or OMe. In some embodiments, R₂₄ and R₂₅ are H and R₂₆ is H, Me,OH, CF₃, or OMe.

In some embodiments of compounds of Formula I or Formula II, AA is

In some embodiments, W is O. In some embodiments, X is O. In someembodiments, R₂ and R₃ are independently H, optionally substituted C₁-C₆alkyl, optionally substituted C₁-C₆ hydroxyalkyl, optionally substitutedC₁-C₆ alkoxy, optionally substituted cycloalkyl, or optionallysubstituted cycloheteroalkyl. In some embodiments, R₂ and R₃ are thesame. In some embodiments, R₂ and R₃ are ethyl.

In some embodiments, D₁ is

In some embodiments, one of R₂₄, R₂₅, and R₂₆ is H. In some embodiments,two of R₂₄, R₂₅, and R₂₆ are H and the other member is as definedherein. In some embodiments, D₁ is

In some embodiments, D₁ is

In some embodiments, R₂₄ is H. In some embodiments, R₂₄ is OH. In someembodiments, D₁ is

In some embodiments, R₂₄ is OMe.

In some embodiments, D₁ is

In some embodiments, one of R₂₄, R₂₅, and R₂₆ is H. In some embodiments,two of R₂₄, R₂₅, and R₂₆ are H and the other member is as definedherein.

In some embodiments, D₁ is

In some embodiments, D₁ is

In some embodiments, D₁ is

In some embodiments, R₂₄ is halide. In some embodiments, R₂₄ is F.

In some embodiments, R₂₄ is Me. In some embodiments, R₂₄ is OMe. In someembodiments, R₂₄ is OH.

In some embodiments of compounds of Formula I or Formula II, R₂ and R₃are together

In some embodiments, n is 1.

In some embodiments of compounds of Formula I or Formula II, AA is

In some embodiments, Y₁ is NR₅. In some embodiments, R₅ is H.

In some embodiments, Y₂ is C═NR₆. In some embodiments, R₆ is H.

In some embodiments, Y₂ is C═O. In some embodiments, Y₃ is O. In someembodiments, Y₃ is CH₂. In some embodiments, m is 0. In someembodiments, m is 1.

In some embodiments of compounds of Formula I or Formula II, AA is

In some embodiments, A₁ is O. In some embodiments, A₁ is S. In someembodiments, A₂ is N. In some embodiments, A₃ is N. In some embodiments,A₃ is CR₂₉. In some embodiments, R₂₉ is H.

In some embodiments, A₂ is CR₂₉. In some embodiments, R₂₉ is H.

In some embodiments, A₁ is NR₇. In some embodiments, R₇ is Me,

In some embodiments, D₁ is

and one of R₂₁, R₂₂, and R₂₃ is H.

In some embodiments, D₁ is

and two of R₂₁, R₂₂, and R₂₃ are H. In some embodiments, D₁ is

In some embodiments, R₂₁ is optionally substituted C₁-C₆ alkyl. In someembodiments, R₂₁ is ethyl or methyl. In some embodiments, D₁ is

In some embodiments of compounds of Formula I or Formula II, D₁ is

wherein:

Z₆ is O, S, NR₄₀, or CHR₃₇;

Z₇, Z₈, Z₉ and Z₁₀ are independently N or CR₄₁;

R₃₅, R₃₆, R₃₇, R₄₀, and R₄₁ are each independently H, OH, NH₂, cycle,aryl, branched or unbranched alkyl alcohol, halo, branched or unbranchedalkyl, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, oralkylsulfanyl; or R₃₅ and R₃₆ together form an aryl or cycle that isattached to one or more of the atoms of D₁.

In some embodiments, one of R₃₅ and R₃₆ is H. In some embodiments, bothR₃₅ and R₃₆ are H. In some embodiments, Z₆ is NH. In some embodiments,one of Z₇, Z₈ and Z₉ is N.

In some embodiments, Z₇ is N. In some embodiments, Z₈ is CH. In someembodiments, Z₉ is CH. In some embodiments, both Z₈ and Z₉ are CH.

In some embodiments, AA is

In some embodiments, W is O. In some embodiments, X is O. In someembodiments, R₂ and R₃ are independently H, optionally substituted C₁-C₆alkyl, optionally substituted C₁-C₆ hydroxyalkyl, optionally substitutedC₁-C₆ alkoxy, optionally substituted cycloalkyl, or optionallysubstituted cycloheteroalkyl. In some embodiments, both R₂ and R₃ arethe same. In some embodiments, both R₂ and R₃ are methyl or ethyl. Insome embodiments, n is 1. In some embodiments, D₁ is pyrazoly. In someembodiments, D₁ is

In some embodiments, the compound, or a pharmaceutically acceptable saltthereof, is a compound of Formula I having a formula of

or a pharmaceutically acceptable salt thereof, wherein Z₁, Z₂, and Z₃are as defined herein and above.

In some embodiments, Z₂ is N. In some embodiments, Z₁ is N. In someembodiments, Z₃ is O. In some embodiments, Z₂ and Z₁ are N and Z₃ is asdefined herein. In some embodiments, Z₂ and Z₁ are N and Z₃ is O. Insome embodiments, the compound is a compound of Formula I having aformula of

or a pharmaceutically acceptable salt thereof.

In some embodiments of compounds of Formula II, D₁ and B₁ is

In some embodiments, Z₃ is O and Z₁ and Z₂ are independently N or CR₃₉.

In some embodiments, Z₁ is N, Z₂ is N or CR₃₉ and Z₃ is O, S, or NR₂₇.In some embodiments, Z₁ and Z₂ are N and Z₃ is O.

In some embodiments, the compound is a compounds of Formula II having aformula of

or a pharmaceutically acceptable salt thereof. In some embodiments, R₃₀is CN. In some embodiments, V is NH. In some embodiments, R₃₁ is C—C₅alkyl. In some embodiments, R₃₁ is

In some embodiments, R₃₁ is C—C₅ haloalkyl.

In some embodiments, R₃₁ is

In some embodiments of compounds of Formula II, D₁, B₁, and AA togetheris

In some embodiments, R₃₀ is CF₃. In some embodiments, V is O or NH.

In some embodiments, R₃₀ is CF₃.

In some embodiments, B₁-D₁ is

wherein D1 is as defined herein and above. In some embodiments, D₁ is

In some embodiments, R₃₁ is

In the preceding embodiments, or as shown below, or as illustrated inthe appending claims, if a variable (substituent) is not explicitlydefined then the variable is as defined above, which would be readilyapparent based upon the present embodiments.

In some embodiments, the compound has a formula of:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the present embodiments provide a pharmaceuticalcomposition comprising one or more compounds as provided or describedherein, such as any compound of Formula I or Formula II, or apharmaceutically acceptable salt thereof.

In some embodiments, the present embodiments provide methods of treatingor preventing neuropathy, pain, inflammatory pain, cancer pain, bonecancer pain, tumor pain, pain or neuropathy resulting from disorders ofthe central or peripheral nervous system, neuropathic pain, painassociated with dysesthesia, allodynia or hypersensitivity, chemotherapyinduced neuropathic pain, chemotherapy induced peripheral neuropathy,diabetic neuropathy or pain associated with diabetic neuropathy, postherpetic neuralgia or pain associated with post herpetic neuralgia,hiv-related neuropathy or pain associated with hiv-related neuropathy,pain or neuropathy resulting from spinal cord injury, nerve lesions,tissue injury, multiple sclerosis, stroke, nutritional deficiencies, ortoxins, fibromyalgia or pain associated with fibromyalgia, phantom limbpain, complex regional pain syndrome, carpal tunnel syndrome, sciatica,pudendal neuralgia, back or neck pain, including those resulting fromdegenerative disk disease, trigeminal neuralgia, headache disordersincluding, but not limited to migraine and cluster headache, orofacialpain, odontalgia, temporomandibular joint pain, endometrial pain,osteoarthritis, rheumatoid arthritis, atypical odontalgia, interstitialcystitis, uveitis, or any combination thereof in a subject comprisingadministering to the subject one or more compounds described herein, ora pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition comprising one or more compounds described herein.

In some embodiments, the present embodiments provide methods of treatingor preventing neuropathy, chemotherapy induced neuropathic pain,chemotherapy induced peripheral neuropathy, diabetic neuropathy or painassociated with diabetic neuropathy in a subject, the method comprisingadministering to the subject one or more compounds described herein, ora pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition comprising one or more compounds described herein.

In some embodiments, the present embodiments provide methods of treatingcancer in a subject, the method comprising administering to the subjectone or more compounds described herein, or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition comprising one or morecompounds described herein.

In some embodiments, the present embodiments provide methods of treatingcancer in a subject, wherein the cancer is ovarian, breast, lung, brain,colon, prostate, esophageal, pancreatic, brain, glioblastoma, leukemia,multiple myeloma, lymphoma, skin cancer, acute Lymphoblastic Leukemia,acute myeloid leukemia, basal cell cancer, bile duct cancer, bladdercancer, bone cancer (Ewing sarcoma, osteosarcoma), CLL, CML, uterinecancer, cervical cancer, hairy cell leukemia, melanoma, thyroid cancer,rectal cancer, renal cell cancer, small cell lung cancer, non-small celllung cancer, or stomach cancer.

In some embodiments, wherein the subject is a subject in need thereof.In some embodiments, wherein the cancer therapeutic is selected fromthose described herein.

In some embodiments, the condition is prevented.

In some embodiments, a compound, or a pharmaceutically acceptable saltthereof, is chosen from a compound of as shown in the following tableand/or as described herein, including in the Examples section of thepresent disclosure. Any of the compounds provided for herein can beprepared as pharmaceutically acceptable salts and/or as part of apharmaceutical composition as provided for herein. Examples of suchsalts are provided for herein. As described herein, the compounds can beprepared according to the schemes and methods described herein.

Compound Chemical Structure Number Name

1 1-cyclopentyl-5-{3-[3-fluoro-4- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

2 5-(2-bromophenyl)-3-(1-ethyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole

3 1-(2-methylpropyl)-6-[3-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

4 l-cyclopentyl-5-{3-[4-(pyridin-3- ylmethoxy)-3-(trifluoromethyl)phenyl]-1,2,4- oxadiazol-5-yl}-1H-1,2,3- benzotriazole

5 5-[3-(4-fluorophenyl)-1,2,4- oxadiazol-5-yl]-1-propyl-1H-1,2,3-benzotriazole

6 5-[3-(5-methylpyrazin-2-yl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

7 1-cyclopentyl-5-(3-phenyl-1,2,4- oxadiazol-5-yl)-1H-1,2,3-benzotriazole

8 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methylpyridin-4-yl)-1,2,4- oxadiazole

9 5-[3-(5-phenylpyridin-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

10 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole

11 l-cyclohexyl-5-[3-(3- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

12 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(trifluoromethyl)phenyl)-1,2,4- oxadiazole

13 4-[5-(1-cyclopentyl-1H-1,2,3- benzotriazol-5-yl)-1,2,4-oxadiazol-3-yl]phenol

14 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4- isopropoxy-3-(trifluoromethyl)phenyl)-1,2,4- oxadiazole

15 5-[3-(4-phenoxyphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

16 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(methylthio)phenyl)-1,2,4- oxadiazole

17 5-[3-(2-chlorophenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

18 5-(5-cyclobutyl-1,2,4-oxadiazol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole

19 5-[3-(6-methoxypyridin-2-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

20 3-(4-isopropoxy-3- (trifluoromethyl)phenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

21 5-[4-(2-fluorophenyl)-1,3-oxazol-2- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

22 2-isopropoxy-5-(3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

23 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(phenoxymethyl)phenyl)-1,2,4- oxadiazole

24 3-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol

25 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(6-isopropylpyridin-3-yl)-1,2,4- oxadiazole

26 l-[5-{3-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol

27 2,2-diethyl-6-{3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

28 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,3,4-oxadiazol-2-yl)chroman-4- one

29 2,2-diethyl-6-(3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-thiadiazol-5-yl)chroman-4-one

30 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N,N-dimethylbenzenesulfonamide

31 2,2-diethyl-6-(3-(3-methylpyridin- 4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

32 3-(benzo[d][1,3]dioxol-4-yl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

33 3-(1-isopropylbenzotriazol-5-yl)-5-[2-(trifluoromethyl)phenyl]-1,2,4- oxadiazole

34 2,2-diethyl-6-(3-(5-methylthiophen- 2-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

35 5-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

36 4′,4′-difluoro-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[l-benzopyran-2,1′- cyclohexane]-4-one

37 5-(4-fluorophenyl)-2-(1- isopropylbenzotriazol-5-yl)thiazole

38 2,2-diethyl-6-(3-(2- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

39 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 2-(prop-2-en-1-yl)-2H-1,2,3-benzotriazole

40 5-(2-bromophenyl)-3-(1- cyclopentyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

41 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[l-benzopyran-2,l′-cyclohexane]-4- one

42 3-(1-allyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-bromophenyl)-1,2,4-oxadiazole

43 5-(2-bromophenyl)-3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole

44 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methylpyrazin-2-yl)-1,2,4- oxadiazole

45 5-(2-bromophenyl)-3-(1-(pyridin-2- ylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

46 l-cyclopentyl-5-{3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

47 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(methylthio)phenyl)-1,2,4- oxadiazole

48 5-(2-bromophenyl)-3-(1-(pyridin-4- ylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

49 5-{3-[4-(phenoxymethyl)phenyl]- 1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

50 5-[4-(4-chlorophenyl)-5-methyl- 1,3-oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

51 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methoxypyrazin-2-yl)-1,2,4- oxadiazole

52 3-(1-benzyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-bromophenyl)-1,2,4-oxadiazole

53 5-{3-[4-(benzyloxy)phenyl]-1,2,4- oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

54 5-[3-(3-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-propyl-1H-1,2,3-benzotriazole

55 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(4-methoxy-2-methylphenyl)-1,2,4- oxadiazole

56 5-[3-(2-methyl-1-phenylpropyl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

57 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

58 4′,4′-dimethyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′- cyclohexane]-4-one

59 l-tert-butyl-5-[3-(2-methylphenyl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

60 6-(3-(4-(dimethylamino)phenyl)- 1,2,4-oxadiazol-5-yl)-2,2-diethylchroman-4-one

61 2-(allylamino)-5-(3-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

62 3-(2-isopropoxyphenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

63 5-(2-fluorophenyl)-2-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)thiazole

64 5-(3-fluorophenyl)-3-(1- isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole

65 2,2-diethyl-6-(3-(4- methoxyphenyl)-1,2,4-oxadiazol-5-yl)chroman-4-one

66 2,2-diethyl-6-(3-(o-tolyl)-1,2,4- oxadiazol-5-yl)chroman-4-one

67 2,2-diethyl-6-(5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,3,4-thiadiazol-2-yl)chroman-4-one

68 6-[3-(4-chlorophenyl)-1,2,4- oxadiazol-5-yl]-2,2-diethyl-chroman-4-one

69 3-(1-isopropylbenzotriazol-5-yl)-5- (4-methoxyphenyl)-1,2,4-oxadiazole

70 2-{5-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,3,4-thiadiazol-2-yl}phenol

71 2,2-diethyl-6-(3-(3- methoxyphenyl)-1,2,4-oxadiazol-5-yl)chroman-4-one

72 2,2-diethyl-6-[3-(4- hydroxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

73 5-(2-bromophenyl)-3-(1-methyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole

74 5-[5-(5-methylthiophen-2-yl)-1,2,4- oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

75 l-(2-methylpropyl)-5-{3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

76 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-propyl-1H-1,2,3-benzotriazole

77 5-[3-(2-methoxypyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1-methyl-2,3-dihydro-1H-1,2,3-benzotriazole; cyclopentane

78 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(pyrazin-2-yl)-1,2,4-oxadiazole

79 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- l-(propan-2-yl)-1H-1,2,3-benzotriazole

80 l-cyclopentyl-5-{3-[4- (difluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

81 methyl2-(5-(5-(2-bromophenyl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)acetate

82 5-[3-(5-chlorothiophen-2-yl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

83 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1-cyclopropyl-1H-1,2,3-benzotriazole

84 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole

85 5-{3-[4-(benzyloxy)-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopropyl-1H- 1,2,3-benzotriazole

86 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methyipyridin-4-yl)-1,2,4- oxadiazole

87 l-cyclopropyl-5-[3-(6- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

88 5-(3-benzyl-1,2,4-oxadiazol-5-yl)- l-(propan-2-yl)-1H-1,2,3-benzotriazole

89 5-[5-(oxan-4-yl)-1,2,4-oxadiazol-3- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

90 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxy-2-methylphenyl)-1,2,4- oxadiazole

91 1-cyclopentyl-5-[3-(4- methoxynaphthalen-1-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

92 5-(3-benzyl-1,2,4-oxadiazol-5-yl)- l-cyclopentyl-1H-1,2,3-benzotriazole

93 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

94 l-cyclopropyl-5-[3-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

95 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

96 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(2-methylpropyl)-1H-1,2,3- benzotriazole

97 3-(1H-benzo[d][1,2,3]triazol-5-yl)- 5-(2-bromophenyl)-1,2,4-oxadiazole

98 5-(2-bromophenyl)-3-(1- (cyclopropylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

99 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(o-tolyl)-1,2,4-oxadiazole

100 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methylpyridin-3-yl)-1,2,4- oxadiazole

101 5-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

102 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

103 2,2-diethyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

104 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,3,4-thiadiazol-2-yl)chroman-4-one

105 2,2-diethyl-6-[3-(6-hydroxy-3- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

106 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide

107 2-(isopropylamino)-5-(3-(2- oxoindolin-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

108 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxyphenyl)thiazole

109 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxyphenyl)thiazole

110 5-(3-fluorophenyl)-2-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)thiazole

111 2,2-diethyl-6-[3-(2-pyridyl)-1,2,4- oxadiazol-5-yl]chroman-4-one

112 2-{3-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-thiadiazol-5-yl}phenol

113 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 1H-1,2,3-benzotriazole

114 5-{3-[4-bromo-2- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentyl-1H- 1,2,3-benzotriazole

115 5-(2-bromophenyl)-3-(1- cyclohexyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

116 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxypyridin-4-yl)-1,2,4- oxadiazole

117 1-cyclohexyl-5-[3-(4- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

118 l-cyclopentyl-5-{3-[3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

119 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(6-methylpyridin-3-yl)-1,2,4- oxadiazole

120 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole

121 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-isopropoxyphenyl)-1,2,4- oxadiazole

122 5-{3-[3-fluoro-4- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-(3-methylbutyl)- 1H-1,2,3-benzotriazole

123 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

124 l-cyclopentyl-5-[3-(6- methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

125 5-[5-(4,4-difluorocyclohexyl)- 1,2,4-oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

126 5-{3-[(3,5-dimethyiphenyl)methyl]-1,2,4-oxadiazol-5-yl}-1-(propan-2- yl)-1H-1,2,3-benzotriazole

127 5-(5-cyclohexyl-1,2,4-oxadiazol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole

128 l-(propan-2-yl)-5-(3- {[1,2,4]triazolo[4,3-a]pyridin-6-yl}-1,2,4-oxadiazol-5-yl)-1H-1,2,3- benzotriazole

129 5-{3-(4-methoxynaphthalen-1-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

130 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxyphenyl)-1,2,4-oxadiazole

131 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-(phenoxymethyl)phenyl)-1,2,4- oxadiazole

132 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole

133 5-(5,6-dimethylpyrazin-2-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

134 3-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1- yl)propanoicacid

135 5-[3-(2-ethylpyrimidin-5-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

136 5-[3-(2,4-dimethoxy-6- methyiphenyl)-1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole

137 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,2,4-thiadiazol-3-yl)chroman-4-one

138 5-[5-(2-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

139 2-methyl-1-{5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1- yl}propan-2-ol

140 2-methyl-1-{5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazol-1-yl}propan-2-ol

141 5-(3-(1H-indazol-5-yl)-1,2,4- oxadiazol-5-yl)-2-(allylamino)benzonitrile

142 3-(1-isopropyl-1H-indol-5-yl)-5-(3- methyipyridin-4-yl)-1,2,4-oxadiazole

143 2,2-diethyl-6-(5-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- thiadiazol-3-yl)chroman-4-one

144 5-[5-(2-methoxyphenyl)-1,3,4- thiadiazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

145 5-(3-(1H-benzo[d][1,2,3]triazol-5- yl)-1,2,4-oxadiazol-5-yl)-2-(allylamino)benzonitrile

146 2,2-diethyl-6-(3-(2-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one

147 2,2-diethyl-6-(3-(2- methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

148 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[l-benzopyran-2,4′-oxane]-4-one

149 N-(4-(5-(4-(allylamino)-3- cyanophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanesulfonamide

150 2-(allylamino)-5-(3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

151 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N,N-dimethylbenzamide

152 6-(3-(1H-indazol-5-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

153 2,2-diethyl-6-(3-(4- (methylamino)phenyl)-1,2,4-oxadiazol-5-yl)chroman-4-one

154 5-{3-[l-(2-methyiphenyl)ethyl]- 1,2,4-oxadiazol-5-yl}-1-(2-methylpropyl)-1H-1,2,3- benzotriazole

155 l-cyclopropyl-5-[3-(2- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

156 5-(2,6-dimethylpyridin-4-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

157 5-[3-(5-methylpyrazin-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

158 l-cyclohexyl-5-[3-(3,5- dimethylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

159 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methylpyridin-3-yl)-1,2,4- oxadiazole

160 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 1-propyl-1H-1,2,3-benzotriazole

161 methyl 3-(5-(5-(2-bromophenyl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1- yl)propanoate

162 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(o-tolyl)-1,2,4-oxadiazole

163 5-[4-(2-chlorophenyl)-2,3-dihydro- 1,3-oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

164 l-cyclopentyl-5-[3-(4- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

165 l-(propan-2-yl)-5-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

166 5-(2,4-dimethylphenyl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

167 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-isopropylpyridin-4-yl)-1,2,4- oxadiazole

168 2-{5-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}quinoline

169 5-[3-(3-methylthiophen-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

170 5-[3-(5-chlorothiophen-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

171 l-cyclopropyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

172 5-{3-[l-(2-methylphenyl)ethyl]- 1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

173 l-cyclopropyl-5-[3-(2- methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

174 l-cyclopentyl-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

175 1-cyclopentyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

176 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[l-benzopyran-2,1′-cyclopentane]-4- one

177 5-(3-(1H-benzo[d]imidazol-5-yl)- 1,2,4-oxadiazol-5-yl)-2-(allylamino)benzonitrile

178 2,2-diethyl-6-(5-(2- methoxyphenyl)-1,3,4-thiadiazol-2-yl)chroman-4-one

179 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)benzamide

180 2-(5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-3-yl)phenol

181 N-(benzo[d]isoxazol-3-yl)-1- isopropyl-1H-benzo[d][1,2,3]triazole-5- carboxamide

182 l-(2,2-difluoroethyl)-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

183 5-[4-(2-bromophenyl)-1,3-oxazol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

184 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxyphenyl)thiazole

185 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N-methylbenzamide

186 2,2-bis(methoxymethyl)-6-[3- (pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one

187 2,2-diethyl-6-[3-(2- hydroxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

188 2,2-dibutyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

189 2-(allylamino)-5-(3-(2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

190 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1H-1,2,3- benzotriazole

192 l-cyclopentyl-5-[3-(5- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

193 5-{3-[3-fluoro-4- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-propyl-1H-1,2,3- benzotriazole

194 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methylpyridin-3-yl)-1,2,4- oxadiazole

195 2-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)acetic acid

196 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxyphenyl)-1,2,4-oxadiazole

197 1-cyclopentyl-5-{3-[4-methoxy-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

198 5-[3-(2-chloropyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-cyclopentyl-1H-1,2,3-benzotriazole

199 5-[3-(2-chloropyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(cyclopropylmethyl)-1H-1,2,3- benzotriazole

200 5-[5-(adamantan-1-yl)-1,2,4- oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

201 5-(5,6-dimethylpyridin-3-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

202 5-{3-[(2-methyiphenyl)methyl]- 1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

203 1-cyclopentyl-5-[3-(3- methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

204 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

205 l-propyl-5-[3-(pyridin-4-yl)-1,2,4- oxadiazol-5-yl]-1H-1,2,3-benzotriazole

206 2-methyl-1-{5-[3-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan-2- ol

207 l-tert-butyl-5-[3-(2- methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

208 5-(3-(1H-indol-5-yl)-1,2,4- oxadiazol-5-yl)-2-(allylamino)benzonitrile

209 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide

210 2-((cyclopropylmethyl)amino)-5- (3-(2-oxoindolin-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

211 6-(3-(1H-benzo[d]imidazol-5-yl)- 1,2,4-oxadiazol-5-yl)-2,2-diethylchroman-4-one

212 2,2-diethyl-6-(3-(3- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

213 5-[3-(2-methoxyphenyl)-1,2,4- thiadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

214 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[l-benzopyran-2,4′-oxane]-4-one

215 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(trifluoromethyl)phenyl)thiazole

216 2-(1-isopropylbenzotriazol-5-yl)-5- (o-tolyl)thiazole

217 4′,4′-difluoro-6-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[l-benzopyran-2,1′- cyclohexane]-4-one

218 2,2-dipropyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

219 5-{8H-indeno[1,2-d][1,3]oxazol-2- yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

220 5-(2-bromophenyl)-2-(1- isopropylbenzotriazol-5-yl)thiazole

221 6-(3-(2-chlorophenyl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

222 2,2-diethyl-6-(5-(2- methoxyphenyl)-1,2,4-thiadiazol-3-yl)chroman-4-one

223 2,2-diethyl-6-(5-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,3,4- oxadiazol-2-yl)chroman-4-one

224 2-(allylamino)-5-(3-(2-oxoindolin- 5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

225 2,2-diethyl-6-(3-(m-tolyl)-1,2,4- oxadiazol-5-yl)chroman-4-one

226 2,2-diethyl-6-(3-(3-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one

227 2,2-diethyl-6-[3-(3- hydroxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

228 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methoxyphenyl)-1,2,4-oxadiazole

229 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(6-methyipyrazin-2-yl)-1,2,4- oxadiazole

230 3-(3,4-dimethoxyphenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

231 5-[3-(2-methoxyphenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

232 1-cyclopentyl-5-[3-(4- fluorophenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

233 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

234 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methyipyrazin-2-yl)-1,2,4- oxadiazole

235 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(p-tolyl)-1,2,4-oxadiazole

236 5-[3-(6-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

237 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-(methylthio)phenyl)-1,2,4- oxadiazole

238 2-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)ethanol

239 l-(cyclopropylmethyl)-5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

240 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole

241 l-(propan-2-yl)-5-[3-(pyridin-2-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

242 l-propyl-5-{3-[3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

243 3-(2,6-dimethylphenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

244 l-(propan-2-yl)-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

245 1-cyclohexyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

246 5-(4-isopropoxy-3- (trifluoromethyl)phenyl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

247 5-(5-methyl-4-phenyl-1,3-oxazol-2- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole

248 5-([l,l′-biphenyl]-4-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

249 l-(propan-2-yl)-5-[3-(pyrimidin-5-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

250 5-[4-(4-methoxyphenyl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

251 3-(2,6-dimethoxyphenyl)-5-(1- isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole

252 5-(3-(1H-pyrazol-4-yl)-1,2,4- oxadiazol-5-yl)-2-(allylamino)benzonitrile

253 1-tert-butyl-5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

254 4′,4′-dimethyl-6-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[l-benzopyran-2,1′- cyclohexane]-4-one

255 5-(4-fluorophenyl)-3-(1- isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole

256 6-(3-(4-aminophenyl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

257 2,2-diethyl-6-(3-(2- methoxyphenyl)-1,2,4-thiadiazol-5-yl)chroman-4-one

258 2,2-diethyl-6-(3-(2-hydroxypyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

259 2-(isopropylamino)-5-(3-(2-oxo- 1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

260 3-(2-fluoro-6-methoxy-phenyl)-5- (1-isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole

261 6-[3-(3-chlorophenyl)-1,2,4- oxadiazol-5-yl]-2,2-diethyl-chroman-4-one

262 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)phenyl)methanesulfonamide

263 2,2-diethyl-6-[3-(2-hydroxy-4- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

264 6-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

265 2,2-diethyl-6-(3-(3-methylthiophen- 2-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

266 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N-methylbenzenesulfonamide

267 2-(allylamino)-5-(3-(2- aminobenzo[d]thiazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

268 2,2-diethyl-6-[3-(2- methoxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

269 2,2-diethyl-6-[3-(p-tolyl)-1,2,4- oxadiazol-5-yl]chroman-4-one

270 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- l-(prop-2-en-1-yl)-1H-1,2,3-benzotriazole

271 l-(3-methylbutyl)-5-(3-phenyl- 1,2,4-oxadiazol-5-yl)-1H-1,2,3-benzotriazole

272 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methoxypyridin-3-yl)-1,2,4- oxadiazole

273 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(m-tolyl)-1,2,4-oxadiazole

274 2,2-dimethyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

275 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole

276 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(methylthio)phenyl)-1,2,4- oxadiazole

277 5-[4-(2-methoxyphenyl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

278 5-(5-cyclopentyl-1,2,4-oxadiazol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole5-(5-cyclopentyl- 1,2,4-oxadiazol-3-yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole

279 2-(3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

280 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′-cyclohexane]-4- one

281 1-cyclopentyl-5-[3-(2- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

282 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

283 5-(2-bromophenyl)-3-(1-(pyridin-3- ylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

284 1-cyclohexyl-5-{3-[4-methoxy-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

285 1-cyclopropyl-5-[3-(4- phenoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

286 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole

287 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole

288 1-(cyclopropylmethyl)-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

289 5-[3-(2-chlorophenyl)-1,2,4- oxadiazol-5-yl]-1-(2-methylpropyl)-1H-1,2,3- benzotriazole

290 5-(4-cyclohexylphenyl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole

291 2,2-dimethyl-6-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

292 1-cyclohexyl-5-(3-phenyl-1,2,4- oxadiazol-5-yl)-1H-1,2,3-benzotriazole

293 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

294 5-(4-phenyl-1,3-oxazol-2-yl)-1- (propan-2-yl)-1H-1,2,3-benzotriazole

295 1-cyclopropyl-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

296 5-{3-[4-(benzyloxy)-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)- 1H-1,2,3-benzotriazole

297 5-{4H,5H-naphtho[2,1- d][1,3]oxazol-2-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

298 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′-cyclopentane]-4- one

299 3-(1-isopropylbenzotriazol-5-yl)-5- (3-methoxyphenyl)-1,2,4-oxadiazole

300 2,2-diethyl-6-(5-(2- methoxyphenyl)-1,3,4-oxadiazol-2-yl)chroman-4-one

301 2,2-diethyl-6-[3-(6-methoxy-3- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

302 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4- oxadiazol-5-yl)benzonitrile

303 2,2-diethyl-6-(3-(4- methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

304 3-chroman-8-yl-5-(1- isopropylbenzotriazol-5-yl)-1,2,4- oxadiazole

305 2,2-diethyl-6-(3-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazol-5-yl)chroman-4-one

306 1-cyclobutyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

307 5-(2-fluorophenyl)-3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole

308 6-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

309 2,2-diethyl-6-(3-(pyridin-3-yl)- 1,2,4-thiadiazol-5-yl)chroman-4-one

310 2,2-diethyl-6-[3-(5-hydroxy-3- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one

311 2,2-diethyl-6-(3-(5- methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

312 2,2-diethyl-6-(3-(3-hydroxypyridin- 4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

313 2,2-diethyl-6-(3-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one

314 2,2-diethyl-6-(3-(2- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one

315 2,2-diethyl-6-(3-(2-methylpyridin- 4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

316 N-(4-(5-(3-cyano-4- (isopropylamino)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide

320 3-(2-chlorophenyl)-5-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole

321 5-(1-isopropyl-1H-indol-5-yl)-3-(2- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole

322 3-(2-bromophenyl)-5-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole

323 2-(5-(1-isopropyl-1H-indol-5-yl)- 1,2,4-oxadiazol-3-yl)phenol

324 3-(2-isopropoxyphenyl)-5-(1- isopropyl-1H-indol-5-yl)-1,2,4-oxadiazole

325 3-(2,6-dimethoxyphenyl)-5-(1- isopropylindol-5-yl)-1,2,4- oxadiazole

326 3-(benzo[d][1,3]dioxol-4-yl)-5-(1- isopropyl-1H-indol-5-yl)-1,2,4-oxadiazole

327 3-chroman-8-yl-5-(1- isopropylindol-5-yl)-1,2,4- oxadiazole

328 3-(2-fluoro-6-methoxy-phenyl)-5- (1-isopropylindol-5-yl)-1,2,4-oxadiazole

329 5-(1-isopropyl-1H-indazol-5-yl)-3- (o-tolyl)-1,2,4-oxadiazole

330 3-(2-chlorophenyl)-5-(1-isopropyl- 1H-indazol-5-yl)-1,2,4-oxadiazole

331 5-(1-isopropyl-1H-indazol-5-yl)-3-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole

332 3-(2-bromophenyl)-5-(1-isopropyl- 1H-indazol-5-yl)-1,2,4-oxadiazole

333 2-(5-(1-isopropyl-1H-indazol-5-yl)- 1,2,4-oxadiazol-3-yl)phenol

334 3-(2-isopropoxyphenyl)-5-(1- isopropyl-1H-indazol-5-yl)-1,2,4-oxadiazole

335 3-(2,6-dimethoxyphenyl)-5-(1- isopropylindazol-5-yl)-1,2,4-oxadiazole

336 3-(benzo[d][1,3]dioxol-4-yl)-5-(1- isopropyl-1H-indazol-5-yl)-1,2,4-oxadiazole

337 3-chroman-8-yl-5-(1- isopropylindazol-5-yl)-1,2,4- oxadiazole

338 3-(2-fluoro-6-methoxy-phenyl)-5- (1-isopropylindazol-5-yl)-1,2,4-oxadiazole

339 5-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1,3-dihydro-2,1-benzoxazol-3-one

340 5-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1-methyl-1,3-dihydro-2,1-benzoxazol-3-one

341 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1,2,3,4-tetrahydroquinolin-2-one

342 methyl N-({6-[5-(2- methoxyphenyl)-1,3,4-oxadiazol-2-yl]-2-oxo-2,3-dihydro-1,3- benzoxazol-3- yl}sulfonyl)carbamate

343 2-[(2-fluoroethyl)amino]-5-[3-(2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5- yl]benzonitrile

344 2-[(2,2-difluoroethyl)amino]-5-[3-(2-oxo-1,2,3,4-tetrahydroquinolin- 6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile

345 2-amino-5-[3-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile

346 2-[(2-fluoroprop-2-en-1-yl)amino]- 5-[3-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4- oxadiazol-5-yl]benzonitrile

347 2-[(2,2-difluoropropyl)amino]-5-[3-(2-oxo-1,2,3,4-tetrahydroquinolin- 6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile

348 2-[(2-fluoropropyl)amino]-5-[3-(2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5- yl]benzonitrile

349 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-2,3-dihydro-1,3-benzoxazol-2-one

350 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one

351 5-[5-(1H-indazol-5-yl)-1,3,4- oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile

352 2-[(cyclopropylmethyl)amino]-5- [5-(1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

353 2-[(2-fluoroethyl)amino]-5-[5-(1H- indazol-5-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

354 2-[(2,2-difluoroethyl)amino]-5-[5-(1H-indazol-5-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

355 2-[(2,2-difluoropropyl)amino]-5-{5-(1H-indazol-5-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

356 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile

357 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(cyclopropylmethyl)amino]benzo- nitrile

358 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2-fluoroethyl)amino]benzonitrile

359 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2,2-difluoroethyl)amino]benzonitrile

360 5-(4-methyl-2-phenyl-1,3-oxazol-5- yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one

361 4-[5-(4-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1H-indole

362 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1,3-benzothiazole

363 5-[3-(4-methoxyphenyl)-1,2,4- thiadiazol-5-yl]-1H-indole

364 5-[5-(3-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1H-indole

365 6-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2-one

366 5-[5-(3-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-indole

367 1-methyl-6-[3-(2-methylphenyl)- 1,2,4-oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2-one

368 5-(1H-indol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole

369 5-(1H-benzo[d]imidazol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole

370 5-(1-isopropyl-1H-indazol-5-yl)-3- (2-methoxyphenyl)-1,2,4-oxadiazole

371 5-(1H-indazol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole

372 5-(1-isopropyl-1H-indol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole

373 5-(1-isopropyl-1H- benzo[d]imidazol-5-yl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole

374 5-[3-(2-fluorophenyl)-1,2,4- thiadiazol-5-yl]-1-(propan-2-yl)-1H-indole

375 5-[5-(2-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-indole

376 4-methyl-3-(5-{thieno[2,3- b]pyridin-6-yl}-1,2,4-oxadiazol-3-yl)pyridine

377 1-methyl-5-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-2,3-dihydro-1H-indol-2-one

378 8-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}cubane-1-carboxylate

379 8-{3-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}cubane-1-carboxylicacid

380 5-[5-(2-fluorophenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-indole

381 5-[3-(2-methylphenyl)-1,2,4- thiadiazol-5-yl]-1-(propan-2-yl)-1H-indole

382 3-(2-methylphenyl)-5-[3-(propan-2- yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazole

383 3-(2-methoxyphenyl)-5-[3-(propan- 2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazole

384 1-methyl-6-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2-one

385 5-[4-(3-methoxyphenyl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

386 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2- one

387 5-(2-fluorophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole

388 5-(2-bromophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole

389 3-(1-isopropyl-1H-indol-5-yl)-5-(o- tolyl)-1,2,4-oxadiazole

390 3-(1-isopropyl-1H-indol-5-yl)-5-(2- (trifluoromethyl)phenyl)-1,2,4-oxadiazole

391 3-(1-isopropyl-1H-indol-5-yl)-5-(3- methoxypyridin-4-yl)-1,2,4-oxadiazole

392 3-(1-isopropyl-1H-indol-5-yl)-5-(3- methoxyphenyl)-1,2,4-oxadiazole

393 3-(1-isopropyl-1H-indol-5-yl)-5-(4- methoxyphenyl)-1,2,4-oxadiazole

394 5-(3-fluorophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole

395 3-(1-isopropyl-1H-indol-5-yl)-5- (pyridin-4-yl)-1,2,4-oxadiazole

396 3-(1-isopropyl-1H-indol-5-yl)-5- (pyridin-3-yl)-1,2,4-oxadiazole

397 3-(1-isopropyl-1H-indol-5-yl)-5- (pyridin-2-yl)-1,2,4-oxadiazole

398 3-(1-isopropyl-1H-indol-5-yl)-5-(2- methoxyphenyl)-1,2,4-oxadiazole

399 5-(3-fluoropyridin-4-yl)-3-(1- isopropyl-1H-indol-5-yl)-1,2,4-oxadiazole

400 5-(4-fluorophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole

401 2-(1-isopropyl-1H-pyrrolo[2,3- b]pyridin-5-yl)-4-(2-methoxyphenyl)thiazole

402 4-(2-fluorophenyl)-2-(1-isopropyl- 1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole

403 4-(2-fluorophenyl)-2-(1- isopropylindol-5-yl)thiazole

404 2-(1-isopropylindol-5-yl)-4-[2- (trifluoromethyl)phenyl]thiazole

405 2-(1-isopropylindol-5-yl)-4-(3- methoxyphenyl)thiazole

406 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one

407 2-(1-isopropylpyrrolo[2,3- b]pyridin-5-yl)-4-(o-tolyl)thiazole

408 2-(1-isopropylpyrrolo[2,3- b]pyridin-5-yl)-4-[2-(trifluoromethyl)phenyl]thiazole

409 2-(1-isopropylpyrrolo[3,2- b]pyridin-5-yl)-4-(o-tolyl)thiazole

410 2-(1-isopropylpyrrolo[3,2- b]pyridin-5-yl)-4-(3-methoxyphenyl)thiazole

411 2-(1-isopropyl-1H-pyrrolo[3,2- b]pyridin-5-yl)-4-(2-methoxyphenyl)thiazole

412 4-(2-bromophenyl)-2-(1-isopropyl- 1H-pyrrolo[3,2-b]pyridin-5-yl)thiazole

413 3-(2-bromophenyl)-5-[3-(propan-2- yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazole

414 4-methyl-3-{5-[3-(propan-2-yl)- 3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazol-3-yl}pyridine

415 6-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-3,4-dihydroquinolin-2(1H)-one

416 5-(5-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)indolin-2- one

417 1-cyclobutyl-5-[3-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole

418 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methyibenzo[d]oxazole

419 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methylbenzo[d]oxazole

420 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methylbenzo[d]oxazole

421 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-7-methyIbenzo[d]oxazole

422 2-(isopropylamino)-5-(3-(2-oxo- 2,3-dihydrobenzo[d]oxazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

423 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-1,2,4- oxadiazol-5-yl)benzonitrile

424 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methoxybenzo[d]oxazole

425 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methoxybenzo[d]oxazole

426 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methoxybenzo[d]oxazole

427 4-chloro-2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole

428 4-bromo-2-(1- isopropylbenzotriazol-5-yl)-1,3- benzoxazole

429 7-bromo-2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole

430 N-[(4Z)-2,2-diethyl-6-[3-(pyridin- 3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4- ylidene]hydroxylamine

431 N-[(4E)-2,2-diethyl-6-[3-(pyridin- 3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4- ylidene]hydroxylamine

432 l-(propan-2-yl)-5-{4-[2- (trifluoromethyl)phenyl]-1,3-oxazol-2-yl}-1H-1,2,3- benzotriazole

433 5-[4-(2-methylphenyl)-1,3-oxazol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

434 4-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-5-oxa-3-azatricyclo[8.4.0.02,6]tetradeca- 1(14),2(6),3,10,12-pentaene

435 2-(isopropylamino)-5-(3-(2-oxo- 1,2,3,4-tetrahydroquinolin-7-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

436 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methoxy-4-methyibenzo[d]oxazole

437 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methyibenzo[d]oxazole

438 2-{2-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,3-oxazol-4-yl}aniline

439 5-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

440 5-(3-(2-aminobenzo[d]thiazol-5- yl)-1,2,4-oxadiazol-5-yl)-2-((cyclopropylmethyl)amino)benzo nitrile

441 5-(3-(2-aminobenzo[d]thiazol-5- yl)-1,2,4-oxadiazol-5-yl)-2-(isopropylamino)benzonitrile

442 2-(isopropylamino)-5-(3-(1-oxo- 1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

443 5-(3-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-5-yl)-2-(isopropylamino)benzonitrile

444 2-((cyclopropylmethyl)amino)-5- (3-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-5- yl)benzonitrile

445 6-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)benzo[d]oxazol-2(3H)-one

446 6-(3-(2-aminobenzo[d]thiazol-5- yl)-1,2,4-oxadiazol-5-yl)-2,2-diethylchroman-4-one

447 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methyibenzo[d]oxazole

448 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methylbenzo[d]oxazole

449 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-7-methylbenzo[d]oxazole

450 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methoxybenzo[d]oxazole

451 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methoxybenzo[d]oxazole

452 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methoxybenzo[d]oxazole

453 4-chloro-2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole

454 7-bromo-2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole

455 l-(propan-2-yl)-5-{3-[3- (trifluoromethyl)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole

456 4-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-5-oxa-10-thia-3-azatricyclo[7.3.0.02,6]dodeca- 1(9),2(6),3,11-tetraene

457 4-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-5-oxa-10-thia-3-azatricyclo[7.3.0.02,6]dodeca- 1(9),2(6),3,7,1l-pentaene

458 N-(2-{2-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,3-oxazol-4-yl}phenyl)acetamide

459 l-(propan-2-yl)-5-[4-(thiophen-2- yl)-1,3-oxazol-2-yl]-1H-1,2,3-benzotriazole

460 2-methyl-1-(5-{3-[3- (trifluoromethyl)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazol-1-yl)propan-2-ol

461 4-bromo-2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole

462 5-{4H-chromeno[4,3- d][1,3]oxazol-2-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

463 5-[4-(3-chlorothiophen-2-yl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

464 6-(3-(1H-pyrrol-2-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

465 2,2-diethyl-6-(3-(furan-2-yl)-1,2,4- oxadiazol-5-yl)chroman-4-one

466 6-(3-(1H-imidazol-5-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

467 2,2-diethyl-6-(3-(thiophen-2-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

468 2,2-diethyl-6-(3-(thiophen-3-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

469 6-(3-(1H-pyrazol-4-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

470 6-(3-(1H-pyrazol-5-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

471 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-1,2,4- oxadiazol-5-yl)benzonitrile

472 5-[3-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl]-2-[(2,2,2- trifluoroethyl)amino]benzonitrile

473 5-[5-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

474 l-(propan-2-yl)-5-[4-(pyridin-2-yl)- 1,3-oxazol-2-yl]-1H-1,2,3-benzotriazole

475 2-[(cyclopropylmethyl)amino]-5- [5-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4- oxadiazol-2-yl]benzonitrile

476 2-[(2-fluoroethyl)amino]-5-[-(2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

477 2-[(2,2-difluoroethyl)amino]-5-[5-(2-oxo-1,2,3,4-tetrahydroquinolin- 6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

478 2,2-bis(hydroxymethyl)-6-[3- (pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one

479 3-bromo-2,2-bis(hydroxymethyl)-6- [3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one

480 2,2-dimethyl-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-2,3-dihydro-1-benzofuran-3-one

481 2,2-dimethyl-5-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-2,3-dihydro-1-benzofuran-3-one

482 2,2-bis(hydroxymethyl)-6-[3- (pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one

483 3-bromo-2,2-bis(hydroxymethyl)-6- [3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one

484 5-[5-(2-oxo-2,3-dihydro-1,3- benzoxazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

485 6-(3-(1H-pyrrol-3-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

486 2-[(cyclopropylmethyl)amino]-5- [5-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

487 2-[(2-fluoroethyl)amino]-5-[5-(2- oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

488 2-[(2,2-difluoroethyl)amino]-5-[5- (2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

489 5-[3-(1H-1,3-benzodiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2,2,2-trifluoroethyl)amino]benzonitrile

490 5-[3-(2,5-dimethylfuran-3-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

491 5-[3-(2-methylfuran-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

492 2-methyl-1-{5-[3-(2-methylfuran-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazol-1-yl}propan-2-ol

493 l-{5-[3-(2,5-dimethylfuran-3-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methyipropan- 2-ol

494 2,2-bis(methoxymethyl)-6-{3- (pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one

495 2,2-diethyl-6-(3-(furan-3-yl)-1,2,4- oxadiazol-5-yl)chroman-4-one

496 2-(isopropylamino)-5-(3-(2- oxoindolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

497 2-((cyclopropylmethyl)amino)-5- (3-(2-oxoindolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

498 5-{5-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}-2,1,3-benzoxadiazole

499 5-[3-(2-chloropyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

500 6-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2,2-diethyl-3,4-dihydro-2H-1-benzopyran-4- one

501 l-{5-[3-(1H-1,3-benzodiazol-6-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methyipropan- 2-ol

502 6-(3-(5-aminopyridin-3-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

503 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)oxazolo[5,4-c]pyridine

504 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)oxazolo[5,4-c]pyridine

505 2,2-dimethyl-3-(5-(5-(o-tolyl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol

506 4-isopropoxy-4′-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-[l,1′-biphenyl]-3-carbonitrile

507 4′-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-(isopropylamino)-[1,1′-biphenyl]-3- carbonitrile

508 4-(allylamino)-4′-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-[l,1′- biphenyl]-3-carbonitrile

509 2,2-diethyl-6-(5-(pyridin-3- yl)pyrimidin-2-yl)chroman-4-one

510 2,2-diethyl-6-(5-(pyridin-4- yl)pyrimidin-2-yl)chroman-4-one

511 5-[3-(1H-1,3-benzodiazol-6-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

512 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)acetamide

513 6-(3-(2-aminopyridin-4-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

514 2-(isopropylamino)-5-(3-(1-oxo- 1,2,3,4-tetrahydroisoquinolin-7-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

515 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-7-methoxybenzo[d]oxazole

516 5-[4-(2-methylphenyl)-1H-pyrrol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

517 5-[l-methyl-4-(2-methyiphenyl)- 1H-pyrrol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

518 l-{5-[3-(l,4-dimethyl-1H-pyrazol- 3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol

519 5-[3-(l,4-dimethyl-1H-pyrazol-3- yl)-1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole

520 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2,2-difluoropropyl)amino]benzonitrile

521 2,2-diethyl-6-(3-(quinolin-6-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

522 2,2-diethyl-6-(3-(isoquinolin-6-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

523 3-(5-(5-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2,2-dimethyipropan-1-ol

524 2,2-dimethyl-3-(5-(5-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

525 3-(5-(5-(2-methoxyphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2,2- dimethylpropan-1-ol

526 3-(5-(5-(2-chlorophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2,2- dimethylpropan-1-ol

527 3-(5-(5-(2-ethylphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2,2- dimethylpropan-1-ol

528 2,2-dimethyl-3-(5-(5-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

529 2,2-dimethyl-3-(5-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

530 2,2-diethyl-6-(5-(pyridin-2- yl)pyrimidin-2-yl)chroman-4-one

531 N-{4-[5-(2,2-diethyl-4-oxo-3,4- dihydro-2H-1-benzopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3- methoxyphenyl}acetamide

532 N-(3-methoxy-4-{5-[l-(propan-2- yl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-3- yl}phenyl)acetamide

533 N-{4-[5-(2,1,3-benzoxadiazol-5- yl)-1,2,4-oxadiazol-3-yl]-3-methoxyphenyl}acetamide

534 5-[l-(2-methoxyethyl)-4-(2- methylphenyl)-1H-pyrrol-2-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole

535 2-methyl-7-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one

536 2-methyl-7-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one

537 5-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)nicotinamide

538 N-(5-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-3-yl)acetamide

539 5-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d]imidazol-2(3H)-one

540 2,2-dimethyl-3-(5-(5-(3- methyipyrazin-2-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

541 2,2-dimethyl-3-(5-(5-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

542 5-[4-(2-fluorophenyl)-1H-pyrrol-2- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

543 5-(5-phenyl-1H-pyrrol-3-yl)-1- (propan-2-yl)-1H-1,2,3- benzotriazole

544 5-(1-methyl-5-phenyl-1H-pyrrol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole

545 N-(5-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-3- yl)methanesulfonamide

546 2,2-diethyl-6-(3-(6-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one

547 2,2-diethyl-6-(3-(2-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one

548 2,2-diethyl-6-(3-(6- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one

549 2,2-diethyl-6-(3-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

550 2,2-diethyl-6-(3-(6-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

551 2,2-diethyl-6-(3-(5-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one

552 2,2-diethyl-6-(5-(2-hydroxypyridin-4-yl)pyrimidin-2-yl)chroman-4-one

553 2,2-diethyl-6-[3-(6- methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one

554 2,2-diethyl-6-(3-(thiophen-3-yl)- 1,2,4-oxadiazol-5-yl)-2,3-dihydroquinolin-4(1H)-one

555 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)picolinamide

556 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-2- yl)methanesulfonamide

557 2,2-diethyl-6-(3-(5- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one

558 2,2-diethyl-6-(3-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one

559 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,2,4-oxadiazol-3-yl)chroman-4- one

560 5-[5-(2-methyl-1H-1,3- benzodiazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

561 2-[(2,2-difluoroethyl)amino]-5-{5- (2-methyl-1H-1,3-benzodiazol-5-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

562 2,2-diethyl-6-(3-(2- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one

563 2,2-diethyl-6-(3-(5-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

564 2,2-diethyl-6-(3-(2-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

565 1-isopropyl-5-(5-(2- methoxyphenyl)pyrimidin-2-yl)-1H-benzo[d][1,2,3]triazole

566 5-[4-(2-methoxyphenyl)-1H-pyrrol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

567 2-methyl-1-{5-[3-(1-methyl-1H- imidazol-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1- yl}propan-2-ol

568 N-{4-[5-(2,2-diethyl-4-oxo-3,4- dihydro-2H-1-benzopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3- methoxyphenyl}methanesulfon amide

569 5-[3-(1-methyl-1H-imidazol-2-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

570 2-methyl-1-{5-[3-(1,3-oxazol-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan-2-ol

571 5-[5-(2-methyl-1H-1,3- benzodiazol-5-yl)-1,2,4-oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole

572 5-[5-(1-methyl-1H-1,3- benzodiazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

573 2-[(2,2-difluoroethyl)amino]-5-[5- (1-methyl-1H-1,3-benzodiazol-5-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

574 5-{5-[l-(2-hydroxyethyl)-1H-1,3- benzodiazol-5-yl]-1,3,4-oxadiazol-2-yl}-2-[(propan-2- yl)amino]benzonitrile

575 5-[2-(2-methoxyphenyl)-1,3- oxazol-4-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

576 2-{3-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}aniline

577 l-{5-[3-(1H-indol-7-yl)-1,2,4- oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methylpropan- 2-ol

578 2-[(2,2-difluoroethyl)amino]-5-{5- [l-(2-hydroxyethyl)-1H-1,3-benzodiazol-5-yl]-1,3,4-oxadiazol- 2-yl}benzonitrile

579 5-[5-(1-methyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

580 2-[(2,2-difluoroethyl)amino]-5-[5- (1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

581 [(4-[5-[l-(2-hydroxy-2- methylpropyl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol- 3-yl]phenyl)methyl]phosphonate

582 N-{3-methoxy-4-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]phenyl}acetamide

583 diethyl[(4-{5-[l-(propan-2-yl)-1H- 1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-3- yl}phenyl)methyl]phosphonate

584 N-{4-[5-(2,2-diethyl-4-oxo-3,4- dihydro-2H-1-benzopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3- (trifluoromethoxy)phenyl} acetamide

585 5-[5-(1H-1,3-benzodiazol-4-yl)- 1,3,4-oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile

586 5-[5-(1H-1,3-benzodiazol-4-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2,2-difluoroethyl)amino]benzonitrile

587 N-methyl-2-{2-[1-(propan-2-yl)- 1H-1,2,3-benzotriazol-5-yl]-1,3-oxazol-4-yl}aniline

588 2-ethyl-7-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

589 2-ethyl-7-[3-(pyridin-4-yl)-1,2,4- oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

590 l-{5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methyipropan- 2-ol

591 2,2-diethyl-6-(3-(thiophen-2-yl)- 1,2,4-oxadiazol-5-yl)-2,3-dihydroquinolin-4(1H)-one

592 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N-methylpicolinamide

593 2-methyl-1-(5-(5-(o-tolyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol

594 2,2-diethyl-6-(5-(2- methoxyphenyl)pyrimidin-2- yl)chroman-4-one

595 2-isopropoxy-5-(5-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)pyrimidin-2-yl)benzonitrile

596 5-(5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)pyrimidin-2-yl)-2- (isopropylamino)benzonitrile

597 2-methyl-1-{5-[3-(3-methylpyridin- 4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan-2- ol

598 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-(cyclopropylamino)benzonitrile

599 N-methyl-2-{3-1-(propan-2-yl)- 1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}aniline

600 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(1,3-difluoropropan-2- yl)amino]benzonitrile

601 5-[5-(2-methylphenyl)-1H-pyrrol- 3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

602 2-{3-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}pyridin-3-ol

603 5-(5-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridine-3- sulfonamide

604 2,2-diethyl-6-(3-(3- methoxythiophen-2-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

605 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxypyridin-3-yl)-1,2,4- oxadiazole

606 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxypyridin-4-yl)-1,2,4- oxadiazole

607 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxypyridin-3-yl)-1,2,4- oxadiazole

608 4-{3-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}-2,3-dihydro-1H-inden-1-one

609 2-methyl-2-(5-(5-(o-tolyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- l-ol

610 2-(5-(5-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2-methylpropan-1-ol

611 2-methyl-2-(5-(5-(3- methylthiophen-2-yl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol

612 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxypyridin-2-yl)-1,2,4- oxadiazole

613 7-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin-2-one

614 7-[3-(2-methoxyphenyl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin-2-one

615 N,N-dimethyl-2-{3-[l-(propan-2- yl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}aniline

616 4-(5-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridine-2- sulfonamide

617 2,2-diethyl-6-(3-(pyrazin-2-yl)- 1,2,4-oxadiazol-5-yl)chroman-4- one

618 2-(5-(5-(2-chlorophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol

619 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-methoxypyridin-3-yl)-1,2,4- oxadiazole

620 2,2-diethyl-6-(3-(pyrimidin-5-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

621 2,2-diethyl-6-(3-(pyridazin-3-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

622 6-(3-(benzo[d]oxazol-6-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one

623 2-(5-(5-(2-methoxyphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol

624 2-(5-(5-(2-ethyiphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol

625 2-methyl-2-(5-(5-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- l-ol

626 2-methyl-2-(5-(5-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

627 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methoxypyridin-2-yl)-1,2,4- oxadiazole

628 2-(isopropylamino)-5-(5-(2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)benzonitrile

629 7-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin- 2-one

630 2-propyl-7-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one

631 2,2-diethyl-6-[5-(5-fluoropyridin-3- yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one

632 2,2-diethyl-6-[5-(5-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one

633 2-butyl-7-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

634 2-[(1-hydroxy-2-methylpropan-2- yl)amino]-5-[5-(1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

635 2-[(2,2-difluoro-3- hydroxypropyl)amino]-5-[5-(1-methyl-1H-1,3-benzodiazol-6-yl)- 1,3,4-oxadiazol-2-yl]benzonitrile

636 4-{3-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}-2,3-dihydro-1H-inden-1-ol

637 5-[5-(2-oxo-2,3-dihydro-1,3- benzoxazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

638 5-[5-(1-oxo-1,2,3,4- tetrahydroisoquinolin-7-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

639 2,2-diethyl-6-(3-(pyrimidin-4-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

640 2,2-diethyl-6-(3-(pyrimidin-2-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

641 2-methyl-2-(5-(5-(3-methylpyrazin- 2-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol

642 2-(5-(5-(1H-benzo[d]imidazol-6- yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol

643 2-(5-(5-(2-fluoropyridin-3-yl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol

644 2-methyl-2-(5-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- l-ol

645 7-[3-(1H-pyrazol-4-yl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin-2-one

646 l-(propan-2-yl)-5-[3-(1H-pyrazol- 4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole

647 l-{5-[3-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol

648 2,2-diethyl-6-(3-(pyridazin-4-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one

649 2-(isopropylamino)-5-(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)benzonitrile

650 5-(3-(1-(1-hydroxy-2- methylpropan-2-yl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazol-5-yl)indolin-2-one

651 2-[(2,2-difluoroethyl)amino]-5-{5- (2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

652 2-[(2,2-difluoroethyl)amino]-5-{5- (1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)-1,3,4- oxadiazol-2-yl]benzonitrile

653 2-methyl-1-{6-[3-(1H-pyrazol-4- yl)-1,2,4-oxadiazol-5-yl]-3H-indazol-3-yl}propan-2-ol

654 1-(5-(5-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2-methylpropan-2-ol

655 2-methyl-1-(5-(5-(3- methylthiophen-2-yl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol

656 l-(5-(5-(2-methoxyphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-2-ol

657 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methoxypyridin-4-yl)-1,2,4- oxadiazole

662 l-{5-[3-(2-methoxy-4- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol

663 2,2-diethyl-6-[5-(2-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one

664 2,2-diethyl-6-[5-(5-hydroxypyridin- 3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one

665 5-[5-(1-tert-butyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

666 2,2-diethyl-N-[(1E)- (hydroxyimino)[2- (trifluoromethyl)pyridin-3-yl]methyl]-4-oxo-3,4-dihydro-2H- 1-benzopyran-7-carboxamide

667 2-(isopropylamino)-5-(5-(pyridin- 4-yl)-1,3,4-oxadiazol-2-yl)benzonitrile

668 2-methyl-1-(5-(5-(3-methylpyrazin- 2-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol

669 l-(5-(5-(2-chlorophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-2-ol

670 1-(5-(5-(2-ethylphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-2-ol

671 2-methyl-1-(5-(5-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol

672 2-methyl-1-(5-(5-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 2-ol

673 2-methyl-1-(5-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 2-ol

675 l-{5-[3-(2,6-dimethylpyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methyipropan- 2-ol

676 5-[5-(1-tert-butyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(2,2- difluoroethyl)amino]benzonitrile

677 2,2-diethyl-6-[3-(1-methyl-1H- indol-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4- one

678 5-[3-(1-methyl-1H-indol-3-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

679 5-[3-(2,6-dimethylpyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

680 2-methyl-1-{5-[3-(4-methyl-1,3- oxazol-5-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan- 2-ol

681 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(4-methoxypyridin-3-yl)-1,2,4- oxadiazole

682 5-[3-(1-methyl-1H-indol-3-yl)- 1,2,4-oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile

683 5-[3-(4-methyl-1,3-oxazol-5-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

684 2,2-diethyl-6-[3-(1-ethyl-1H-indol- 3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one

685 5-[5-(1-methyl-1H-1,3- benzodiazol-4-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

686 2-[(2,2-difluoroethyl)amino]-5-{5- (1-methyl-1H-1,3-benzodiazol-4-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

687 4-{5-[l-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}-2,3-dihydro-1H-inden-1-one

688 2-((2,2-difluoroethyl)amino)-5-(5- (pyridin-4-yl)-1,3,4-oxadiazol-2-yl)benzonitrile

689 5-(5-(1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)-2-(isopropylamino)benzonitrile

690 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methyipyridin-2-yl)-1,2,4- oxadiazole

691 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-methylpyridin-3-yl)-1,2,4- oxadiazole

692 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methyipyridin-4-yl)-1,2,4- oxadiazole

693 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methyipyridin-2-yl)-1,2,4- oxadiazole

694 5-{5-[l-(propan-2-yl)-1H-1,3- benzodiazol-6-yl]-1,3,4-oxadiazol-2-yl}-2-[(propan-2- yl)amino]benzonitrile

695 5-{5-(1-ethyl-1H-1,3-benzodiazol- 6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile

696 2,2-diethyl-6-[5-(2- methoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1- benzopyran-4-one

697 2,2-diethyl-6-{5-[4- (trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-3,4-dihydro- 2H-1-benzopyran-4-one

698 2,2-diethyl-6-[5-(2-fluoropyridin-3- yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one

699 2,2-diethyl-6-{5-[2- (trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-3,4-dihydro- 2H-1-benzopyran-4-one

700 6-[5-(5-aminopyridin-3-yl)-1,2,4- oxadiazol-3-yl]-2,2-diethyl-3,4-dihydro-2H-1-benzopyran-4-one

701 2-[(2,2-difluoroethyl)amino]-5-{5- [l-(propan-2-yl)-1H-1,3-benzodiazol-6-yl]-1,3,4-oxadiazol- 2-yl}benzonitrile

702 2-[(2,2-difluoroethyl)amino]-5-[5-(1-ethyl-1H-1,3-benzodiazol-6-yl)- 1,3,4-oxadiazol-2-yl]benzonitrile

703 5-[3-(1-ethyl-1H-indol-3-yl)-1,2,4- oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile

704 2-[(2-fluoroethyl)amino]-5-[5-(1- methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

705 5-[5-(1-methyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-1H-indazol-3-amine

706 2-[(2,2-difluoropropyl)amino]-5-[5- (1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

707 2-(cyclopropylamino)-5-[5-(1- methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

708 2-[(1,3-difluoropropan-2- yl)amino]-5-[5-(1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

709 5-[3-(3-methoxypyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole

710 5-[5-(1,2-dimethyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile

711 2-[(2,2-difluoroethyl)amino]-5-[5- (1,2-dimethyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile

712 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2,2,2-trifluoroethyl)amino]benzonitrile

713 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2-fluoroethyl)amino]benzonitrile

718 2,2-diethyl-6-(5-(2-methylpyridin- 3-yl)-1,3,4-oxadiazol-2-yl)chroman-4-one

719 2,2-diethyl-6-(5-(2-methylpyridin- 3-yl)-1,3,4-thiadiazol-2-yl)chroman-4-one

720 2,2-diethyl-6-(5-(2-fluoropyridin-3-yl)-1,3,4-thiadiazol-2-yl)chroman- 4-one

721 5-(5-(1H-indol-5-yl)-1,3,4- oxadiazol-2-yl)-2-(isopropylamino)benzonitrile

724 2,2-diethyl-6-(5-(5-methylpyridin- 3-yl)-1,3,4-thiadiazol-2-yl)chroman-4-one

725 2,2-diethyl-6-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)chroman-4- one

726 2-(cyclopropylmethylamino)-5-[3- (2-oxo-3H-1,3-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile

727 2-((cyclopropylmethyl)amino)-5- (3-(1-oxoisoindolin-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile

728 2-(isopropylamino)-5-(3-(2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1,2,4-oxadiazol-5- yl)benzonitrile

729 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1,2,4- oxadiazol-5-yl)benzonitrile

730 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile

730 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile

731 N-[4-(5-{3-cyano-4-[(propan-2- yl)amino]phenyl}-1,2,4-oxadiazol-3-yl)-3-methoxyphenyl]acetamide

732 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2,2-difluoroethyl)amino]benzonitrile

733 2-[(2,2-difluoroethyl)amino]-5-{5-(isoquinolin-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile

734 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(cyclopropylmethyl)amino]benzo nitrile

735 5-[5-(isoquinolin-6-yl)-1,3,4- oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile

736 2-[(propan-2-yl)amino]-5-[5- (quinolin-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

736 2-[(propan-2-yl)amino]-5-[5- (quinolin-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

737 2-(isopropylamino)-5-(5-(pyridin- 3-yl)pyrimidin-2-yl)benzonitrile

738 2-isopropoxy-5-(5-(pyridin-3- yl)pyrimidin-2-yl)benzonitrile

739 2-(isopropylamino)-5-(5-(pyridin- 4-yl)pyrimidin-2-yl)benzonitrile

740 2-isopropoxy-5-(5-(pyridin-4- yl)pyrimidin-2-yl)benzonitrile

741 2-(isopropylamino)-5-(5-(pyridin- 2-yl)pyrimidin-2-yl)benzonitrile

742 2-isopropoxy-5-(5-(pyridin-2- yl)pyrimidin-2-yl)benzonitrile

743 5-(5-(2-hydroxypyridin-4- yl)pyrimidin-2-yl)-2-(isopropylamino)benzonitrile

744 5-(5-(2-hydroxypyridin-4- yl)pyrimidin-2-yl)-2-isopropoxybenzonitrile

745 2-isopropoxy-5-(5-(2- methoxyphenyl)pyrimidin-2- yl)benzonitrile

746 5-(5-(2,2-diethyl-4-oxochroman-6- yl)pyrimidin-2-yl)-2-(isopropylamino)benzonitrile

747 2-(isopropylamino)-5-(5-(2- methoxyphenyl)pyrimidin-2-yl)benzonitrile

748 5-(5-(benzo[c][1,2,5]oxadiazol-5- yl)pyrimidin-2-yl)-2-isopropoxybenzonitrile

749 5-(5-(benzo[c][1,2,5]oxadiazol-5- yl)pyrimidin-2-yl)-2-(isopropylamino)benzonitrile

750 N-isopropyl-4-(5-(2- methoxyphenyl)pyrimidin-2-yl)-2-(trifluoromethyl)aniline

751 2-(4-isopropoxy-3- (trifluoromethyl)phenyl)-5-(2-methoxyphenyl)pyrimidine

752 2-(4-isopropoxy-3- (trifluoromethyl)phenyl)-5-(pyridin-4-yl)pyrimidine

Although the compounds described herein may be shown with specificstereochemistries around certain atoms, such as cis or trans, thecompounds can also be made in the opposite orientation or in a racemicmixture. Such isomers or racemic mixtures are encompassed by the presentdisclosure. Additionally, although the compounds are shown collectivelyin a table, any compounds, or a pharmaceutically acceptable saltthereof, can be chosen from the table and used in the embodimentsprovided for herein.

In some embodiments, pharmaceutical compositions comprising a compoundor pharmaceutically acceptable salt thereof of any compound describedherein are provided.

The compounds described herein can be made according to the methodsdescribed herein and in the examples. The methods described herein canbe adapted based upon the compounds desired and described herein. Insome embodiments, the method is made according to the following schemes,wherein Q and L are the substituents as shown and described herein andwould be apparent to one of skill in the art based upon the presentdisclosure. In some embodiments, this method can be used to make one ormore compounds as described herein and will be apparent to one of skillin the art which compounds can be made according to the methodsdescribed herein.

The conditions and temperatures can be varied, such as shown in theexamples described herein. These schemes are non-limiting syntheticschemes and the synthetic routes can be modified as would be apparent toone of skill in the art reading the present specification. The compoundscan also be prepared according to the schemes described in the Examples.

The compounds can be used to modulate the S₁P₁ receptor. Thus, in someembodiments, the compounds can be referred to as S₁P₁ receptormodulating compounds.

Although the compounds in the tables above or in the examples sectionare shown with specific stereochemistries around certain atoms, such ascis or trans, the compounds can also be made in the opposite orientationor in a racemic mixture.

In some embodiments, the present embodiments provide pharmaceuticalcompositions comprising a compound or pharmaceutically acceptable saltthereof any compound described herein.

The compounds described herein can be made according to the methodsdescribed herein and in the examples. The methods described herein canbe adapted based upon the compounds desired and described herein. Insome embodiments, the method is made according to the following schemes,wherein Q and L are the substituents as shown and described herein andwould be apparent to one of skill in the art based upon the presentdisclosure. In some embodiments, this method can be used to make one ormore compounds as described herein and will be apparent to one of skillin the art which compounds can be made according to the methodsdescribed herein.

In some embodiments, the compounds are made according to schemesdescribed in the examples. The schemes can be used to prepare thecompounds and compositions described herein. The conditions andtemperatures can be varied, or the synthesis can be performed accordingto the examples described herein with modifications that are readilyapparent based upon the compound being synthesized.

The conditions and temperatures can be varied, such as shown in theexamples described herein. These schemes are non-limiting syntheticschemes and the synthetic routes can be modified as would be apparent toone of skill in the art reading the present specification.

The compounds described herein can be administered in any conventionalmanner by any route where they are active. Administration can besystemic, topical, or oral. For example, administration can be, but isnot limited to, parenteral, subcutaneous, intravenous, intramuscular,intraperitoneal, transdermal, oral, buccal, sublingual, or ocularroutes, or intravaginal, by inhalation, by depot injections, or byimplants. The mode of administration can depend on the conditions ordisease to be targeted or treated. The selection of the specific routeof administration can be selected or adjusted by the clinician accordingto methods known to the clinician to obtain the desired clinicalresponse.

In some embodiments, it may be desirable to administer one or morecompounds, or a pharmaceutically acceptable salt thereof, locally to anarea in need of treatment. This may be achieved, for example, and not byway of limitation, by local infusion during surgery, topicalapplication, e.g., in conjunction with a wound dressing after surgery,by injection, by means of a catheter, by means of a suppository, or bymeans of an implant, wherein the implant is of a porous, non-porous, orgelatinous material, including membranes, such as sialastic membranes,or fibers.

The compounds described herein can be administered either alone or incombination (concurrently or serially) with other pharmaceuticals. Forexample, the compounds can be administered in combination with otheranalgesics, antidepressants, anti-anxiety compounds, anti-overactivebladder compounds, compounds for the treatment of cancer, and the like.Examples of other pharmaceuticals or medicaments are known to one ofskill in the art and include, but are not limited to those describedherein.

The means and methods for administration are known in the art and anartisan can refer to various pharmacologic references for guidance (see,for example, Modern Pharmaceutics, Banker & Rhodes, Marcel Dekker, Inc.(1979); and Goodman & Gilman's The Pharmaceutical Basis of Therapeutics,6th Edition, MacMillan Publishing Co., New York (1980)).

The amount of compound to be administered is that amount which istherapeutically effective. The dosage to be administered will depend onthe characteristics of the subject being treated, e.g., the particularanimal treated, age, weight, health, types of concurrent treatment, ifany, and frequency of treatments, and can be easily determined by one ofskill in the art (e.g., by the clinician). The standard dosing forprotamine can be used and adjusted (i.e., increased or decreased)depending upon the factors described above. The selection of thespecific dose regimen can be selected or adjusted or titrated by theclinician according to methods known to the clinician to obtain thedesired clinical response.

The amount of a compound described herein that will be effective in thetreatment and/or prevention of a particular disease, condition, ordisorder will depend on the nature and extent of the disease, condition,or disorder, and can be determined by standard clinical techniques. Inaddition, in vitro or in vivo assays may optionally be employed to helpidentify optimal dosage ranges. The precise dose to be employed in thecompositions will also depend on the route of administration, and theseriousness of the disorder, and should be decided according to thejudgment of the practitioner and each patient's circumstances. However,a suitable dosage range for oral administration is, generally, fromabout 0.001 milligram to about 200 milligrams per kilogram body weight,from about 0.01 milligram to about 100 milligrams per kilogram bodyweight, from about 0.01 milligram to about 70 milligrams per kilogrambody weight, from about 0.1 milligram to about 50 milligrams perkilogram body weight, from 0.5 milligram to about 20 milligrams perkilogram body weight, or from about 1 milligram to about 10 milligramsper kilogram body weight. In some embodiments, the oral dose is about 5milligrams per kilogram body weight.

In some embodiments, suitable dosage ranges for intravenous (i.v.)administration are from about 0.01 mg to about 500 mg per kg bodyweight, from about 0.1 mg to about 100 mg per kg body weight, from about1 mg to about 50 mg per kg body weight, or from about 10 mg to about 35mg per kg body weight. Suitable dosage ranges for other modes ofadministration can be calculated based on the forgoing dosages as knownby those skilled in the art. For example, recommended dosages forintranasal, transmucosal, intradermal, intramuscular, intraperitoneal,subcutaneous, epidural, sublingual, intracerebral, intravaginal,transdermal administration or administration by inhalation are in therange of from about 0.001 mg to about 200 mg per kg of body weight, fromabout 0.01 mg to about 100 mg per kg of body weight, from about 0.1 mgto about 50 mg per kg of body weight, or from about 1 mg to about 20 mgper kg of body weight. Effective doses may be extrapolated fromdose-response curves derived from in vitro or animal model test systems.Such animal models and systems are well known in the art.

The compounds described herein can be formulated for parenteraladministration by injection, such as by bolus injection or continuousinfusion. The compounds can be administered by continuous infusionsubcutaneously over a period of about 15 minutes to about 24 hours.Formulations for injection can be presented in unit dosage form, such asin ampoules or in multi-dose containers, with an optionally addedpreservative. The compositions can take such forms as suspensions,solutions or emulsions in oily or aqueous vehicles, and can containformulatory agents such as suspending, stabilizing and/or dispersingagents. In some embodiments, the injectable is in the form ofshort-acting, depot, or implant and pellet forms injected subcutaneouslyor intramuscularly. In some embodiments, the parenteral dosage form isthe form of a solution, suspension, emulsion, or dry powder.

For oral administration, the compounds described herein can beformulated by combining the compounds with pharmaceutically acceptablecarriers well known in the art. Such carriers enable the compounds to beformulated as tablets, pills, dragees, capsules, emulsions, liquids,gels, syrups, caches, pellets, powders, granules, slurries, lozenges,aqueous or oily suspensions, and the like, for oral ingestion by apatient to be treated. Pharmaceutical preparations for oral use can beobtained by, for example, adding a solid excipient, optionally grindingthe resulting mixture, and processing the mixture of granules, afteradding suitable auxiliaries, if desired, to obtain tablets or drageecores. Suitable excipients include, but are not limited to, fillers suchas sugars, including, but not limited to, lactose, sucrose, mannitol,and sorbitol; cellulose preparations such as, but not limited to, maizestarch, wheat starch, rice starch, potato starch, gelatin, gumtragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodiumcarboxymethylcellulose, and polyvinylpyrrolidone (PVP). If desired,disintegrating agents can be added, such as, but not limited to, thecross-linked polyvinyl pyrrolidone, agar, or alginic acid or a saltthereof such as sodium alginate.

Orally administered compositions can contain one or more optionalagents, for example, sweetening agents such as fructose, aspartame orsaccharin; flavoring agents such as peppermint, oil of wintergreen, orcherry; coloring agents; and preserving agents, to provide apharmaceutically palatable preparation. Moreover, where in tablet orpill form, the compositions may be coated to delay disintegration andabsorption in the gastrointestinal tract thereby providing a sustainedaction over an extended period of time. Selectively permeable membranessurrounding an osmotically active driving compound are also suitable fororally administered compounds. Oral compositions can include standardvehicles such as mannitol, lactose, starch, magnesium stearate, sodiumsaccharine, cellulose, magnesium carbonate, etc. Such vehicles aresuitably of pharmaceutical grade.

Dragee cores can be provided with suitable coatings. For this purpose,concentrated sugar solutions can be used, which can optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions, and suitable organicsolvents or solvent mixtures. Dyestuffs or pigments can be added to thetablets or dragee coatings for identification or to characterizedifferent combinations of active compound doses.

Pharmaceutical preparations which can be used orally include, but arenot limited to, push-fit capsules made of gelatin, as well as soft,sealed capsules made of gelatin and a plasticizer, such as glycerol orsorbitol. The push-fit capsules can contain the active ingredients inadmixture with filler such as lactose, binders such as starches, and/orlubricants such as talc or magnesium stearate and, optionally,stabilizers. In soft capsules, the active compounds can be dissolved orsuspended in suitable liquids, such as fatty oils, liquid paraffin, orliquid polyethylene glycols. In addition, stabilizers can be added.

For buccal administration, the compositions can take the form of tabletsor lozenges formulated in a conventional manner.

For administration by inhalation, the compounds described herein can bedelivered in the form of an aerosol spray presentation from pressurizedpacks or a nebulizer, with the use of a suitable propellant, such asdichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In thecase of a pressurized aerosol, the dosage unit can be determined byproviding a valve to deliver a metered amount. Capsules and cartridgesof, such as gelatin for use in an inhaler or insufflator, can beformulated containing a powder mix of the compound and a suitable powderbase such as lactose or starch.

The compounds described herein can also be formulated in rectalcompositions such as suppositories or retention enemas, such ascontaining conventional suppository bases such as cocoa butter or otherglycerides. The compounds described herein can also be formulated invaginal compositions such as vaginal creams, suppositories, pessaries,vaginal rings, and intrauterine devices.

In transdermal administration, the compounds can be applied to aplaster, or can be applied by transdermal, therapeutic systems that areconsequently supplied to the organism. In some embodiments, thecompounds are present in creams, solutions, powders, fluid emulsions,fluid suspensions, semi-solids, ointments, pastes, gels, jellies, andfoams, or in patches containing any of the same.

The compounds described herein can also be formulated as a depotpreparation. Such long acting formulations can be administered byimplantation (for example subcutaneously or intramuscularly) or byintramuscular injection. Depot injections can be administered at about 1to about 6 months or longer intervals. Thus, for example, the compoundscan be formulated with suitable polymeric or hydrophobic materials (forexample as an emulsion in an acceptable oil) or ion exchange resins, oras sparingly soluble derivatives, for example, as a sparingly solublesalt.

In some embodiments, the compounds can be delivered in a controlledrelease system. In one embodiment, a pump may be used (see Langer,supra; Sefton, CRC Crit. Ref. Biomed. Eng., 1987, 14, 201; Buchwald etal., Surgery, 1980, 88, 507 Saudek et al., N. Engl. J. Med., 1989, 321,574). In some embodiments, polymeric materials can be used (see MedicalApplications of Controlled Release, Langer and Wise (eds.), CRC Pres.,Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug ProductDesign and Performance, Smolen and Ball (eds.), Wiley, New York (1984);Ranger et al., J. Macromol. Sci. Rev. Macromol. Chem., 1983, 23, 61;see, also Levy et al., Science, 1985, 228, 190; During et al., Ann.Neurol., 1989, 25, 351; Howard et al., J. Neurosurg., 1989, 71, 105). Inyet another embodiment, a controlled-release system can be placed inproximity of the target of the compounds described herein, such as theliver, thus requiring only a fraction of the systemic dose (see, e.g.,Goodson, in Medical Applications of Controlled Release, supra, vol. 2,pp. 115-138 (1984)). Other controlled-release systems discussed in thereview by Langer, Science, 1990, 249, 1527-1533) may be used.

It is also known in the art that the compounds can be contained in suchformulations with pharmaceutically acceptable diluents, fillers,disintegrants, binders, lubricants, surfactants, hydrophobic vehicles,water soluble vehicles, emulsifiers, buffers, humectants, moisturizers,solubilizers, preservatives and the like. The pharmaceuticalcompositions can also comprise suitable solid or gel phase carriers orexcipients. Examples of such carriers or excipients include, but are notlimited to, calcium carbonate, calcium phosphate, various sugars,starches, cellulose derivatives, gelatin, and polymers such aspolyethylene glycols. In some embodiments, the compounds describedherein can be used with agents including, but not limited to, topicalanalgesics (e.g., lidocaine), barrier devices (e.g., GelClair), orrinses (e.g., Caphosol).

In some embodiments, the compounds described herein can be delivered ina vesicle, in particular a liposome (see, Langer, Science, 1990, 249,1527-1533; Treat et al., in Liposomes in the Therapy of InfectiousDisease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York,pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generallyibid.).

Suitable compositions include, but are not limited to, oral non-absorbedcompositions. Suitable compositions also include, but are not limited tosaline, water, cyclodextrin solutions, and buffered solutions of pH 3-9.

The compounds described herein, or pharmaceutically acceptable saltsthereof, can be formulated with numerous excipients including, but notlimited to, purified water, propylene glycol, PEG 400, glycerin, DMA,ethanol, benzyl alcohol, citric acid/sodium citrate (pH3), citricacid/sodium citrate (pH5), tris(hydroxymethyl)amino methane HCl (pH7.0),0.9% saline, and 1.2% saline, and any combination thereof. In someembodiments, excipient is chosen from propylene glycol, purified water,and glycerin.

In some embodiments, the formulation can be lyophilized to a solid andreconstituted with, for example, water prior to use.

When administered to a mammal (e.g., to an animal for veterinary use orto a human for clinical use) the compounds can be administered inisolated form.

When administered to a human, the compounds can be sterile. Water is asuitable carrier when the compound of Formula I is administeredintravenously. Saline solutions and aqueous dextrose and glycerolsolutions can also be employed as liquid carriers, particularly forinjectable solutions. Suitable pharmaceutical carriers also includeexcipients such as starch, glucose, lactose, sucrose, gelatin, malt,rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate,talc, sodium chloride, dried skim milk, glycerol, propylene, glycol,water, ethanol and the like. The present compositions, if desired, canalso contain minor amounts of wetting or emulsifying agents, or pHbuffering agents.

The compositions described herein can take the form of a solution,suspension, emulsion, tablet, pill, pellet, capsule, capsule containinga liquid, powder, sustained-release formulation, suppository, aerosol,spray, or any other form suitable for use. Examples of suitablepharmaceutical carriers are described in Remington's PharmaceuticalSciences, A. R. Gennaro (Editor) Mack Publishing Co.

In some embodiments, the compounds are formulated in accordance withroutine procedures as a pharmaceutical composition adapted foradministration to humans. Typically, compounds are solutions in sterileisotonic aqueous buffer. Where necessary, the compositions can alsoinclude a solubilizing agent. Compositions for intravenousadministration may optionally include a local anesthetic such aslidocaine to ease pain at the site of the injection. Generally, theingredients are supplied either separately or mixed together in unitdosage form, for example, as a dry lyophilized powder or water freeconcentrate in a hermetically sealed container such as an ampoule orsachette indicating the quantity of active agent. Where the compound isto be administered by infusion, it can be dispensed, for example, withan infusion bottle containing sterile pharmaceutical grade water orsaline. Where the compound is administered by injection, an ampoule ofsterile water for injection or saline can be provided so that theingredients may be mixed prior to administration.

The pharmaceutical compositions can be in unit dosage form. In suchform, the composition can be divided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation, the package containing discrete quantities ofthe preparations, for example, packeted tablets, capsules, and powdersin vials or ampules. The unit dosage form can also be a capsule, cachet,or tablet itself, or it can be the appropriate number of any of thesepackaged forms.

In some embodiments, a composition is in the form of a liquid whereinthe active agent (i.e., one of the facially amphiphilic polymers oroligomers disclosed herein) is present in solution, in suspension, as anemulsion, or as a solution/suspension. In some embodiments, the liquidcomposition is in the form of a gel. In other embodiments, the liquidcomposition is aqueous. In other embodiments, the composition is in theform of an ointment.

In some embodiments, the composition is in the form of a solid article.For example, in some embodiments, the ophthalmic composition is a solidarticle that can be inserted in a suitable location in the eye, such asbetween the eye and eyelid or in the conjunctival sac, where it releasesthe active agent as described, for example, U.S. Pat. Nos. 3,863,633;3,867,519; 3,868,445; 3,960,150; 3,963,025; 4,186,184; 4,303,637;5,443,505; and 5,869,079. Release from such an article is usually to thecornea, either via the lacrimal fluid that bathes the surface of thecornea, or directly to the cornea itself, with which the solid articleis generally in intimate contact. Solid articles suitable forimplantation in the eye in such fashion are generally composed primarilyof polymers and can be bioerodible or non-bioerodible. Bioerodiblepolymers that can be used in the preparation of ocular implants carryingone or more compounds include, but are not limited to, aliphaticpolyesters such as polymers and copolymers of poly(glycolide),poly(lactide), poly(epsilon-caprolactone), poly-(hydroxybutyrate) andpoly(hydroxyvalerate), polyamino acids, polyorthoesters, polyanhydrides,aliphatic polycarbonates and polyether lactones. Suitablenon-bioerodible polymers include silicone elastomers.

The compositions described herein can contain preservatives. Suitablepreservatives include, but are not limited to, mercury-containingsubstances such as phenylmercuric salts (e.g., phenylmercuric acetate,borate and nitrate) and thimerosal; stabilized chlorine dioxide;quaternary ammonium compounds such as benzalkonium chloride,cetyltrimethylammonium bromide and cetylpyridinium chloride;imidazolidinyl urea; parabens such as methylparaben, ethylparaben,propylparaben and butylparaben, and salts thereof; phenoxyethanol;chlorophenoxyethanol; phenoxypropanol; chlorobutanol; chlorocresol;phenylethyl alcohol; disodium EDTA; and sorbic acid and salts thereof.

Optionally, one or more stabilizers can be included in the compositionsto enhance chemical stability where required. Suitable stabilizersinclude, but are not limited to, chelating agents or complexing agents,such as, for example, the calcium complexing agent ethylene diaminetetraacetic acid (EDTA). For example, an appropriate amount of EDTA or asalt thereof, e.g., the disodium salt, can be included in thecomposition to complex excess calcium ions and prevent gel formationduring storage. EDTA or a salt thereof can suitably be included in anamount of about 0.010% to about 0.5%. In those embodiments containing apreservative other than EDTA, the EDTA or a salt thereof, moreparticularly disodium EDTA, can be present in an amount of about 0.025%to about 0.1% by weight.

One or more antioxidants can also be included in the compositions.Suitable antioxidants include, but are not limited to, ascorbic acid,sodium metabisulfite, sodium bisulfite, acetylcysteine,polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol,methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium,sorbic acid, or other agents know to those of skill in the art. Suchpreservatives are typically employed at a level of from about 0.001% toabout 1.0% by weight.

In some embodiments, the compounds are solubilized at least in part byan acceptable solubilizing agent. Certain acceptable nonionicsurfactants, for example polysorbate 80, can be useful as solubilizingagents, as can ophthalmically acceptable glycols, polyglycols, e.g.,polyethylene glycol 400 (PEG-400), and glycol ethers.

Suitable solubilizing agents for solution and solution/suspensioncompositions are cyclodextrins. Suitable cyclodextrins can be chosenfrom α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, alkylcyclodextrins(e.g., methyl-β-cyclodextrin, dimethyl-β-cyclodextrin,diethyl-β-cyclodextrin), hydroxyalkylcyclodextrins (e.g.,hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin),carboxy-alkylcyclodextrins (e.g., carboxymethyl-β-cyclodextrin),sulfoalkylether cyclodextrins (e.g., sulfobutylether-β-cyclodextrin),and the like. Ophthalmic applications of cyclodextrins have beenreviewed in Rajewski et al., Journal of Pharmaceutical Sciences, 1996,85, 1155-1159.

In some embodiments, the composition optionally contains a suspendingagent. For example, in those embodiments in which the composition is anaqueous suspension or solution/suspension, the composition can containone or more polymers as suspending agents. Useful polymers include, butare not limited to, water-soluble polymers such as cellulosic polymers,for example, hydroxypropyl methylcellulose, and water-insoluble polymerssuch as cross-linked carboxyl-containing polymers.

One or more acceptable pH adjusting agents and/or buffering agents canbe included in the compositions, including acids such as acetic, boric,citric, lactic, phosphoric and hydrochloric acids; bases such as sodiumhydroxide, sodium phosphate, sodium borate, sodium citrate, sodiumacetate, sodium lactate and tris-hydroxymethylaminomethane; and bufferssuch as citrate/dextrose, sodium bicarbonate and ammonium chloride. Suchacids, bases and buffers are included in an amount required to maintainpH of the composition in an acceptable range.

One or more acceptable salts can be included in the compositions in anamount required to bring osmolality of the composition into anacceptable range. Such salts include, but are not limited to, thosehaving sodium, potassium or ammonium cations and chloride, citrate,ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate orbisulfite anions. In some embodiments, salts include sodium chloride,potassium chloride, sodium thiosulfate, sodium bisulfite and ammoniumsulfate. In some embodiments, the salt is sodium chloride.

Optionally, one or more acceptable surfactants, preferably nonionicsurfactants, or co-solvents can be included in the compositions toenhance solubility of the components of the compositions or to impartphysical stability, or for other purposes. Suitable nonionic surfactantsinclude, but are not limited to, polyoxyethylene fatty acid glyceridesand vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil;and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol10, octoxynol 40; polysorbate 20, 60 and 80;polyoxyethylene/polyoxypropylene surfactants (e.g., Pluronic® F-68, F84and P-103); cyclodextrin; or other agents known to those of skill in theart. Typically, such co-solvents or surfactants are employed in thecompositions at a level of from about 0.010% to about 2% by weight.

In some embodiments, pharmaceutical packs or kits comprising one or morecontainers filled with one or more compounds described herein areprovided. Optionally associated with such container(s) can be a noticein the form prescribed by a governmental agency regulating themanufacture, use or sale of pharmaceuticals or biological products,which notice reflects approval by the agency of manufacture, use or salefor human administration for treating a condition, disease, or disorderdescribed herein. In some embodiments, the kit contains more than onecompound described herein. In some embodiments, the kit comprises acompound described herein in a single injectable dosage form, such as asingle dose within an injectable device such as a syringe with a needle.

Modulation of the S₁P₁ receptor has been found to be a target for thetreatment of certain disorders. The compounds described herein can beused in the preparation of a medicament or pharmaceutical composition totreat and/or prevent neuropathy, pain, inflammatory pain, cancer pain,bone cancer pain, tumor pain, pain or neuropathy resulting fromdisorders of the central or peripheral nervous system, neuropathic pain,pain associated with dysesthesia, allodynia or hypersensitivity,chemotherapy induced neuropathic pain, chemotherapy induced peripheralneuropathy, diabetic neuropathy or pain associated with diabeticneuropathy, post herpetic neuralgia or pain associated with postherpetic neuralgia, hiv-related neuropathy or pain associated withhiv-related neuropathy, pain or neuropathy resulting from spinal cordinjury, nerve lesions, tissue injury, ms, stroke, nutritionaldeficiencies, or toxins, fibromyalgia or pain associated withfibromyalgia, phantom limb pain, complex regional pain syndrome, carpaltunnel syndrome, sciatica, pudendal neuralgia, back or neck pain,including those resulting from degenerative disk disease, trigeminalneuralgia, headache disorders including, but not limited to migraine andcluster headache, orofacial pain, odontalgia, temporomandibular jointpain, endometrial pain, osteoarthritis, rheumatoid arthritis, atypicalodontalgia, interstitial cystitis, uveitis, or any combination thereof.

Embodiments disclosed herein also provide for the compounds for the useof treating or preventing neuropathy, pain, inflammatory pain, cancerpain, bone cancer pain, tumor pain, pain or neuropathy resulting fromdisorders of the central or peripheral nervous system, neuropathic pain,pain associated with dysesthesia, allodynia or hypersensitivity,chemotherapy induced neuropathic pain, chemotherapy induced peripheralneuropathy, diabetic neuropathy or pain associated with diabeticneuropathy, post herpetic neuralgia or pain associated with postherpetic neuralgia, hiv-related neuropathy or pain associated withhiv-related neuropathy, pain or neuropathy resulting from spinal cordinjury, nerve lesions, tissue injury, ms, stroke, nutritionaldeficiencies, or toxins, fibromyalgia or pain associated withfibromyalgia, phantom limb pain, complex regional pain syndrome, carpaltunnel syndrome, sciatica, pudendal neuralgia, back or neck pain,including those resulting from degenerative disk disease, trigeminalneuralgia, headache disorders including, but not limited to migraine andcluster headache, orofacial pain, odontalgia, temporomandibular jointpain, endometrial pain, osteoarthritis, rheumatoid arthritis, atypicalodontalgia, interstitial cystitis, uveitis, or any combination thereof.

In some embodiments, methods of treating and/or preventing neuropathy,pain, inflammatory pain, cancer pain, bone cancer pain, tumor pain, painor neuropathy resulting from disorders of the central or peripheralnervous system, neuropathic pain, pain associated with dysesthesia,allodynia or hypersensitivity, chemotherapy induced neuropathic pain,chemotherapy induced peripheral neuropathy, diabetic neuropathy or painassociated with diabetic neuropathy, post herpetic neuralgia or painassociated with post herpetic neuralgia, hiv-related neuropathy or painassociated with hiv-related neuropathy, pain or neuropathy resultingfrom spinal cord injury, nerve lesions, tissue injury, ms, stroke,nutritional deficiencies, or toxins, fibromyalgia or pain associatedwith fibromyalgia, phantom limb pain, complex regional pain syndrome,carpal tunnel syndrome, sciatica, pudendal neuralgia, back or neck pain,including those resulting from degenerative disk disease, trigeminalneuralgia, headache disorders including, but not limited to migraine andcluster headache, orofacial pain, odontalgia, temporomandibular jointpain, endometrial pain, osteoarthritis, rheumatoid arthritis, atypicalodontalgia, interstitial cystitis, uveitis, or any combination thereof.In some embodiments, the methods comprise administering one or more ofthe compounds described herein, or pharmaceutically acceptable saltsthereof, to the subject to treat or prevent such conditions. In someembodiments, the condition is CINP and CIPN, or other types ofneuropathic pain or neuropathy. In some embodiments, the methods areperformed without causing significant lymphopenia or immunosuppression.In some embodiments, the methods are performed without causinglymphopenia or immunosuppression.

In some embodiments, the compounds, or pharmaceutically acceptable saltsthereof, are administered to the subject for any condition or indicationprovided for herein without causing significant lymphopenia orimmunosuppression. In some embodiments, the methods are performedwithout causing lymphopenia or immunosuppression.

In some embodiments, the methods comprise administering to the subjectone or more compounds described herein or a pharmaceutically acceptablesalt thereof, or a pharmaceutical composition of the same. In someembodiments, the subject is a subject in need of such treatment. Asdescribed herein, in some embodiments, the subject is a mammal, such as,but not limited to, a human.

In some embodiments, also provided are one or more compounds describedabove, or a pharmaceutically acceptable salt thereof, or apharmaceutical composition comprising one or more compounds describedabove, for use in the manufacture of a medicament for the treatment ofmethods of treating and/or preventing pain, including, but not limitedto the conditions described herein, in a subject, such as thosedescribed herein. In some embodiments, the subject is a subject in needthereof.

The present embodiments also provide the use of one or more compoundsdescribed above, or a pharmaceutically acceptable salt thereof, or apharmaceutical composition comprising one or more compounds describedabove, in the modulation of a S₁P₁ receptor activity, such as thepresence on the surface of the cell. In some embodiments, the compounds,pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of the same modulate the internalization, trafficking,and/or degradation of the S₁P₁ receptor. In some embodiments, thecompounds, pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of the same modulate the G-protein modulated pathway of theS₁P₁ receptor.

As used herein, “modulation” can refer to either inhibition orenhancement of a specific activity. For example, the modulation of theS₁P₁ receptor can refer to the inhibition and/or activation of theG-protein mediated pathway of the S₁P₁ receptor. In some embodiments,the modulation refers to the inhibition or activation of the β-arrestinmediated pathway of the S₁P₁ receptor. In some embodiments, themodulation refers to the inhibition or activation of the internalizationof the S₁P₁ receptor. The activity of a S₁P₁ receptor can be measured byany method including but not limited to the methods described herein.

The compounds described herein are agonists or antagonists of the S₁P₁receptor. The ability of the compounds to stimulate or inhibit S₁P₁receptor signaling may be measured using any assay known in the art usedto detect S₁P₁ receptor mediated signaling or S₁P₁ receptor activity, orthe absence of such signaling/activity. “S₁P₁ receptor activity” refersto the ability of a S₁P₁ receptor to transduce a signal. Such activitycan be measured, e.g., in a heterologous cell, by coupling an S₁P₁receptor (or a chimeric S₁P₁ receptor) to a downstream effector such asadenylate cyclase.

A “natural ligand-induced activity” as used herein, refers to activationof the S₁P₁ receptor by a natural ligand of the S₁P₁ receptor. Activitycan be assessed using any number of endpoints to measure S₁P₁ receptoractivity.

Generally, assays for testing compounds that modulate S₁P₁receptor-mediated signal transduction include the determination of anyparameter that is indirectly or directly under the influence of a S₁P₁receptor, e.g., a functional, physical, or chemical effect.

Samples or assays comprising S₁P₁ receptors that are treated with apotential activator, inhibitor, or modulator are compared to controlsamples without the inhibitor, activator, or modulator to examine theextent of inhibition. Control samples (untreated with inhibitors) areassigned a relative S₁P₁ receptor activity value of 100%. Inhibition ofa S₁P₁ receptor is achieved when the S₁P₁ receptor activity valuerelative to the control is about 80%, 50%, or 25%. Activation of a S₁P₁receptor is achieved when the S₁P₁ receptor activity value relative tothe control (untreated with activators) is 110%, 150%, or 200-500%(i.e., two to five fold higher relative to the control), or 1000-3000%or higher.

The effects of the compounds upon the function of an S₁P₁ receptor canbe measured by examining any of the parameters described above. Anysuitable physiological change that affects S₁P₁ receptor activity can beused to assess the influence of a compound on the S₁P₁ receptors andnatural ligand-mediated S₁P₁ receptor activity. When the functionalconsequences are determined using intact cells or animals, one can alsomeasure a variety of effects such as changes in intracellular secondmessengers such as cAMP.

Modulators of S₁P₁ receptor activity can be tested using S₁P₁ receptorpolypeptides as described herein, either recombinant or naturallyoccurring. The protein can be isolated, expressed in a cell, expressedin a membrane derived from a cell, expressed in tissue or in an animal.For example, neuronal cells, cells of the immune system, transformedcells, or membranes can be used to test the S₁P₁ receptor polypeptidesdescribed herein. Modulation is tested using one of the in vitro or invivo assays described herein. Signal transduction and cellulartrafficking can also be examined in vitro with soluble or solid statereactions, using a chimeric molecule such as an extracellular domain ofa receptor covalently linked to a heterologous signal transductiondomain, or a heterologous extracellular domain covalently linked to thetransmembrane and or cytoplasmic domain of a receptor. Furthermore,ligand-binding domains of the protein of interest can be used in vitroin soluble or solid state reactions to assay for ligand binding.

Ligand binding to an S₁P₁ receptor, a domain, or chimeric protein can betested in a number of formats. Binding can be performed in solution, ina bilayer membrane, attached to a solid phase, in a lipid monolayer, orin vesicles. For example, in an assay, the binding of the natural ligandto its receptor is measured in the presence of a candidate modulator,such as the compound described herein. Alternatively, the binding of thecandidate modulator may be measured in the presence of the naturalligand. Often, competitive assays that measure the ability of a compoundto compete with binding of the natural ligand to the receptor are used.Binding can be tested by measuring, e.g., changes in spectroscopiccharacteristics (e.g., fluorescence, absorbance, refractive index),hydrodynamic (e.g., shape) changes, or changes in chromatographic orsolubility properties.

Another technology that can be used to evaluate S₁P₁ receptor-proteininteractions in living cells involves bioluminescence resonance energytransfer (BRET). A detailed discussion regarding BRET can be found inKroeger et al., J. Biol. Chem., 276(16):12736 43 (2001).

After the receptor is expressed in a cell, the cells can be grown inappropriate media in the appropriate cell plate. The cells can beplated, for example, at 5000-10000 cells per well in a 384 well plate.In some embodiments, the cells are plated at about 1000, 2000, 3000,4000, 5000, 6000, 7000, 8000, 9000, or 10000 cells/per well. The platescan have any number of wells and the number of cells can be modifiedaccordingly.

Any medicament having utility in an application described herein can beused in co-therapy, co-administration or co-formulation with acomposition as described above. Such additional medicaments include,medicines for cancer. Many medicines that are used to treat cancer causeCIPN or CINP. Therefore, the compounds described herein can beadministered either before, concurrently with, or after suchtherapeutics are administered to a subject. Non-limiting examples ofsuch therapeutics include, but are not limited to: Platinum-based drugs,such as but not limited to, carboplatin (Paraplatin), cisplatin,oxaliplatin; taxanes: paclitaxel (Taxol), paclitaxel nanoparticlealbumin-bound (Abraxane), docetaxel (Taxotere), and cabazitaxel(Jevtana); Epothilones, such as ixabepilone (Ixempra); Plant alkaloids:vinblastine (Velban, Alkaban-AQ), vincristine (Oncovin, Vincasar PES,Vincrex), vinorelbine (Navelbine), and etoposide (Toposar, VePesid,Etopophos); halidomide (Thalomid), lenalidomide (Revlimid), andpomalidomide (Pomalyst), Bortezomib (Velcade); carfilzomib (Kyprolis),and Eribulin (Halaven). Other examples of therapeutics that thepresently described compounds can be combined with include, but are notlimited to, Abitrexate (Methotrexate Injection), Abraxane (PaclitaxelInjection), Adcetris (Brentuximab Vedotin Injection), Adriamycin(Doxorubicin), Adrucil Injection (5-FU (fluorouracil)), Afinitor(Everolimus), Afinitor Disperz (Everolimus), Alimta (PEMETREXED),Alkeran Injection (Melphalan Injection), Alkeran Tablets (Melphalan),Aredia (Pamidronate), Arimidex (Anastrozole), Aromasin (Exemestane),Arranon (Nelarabine), Arzerra (Ofatumumab Injection), Avastin(Bevacizumab), Beleodaq (Belinostat Injection), Bexxar (Tositumomab),BiCNU (Carmustine), Blenoxane (Bleomycin), Blincyto (BlinatumomabInjection), Bosulif (Bosutinib), Busulfex Injection (BusulfanInjection), Campath (Alemtuzumab), Camptosar (Irinotecan), Caprelsa(Vandetanib), Casodex (Bicalutamide), CeeNU (Lomustine), CeeNU Dose Pack(Lomustine), Cerubidine (Daunorubicin), Clolar (Clofarabine Injection),Cometriq (Cabozantinib), Cosmegen (Dactinomycin), Cotellic(Cobimetinib), Cyramza (Ramucirumab Injection), CytosarU (Cytarabine),Cytoxan (Cytoxan), Cytoxan Injection (Cyclophosphamide Injection),Dacogen (Decitabine), DaunoXome (Daunorubicin Lipid Complex Injection),Decadron (Dexamethasone), DepoCyt (Cytarabine Lipid Complex Injection),Dexamethasone Intensol (Dexamethasone), Dexpak Taperpak (Dexamethasone),Docefrez (Docetaxel), Doxil (Doxorubicin Lipid Complex Injection),Droxia (Hydroxyurea), DTIC (Decarbazine), Eligard (Leuprolide), Ellence(Ellence (epirubicin)), Eloxatin (Eloxatin (oxaliplatin)), Elspar(Asparaginase), Emcyt (Estramustine), Erbitux (Cetuximab), Erivedge(Vismodegib), Erwinaze (Asparaginase Erwinia chrysanthemi), Ethyol(Amifostine), Etopophos (Etoposide Injection), Eulexin (Flutamide),Fareston (Toremifene), Farydak (Panobinostat), Faslodex (Fulvestrant),Femara (Letrozole), Firmagon (Degarelix Injection), Fludara(Fludarabine), Folex (Methotrexate Injection), Folotyn (PralatrexateInjection), FUDR (FUDR (floxuridine)), Gazyva (Obinutuzumab Injection),Gemzar (Gemcitabine), Gilotrif (Afatinib), Gleevec (Imatinib Mesylate),Gliadel Wafer (Carmustine wafer), Used to treat, Brain Tumors Halaven(Eribulin Injection), Herceptin (Trastuzumab), Hexalen (Altretamine),Hycamtin (Topotecan), Hycamtin (Topotecan), Hydrea (Hydroxyurea),Ibrance (Palbociclib), Iclusig (Ponatinib), Idamycin PFS (Idarubicin),Ifex (Ifosfamide), Imbruvica (Ibrutinib), Inlyta (Axitinib), Intron Aalfab (Interferon alfa-2a), Iressa (Gefitinib), Istodax (RomidepsinInjection), Ixempra (Ixabepilone Injection), Jakafi (Ruxolitinib),Jevtana (Cabazitaxel Injection), Kadcyla (Ado-trastuzumab Emtansine),Keytruda (Pembrolizumab Injection), Kyprolis (Carfilzomib), Lanvima(Lenvatinib), Leukeran (Chlorambucil), Leukine (Sargramostim), Leustatin(Cladribine), Lonsurf (Trifluridine and Tipiracil), Lupron (Leuprolide),Lupron Depot (Leuprolide), Lupron DepotPED (Leuprolide), Lynparza(Olaparib), Lysodren (Mitotane), Marqibo Kit (Vincristine Lipid ComplexInjection), Matulane (Procarbazine), Megace (Megestrol), Mekinist(Trametinib), Mesnex (Mesna), Mesnex (Mesna Injection), Metastron(Strontium-89 Chloride), Mexate (Methotrexate Injection), Mustargen(Mechlorethamine), Mutamycin (Mitomycin), Myleran (Busulfan), Mylotarg(Gemtuzumab Ozogamicin), Navelbine (Vinorelbine), Neosar Injection(Cyclophosphamide Injection), Neulasta (filgrastim), Neulasta(pegfilgrastim), Neupogen (filgrastim), Nexavar (Sorafenib), Nilandron(Nilandron (nilutamide)), Nipent (Pentostatin), Nolvadex (Tamoxifen),Novantrone (Mitoxantrone), Odomzo (Sonidegib), Oncaspar (Pegaspargase),Oncovin (Vincristine), Ontak (Denileukin Diftitox), Onxol (PaclitaxelInjection), Opdivo (Nivolumab Injection), Paraplatin (Carboplatin),Perjeta (Pertuzumab Injection), Platinol (Cisplatin), Platinol(Cisplatin Injection), PlatinolAQ (Cisplatin), PlatinolAQ (CisplatinInjection), Pomalyst (Pomalidomide), Prednisone Intensol (Prednisone),Proleukin (Aldesleukin), Purinethol (Mercaptopurine), Reclast(Zoledronic acid), Revlimid (Lenalidomide), Rheumatrex (Methotrexate),Rituxan (Rituximab), RoferonA alfaa (Interferon alfa-2a), Rubex(Doxorubicin), Sandostatin (Octreotide), Sandostatin LAR Depot(Octreotide), Soltamox (Tamoxifen), Sprycel (Dasatinib), Sterapred(Prednisone), Sterapred DS (Prednisone), Stivarga (Regorafenib),Supprelin LA (Histrelin Implant), Sutent (Sunitinib), Sylatron(Peginterferon Alfa-2b Injection (Sylatron)), Sylvant (SiltuximabInjection), Synribo (Omacetaxine Injection), Tabloid (Thioguanine),Taflinar (Dabrafenib), Tarceva (Erlotinib), Targretin Capsules(Bexarotene), Tasigna (Decarbazine), Taxol (Paclitaxel Injection),Taxotere (Docetaxel), Temodar (Temozolomide), Temodar (TemozolomideInjection), Tepadina (Thiotepa), Thalomid (Thalidomide), TheraCys BCG(BCG), Thioplex (Thiotepa), TICE BCG (BCG), Toposar (EtoposideInjection), Torisel (Temsirolimus), Treanda (Bendamustinehydrochloride), Trelstar (Triptorelin Injection), Trexall(Methotrexate), Trisenox (Arsenic trioxide), Tykerb (lapatinib),Unituxin (Dinutuximab Injection), Valstar (Valrubicin Intravesical),Vantas (Histrelin Implant), Vectibix (Panitumumab), Velban(Vinblastine), Velcade (Bortezomib), Vepesid (Etoposide), Vepesid(Etoposide Injection), Vesanoid (Tretinoin), Vidaza (Azacitidine),Vincasar PFS (Vincristine), Vincrex (Vincristine), Votrient (Pazopanib),Vumon (Teniposide), Wellcovorin IV (Leucovorin Injection), Xalkori(Crizotinib), Xeloda (Capecitabine), Xtandi (Enzalutamide), Yervoy(Ipilimumab Injection), Yondelis (Trabectedin Injection), Zaltrap(Ziv-aflibercept Injection), Zanosar (Streptozocin), Zelboraf(Vemurafenib), Zevalin (Ibritumomab Tiuxetan), Zoladex (Goserelin),Zolinza (Vorinostat), Zometa (Zoledronic acid), Zortress (Everolimus),Zydelig (Idelalisib), Zykadia (Ceritinib), Zytiga (Abiraterone), or anycombination thereof. Other examples include, but are not limited to,PD-1 antibodies, such as Nivolumab or Pembrolizumab. In someembodiments, the compounds, or pharmaceutically acceptable saltsthereof, provided herein can be administered with, either concurrentlyor sequentially, or as part of a cancer treatment protocol, theadditional therapeutics provided for herein.

In some embodiments, the compounds provided herein can also be used totreat cancer. In some embodiments, the compounds, or pharmaceuticallyacceptable salts thereof, can be used to inhibit tumor growth. In someembodiments, the compounds, or pharmaceutically acceptable saltsthereof, are used to treat cancers, such as, but not limited to, ovariancancer, breast cancer, lung cancer, brain cancer, colon cancer, prostatecancer, esophageal cancer, pancreatic cancer, brain cancer, glioblastomacancer, leukemia, multiple myeloma, lymphoma, skin cancer, acuteLymphoblastic Leukemia, acute myeloid leukemia, basal cell cancer, bileduct cancer, bladder cancer, bone cancer (Ewing sarcoma, osteosarcoma),CLL, CML, uterine cancer, cervical cancer, hairy cell leukemia,melanoma, thyroid cancer, rectal cancer, renal cell cancer, small celllung cancer, non-small cell lung cancer, or stomach cancer. In someembodiments, the cancer is breast or ovarian cancer. In someembodiments, the compounds, or pharmaceutically acceptable saltsthereof, provided herein are combined with a taxane, such as paclitaxel.

The additional medicament can be administered in co-therapy (includingco-formulation) with the one or more of the compounds described herein.

In some embodiments, the response of the disease or disorder to thetreatment is monitored and the treatment regimen is adjusted, ifnecessary, in light of such monitoring.

Frequency of administration is typically such that the dosing interval,for example, the period of time between one dose and the next, duringwaking hours is from about 2 to about 12 hours, from about 3 to about 8hours, or from about 4 to about 6 hours. It will be understood by thoseof skill in the art that an appropriate dosing interval is dependent tosome degree on the length of time for which the selected composition iscapable of maintaining a concentration of the compound(s) in the subjectand/or in the target tissue (e.g., above the EC₅₀ (the minimumconcentration of the compound which modulates the receptor's activity by90%). Ideally the concentration remains above the EC₅₀ for at least 100%of the dosing interval. Where this is not achievable it is desired thatthe concentration should remain above the EC₅₀ for at least about 60% ofthe dosing interval, or should remain above the EC₅₀ for at least about40% of the dosing interval.

The present disclosure also provides the following non-limitingembodiments: In order that the embodiments disclosed herein may be moreefficiently understood, examples are provided below. It should beunderstood that these examples are for illustrative purposes only andare not to be construed as limiting the embodiments in any manner.Throughout these examples, there may be molecular cloning reactions, andother standard recombinant DNA techniques described and these werecarried out according to methods described in Maniatis et al., MolecularCloning—A Laboratory Manual, 2nd ed., Cold Spring Harbor Press (1989),using commercially available reagents, except where otherwise noted.

The following examples are illustrative, but not limiting, of themethods and compositions described herein. Other suitable modificationsand adaptations of the variety of conditions and parameters normallyencountered in therapy, synthesis, and other embodiments disclosedherein are within the spirit and scope of the embodiments.

EXAMPLES Example 1: Synthesis of Compounds

Certain synthetic schemes, both general and specific, are providedherein. The compounds disclosed herein can be made according to themethods described herein or intermediates that lead to the compoundsdisclosed herein can be made according to the methods described herein.The substitutions can be varied according to the compound orintermediate being made based upon the following examples and othermodifications known to one of skill in the art.

The following compounds were prepared according to the followingexamples or the examples were varied according to one of skill in theart to prepare the compounds.

Com- pound Num- Chemical Exact Actual Structure ber Name Mass Peak

 1 1-cyclopentyl-5-{3-[3-fluoro-4- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 417.37 418.1

 2 5-(2-bromophenyl)-3-(1-ethyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole 370.21 371

 3 1-(2-methylpropyl)-6-[3-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 334.38 355.2

 4 1-cyclopentyl-5-{3-[4-(pyridin-3- ylmethoxy)-3-(trifluoromethyl)phenyl]-1,2,4- oxadiazol-5-yl}-1H-1,2,3- benzotriazole506.49 507.2

 5 5-[3-(4-fluorophenyl)-1,2,4- oxadiazol-5-yl]-1-propyl-1H-1,2,3-benzotriazole 323.33 324.2

 6 5-[3-(5-methylpyrazin-2-yl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 363.38 364.1

 7 1-cyclopentyl-5-(3-phenyl-1,2,4- oxadiazol-5-yl)-1H-1,2,3-benzotriazole 331.38 332.1

 8 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methylpyridin-4-yl)-1,2,4- oxadiazole 320.36 321

 9 5-[3-(5-phenylpyridin-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 382.43 383.1

 10 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole 415.38 416.1

 11 1-cyclohexyl-5-[3-(3- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 359.43 360.2

 12 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(trifluoromethyl)phenyl)-1,2,4- oxadiazole 399.38 400.1

 13 4-[5-(1-cyclopentyl-1H-1,2,3- benzotriazol-5-yl)-1,2,4-oxadiazol-3-yl]phenol 347.38 348.1

 14 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-isopropoxy-3- (trifluoromethyl)phenyl)-1,2,4- oxadiazole 457.46 458.1

 15 5-[3-(4-phenoxyphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 397.44 398.2

 16 3-(1-cyclopentyl-1H- benzo[d]1,2,3[triazol-5-yl)-5-(2-(methylthio)phenyl)-1,2,4-oxadiazole 377.47 378.1

 17 5-[3-(2-chlorophenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 339.78 340.1

 18 5-(5-cyclobutyl-1,2,4-oxadiazol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole 283.34 284

 19 5-[3-(6-methoxypyridin-2-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 336.36 337.1

 20 3-(4-isopropoxy-3- (trifluoromethyl)phenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 431.42 432

 21 5-[4-(2-fluorophenyl)-l,3-oxazol-2- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 322.34 323

 22 2-isopropoxy-5-(3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 388.43 389

 23 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(phenoxymethyl)phenyl)-1,2,4- oxadiazole 411.47 412

 24 3-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 400.24 400

 25 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(6-isopropylpyridin-3-yl)-1,2,4- oxadiazole 348.41 349.3

 26 1-{5-[3-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol 379.42 380.1

 27 2,2-diethyl-6-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 349.39 350.1

 28 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,3,4-oxadiazol-2-yl)chroman-4- one349.39 350.1

 29 2,2-diethyl-6-(3-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- thiadiazol-5-yl)chroman-4-one 447.56448.2

 30 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N,N-dimethylbenzenesulfonamide 455.53 456.1

 31 2,2-diethyl-6-(3-(3-methylpyridin- 4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 363.42 364.2

 32 3-(benzo[d][1,3]dioxol-4-yl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 349.35 350.1

 33 3-(1-isopropylbenzotriazol-5-yl)-5-[2-(trifluoromethyl)phenyl]-1,2,4- oxadiazole 373.34 374.1

 34 2,2-diethyl-6-(3-(5-methylthiophen- 2-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 368.45 369.3

 35 5-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 335.37 336

 36 4′,4′-difluoro-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospirol[1]-benzopyran-2,1′- cyclohexane]-4-one 397.38 298.1

 37 5-(4-fluorophenyl)-2-(1- isopropylbenzotriazol-5-yl)thiazole 338.40339.2

 38 2,2-diethyl-6-(3-(2- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 379.42 380.1

 39 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 2-(prop-2-en-1-yl)-2H-1,2,3-benzotriazole 303.33 304.3

 40 5-(2-bromophenyl)-3-(1- cyclopentyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 410.28 409.9

 41 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′-cyclohexane]-4- one 361.40 262.1

 42 3-(1-allyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-bromophenyl)-1,2,4-oxadiazole 382.22 382

 43 5-(2-bromophenvl)-3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole 384.24 384

 44 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methylpyrazin-2-yl)-1,2,4- oxadiazole 321.34 322.1

 45 5-(2-bromophenyl)-3-(1-(pyridin-2- ylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 433.27 435.1

 46 1-cyclopentyl-5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 351.43 352.1

 47 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-(methylthio)phenyl)-1,2,4- oxadiazole 377.47 378.1

 48 5-(2-bromophenyl)-3-(1-(pyridin-4- ylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 433.27 435

 49 5-{3-[4-(phenoxymethyl)phenyl]- 1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 411.47 412.3

 50 5-[4-(4-chlorophenyl)-5-methyl- 1,3-oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 352.82 353

 51 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methoxypyrazin-2-yl)-1,2,4- oxadiazole 337.34 338

 52 3-(1-benzyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-bromophenyl)-1,2,4-oxadiazole 432.28 432

 53 5-{3-[4-(benzyloxy)phenyl]-1,2,4- oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 411.47 412.3

 54 5-[3-(3-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-propyl-1H-1,2,3-benzotriazole 319.37 320.2

 55 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(4-methoxy-2-methylphenyl)-1,2,4- oxadiazole 349.39 350

 56 5-[3-(2-methyl-1-phenylpropyl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 361.45 362.1

 57 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 293.28 294.1

 58 4′,4′-dimethyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′- cyclohexane]-4-one 389.46 390.2

 59 l-tert-butyl-5-[3-(2-methylphenyl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 333.40 334.1

 60 6-(3-(4-(dimethylamino)phenyl)- 1,2,4-oxadiazol-5-yl)-2,2-diethylchroman-4-one 391.47 392.3

 61 2-(allylamino)-5-(3-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 371.40 372.1

 62 3-(2-isopropoxyphenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 363.42 364.1

 63 5-(2-fluorophenyl)-2-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)thiazole 338.40 339.1

 64 5-(3-fluorophenyl)-3-(1- isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole 323.33 324.1

 65 2,2-diethyl-6-(3-(4- methoxyphenyl)-1,2,4-oxadiazol-5-yl)chroman-4-one 378.43 379.1

 66 2,2-diethyl-6-(3-(o-tolyl)-1,2,4- oxadiazol-5-yl)chroman-4-one362.43 363.1

 67 2,2-diethyl-6-(5-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,3,4- thiadiazol-2-yl)chroman-4-one 447.56448.1

 68 6-[3-(4-chlorophenyl)-1,2,4- oxadiazol-5-yl]-2,2-diethyl-chroman-4-one 382.84 383.1

 69 3-(1-isopropylbenzotriazol-5-yl)-5- (4-methoxyphenyl)-1,2,4-oxadiazole 335.37 336.1

 70 2-{5-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,3,4-thiadiazol-2-yl}phenol 337.40 338

 71 2,2-diethyl-6-(3-(3- methoxyphenyl)-1,2,4-oxadiazol-5-yl)chroman-4-one 378.43 379.1

 72 2,2-diethyl-6-[3-(4- hydroxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 364.40 365.1

 73 5-(2-bromophenyl)-3-(1-methyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole 356.18 356

 74 5-[5-(5-methylthiophen-2-yl)-1,2,4- oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 325.39 326.1

 75 1-(2-methylpropyl)-5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 339.42 340.1

 76 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl-1-propyl-1H-1,2,3-benzotriazole 333.40 334.3

 77 5-[3-(2-methoxypyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1-methyl-2,3-dihydro-1H-1,2,3-benzotriazole; cyclopentane 346.39 347.1

 78 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(pyrazin-2-yl)-1,2,4-oxadiazole 307.32 308

 79 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 1-(propan-2-yl)-1H-1,2,3-benzotriazole 305.34 306.3

 80 1-cyclopentyl-5-{3-[4- (difluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 397.39 398.1

 81 methyl 2-(5-(5-(2-bromophenyl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)acetate 414.22 414.1

 82 5-[3-(5-chlorothiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1-(oxan-4-yl)-1H- 1,2,3-benzotriazole 387.84 388

 83 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1-cyclopropyl-1H-1,2,3-benzotriazole 382.22 382.2

 84 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole 415.38 416

 85 5-{3-[4-(benzyloxy)-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopropyl-1H- 1,2,3-benzotriazole 477.45 478.2

 86 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methylpyridin-4-yl)-1,2,4- oxadiazole 322.37 321.1

 87 1-cyclopropyl-5-[3-(6- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 318.34 319.1

 88 5-(3-benzyl-1,2,4-oxadiazol-5-yl)- 1-(propan-2-yl)-1H-1,2,3-benzotriazole 319.37 320.1

 89 5-[5-(oxan-4-yl)-1,2,4-oxadiazol-3- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 313.36 314

 90 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxy-2-methylphenyl)-1,2,4- oxadiazole 349.39 350.1

 91 l-cyclopentyl-5-[3-(4- methoxynaphthalen-1-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 411.47 412.2

 92 5-(3-benzyl-1,2,4-oxadiazol-5-yl)- 1-cyclopentyl-1H-1,2,3-benzotriazole 345.41 346.1

 93 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 375.43 376.2

 94 1-cyclopropyl-5-[3-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 318.34 319.3

 95 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 361.41 362.1

 96 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(2-methylpropyl)-1H-1,2,3- benzotriazole 333.40 334.2

 97 3-(1H-benzo[d][1,2,3]triazol-5-yl)- 5-(2-bromophenyl)-1,2,4-oxadiazole 342.16 343.9

 98 5-(2-bromophenyl)-3-(1- (cyclopropylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 396.25 396

 99 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(o-tolyl)-1,2,4-oxadiazole 319.37 320

100 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methylpyridin-3-yl)-1,2,4- oxadiazole 320.36 321.1

101 5-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 320.36 321.1

102 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 293.28 294.1

103 2,2-diethyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]3,4-dihydro-2H-1-benzopyran-4-one 349.39 350.2

104 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,3,4-thiadiazol-2-yl)chroman-4-one 365.45 366.1

105 2,2-diethyl-6-[3-(6-hydroxy-3- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 365.39 366.1

106 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3- yl)benzenesulfonamide 427.48 428.1

107 2-(isopropylamino)-5-(3-(2- oxoindolin-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 359.39 360.1

108 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxyphenyl)thiazole 350.44 351.2

109 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxyphenyl)thiazole 350.44 351.1

110 5-(3-fluorophenyl)-2-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)thiazole 338.40 339.1

111 2,2-diethyl-6-[3-(2-pyridyl)-1,2,4- oxadiazol-5-yl]chroman-4-one349.39 350.1

112 2-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl-1,2,4-thiadiazol-5-yl}phenol 337.40 338

113 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 1H-1,2,3-benzotriazole 263.26264.1

114 5-{3-[4-bromo-2- (trifluorornethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentyl-1H- 1,2,3-benzotriazole 478.27 478.1

115 5-(2-bromophenyl)-3-(1- cyclohexyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 424.30 426

116 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxypyridin-4-yl)-1,2,4- oxadiazole 336.36 337

117 1-cyclohexyl-5-[3-(4- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 359.43 360.1

118 1-cyclopentyl-5-{3-[3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 399.38 400.1

119 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(6-methylpyridin-3-yl)-1,2,4- oxadiazole 320.36 321.1

120 3-(1-cyclopentyl-1H- benzo[d]|[1,2,3]triazol-5-yl)-5-(2-methoxyphenyl)-1,2,4- oxadiazole 361.41 362

121 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-isopropoxyphenyl)-1,2,4- oxadiazole 389.46 390.3

122 5-{3-[3-fluoro-4- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-(3-methylbutyl)- 1H-1,2,3-benzotriazole 419.38 420.2

123 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 345.41 346.2

124 1-cyclopentyl-5-[3-(6- methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 362.39 363.1

125 5-[5-(4,4-difluorocyclohexyl)- 1,2,4-oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 347.37 348

126 5-{3-[(3,5-dimethylphenyl)methyl]-1,2,4-oxadiazol-5-yl}-1-(propan-2- yl)-1H-1,2,3-benzotriazole 347.42348.3

127 5-(5-cyclohexyl-1,2,4-oxadiazol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole 311.39 312

128 1-(propan-2-yl)-5-(3- {[1,2,4]triazolo[4,3-a]pyridin-6-yl}-1,2,4-oxadiazol-5-yl)-1H-1,2,3- benzotriazole 346.35 347.1

129 5-[3-(4-methoxynaphthalen-1-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 385.43 386.2

130 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxyphenyl)-1,2,4-oxadiazole 361.41 362

131 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-(phenoxymethyl)phenyl)-1,2,4- oxadiazole 411.47 412

132 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole 389.34 390

133 5-(5,6-dimethylpyrazin-2-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 335.37 356.1

134 3-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1- yl)propanoic acid 414.22 413.9

135 5-[3-(2-ethylpyrimidin-5-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 335.37 336.1

136 5-[3-(2,4-dimethoxy-6- methylphenyl)-1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole 379.42 380.3

137 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,2,4-thiadiazol-3-yl)chroman-4-one 365.45 366

138 5-[5-(2-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 351.43 302

139 2-methyl-1-{5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1- yl}propan-2-ol 349.39 350.1

140 2-methyl-1-{5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazol-1-yl}propan-2-ol 355.42 356.1

141 5-(3-(1H-indazol-5-yl)-1,2,4- oxadiazol-5-yl)-2-(allylamino)benzonitrile 342.36 343.1

142 5-(1-isopropyl-1H-indol-5-yl)-5-(3- methylpyridin-4-yl)-1,2,4-oxadiazole 318.38 318.15

143 2,2-diethyl-6-(5-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- thiadiazol-3-yl)chroman-4-one 447.56448.1

144 5-[5-(2-methoxyphenyl)-1,3,4- thiadiazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 351.43 352

145 5-(3-(1H-benzo[d][1,2,3]triazol-5- yl)-1,2,4-oxadiazol-5-yl)-2-(allylamino)benzonitrile 343.35 344.1

146 2,2-diethyl-6-(3-(2-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one 367.38 368.1

147 2,2-diethyl-6-(3-(2- methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 379.42 380.2

148 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,4′-oxane]-4-one 363.37 364.1

149 N-(4-(5-(4-(allylamino)-3- cyanophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanesulfonamide 395.44 396.1

150 2-(allylamino)-5-(3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 385.43 368.3

151 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N,N-dimethylbenzamide 419.48 420.2

152 6-(3-(1H-indazol-5-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 388.43 389.2

153 2,2-diethyl-6-(3-(4- (methylamino)phenyl)-1,2,4-oxadiazol-5-yl)chroman-4-one 377.44 378.2

154 5-{3-[1-(2-methylphenyl)ethyl]- 1,2,4-oxadiazol-5-yl}-1-(2-methylpropyl)-1H-1,2,3- benzotriazole 361.45 362.2

155 1-cyclopropyl-5-[3-(2- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 334.34 335.1

156 5-(2,6-dimethylpyridin-4-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 334.38 335.2

157 5-[3-(5-methylpyrazin-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 321.34 322.1

158 1-cyclohexyl-5-[3-(3,5- dimethylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 373.46 374.2

159 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methylpyridin-3-yl)-1,2,4- oxadiazole 320.36 321.1

160 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 1-propyl-1H-1,2,3-benzotriazole305.34 306.1

161 methyl 3-(5-(5-(2-bromophenyl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1- yl)propanoate 428.25 429.9

162 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(o-tolyl)-1,2,4-oxadiazole 2445.41 346.1

163 5-[4-(2-chlorophenyl)-2,3-dihydro- 1,3-oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 338.80 339

164 1-cyclopentyl-5-[3-(4- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 345.41 346.3

165 1-(propan-2-yl)-5-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 306.33 307.3

166 5-(2,4-dimethylphenyl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 333.40 334.2

167 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-isopropylpyridin-4-yl)-1,2,4- oxadiazole 348.41 349.1

168 2-{5-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}quinoline 356.39 357.1

169 5-[3-(3-methylthiophen-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 325.39 326.1

170 5-[3-(5-chlorothiophen-2-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 345.81 346.1

171 1-cyclopropyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 317.35 318.3

172 5-{3-[1-(2-methylphenyl)ethyl]- 1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 347.42 348.1

173 1-cyclopropyl-5-[3-(2- methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 333.35 334.2

174 1-cyclopentyl-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 332.37 333.1

175 1-cyclopentyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 345.41 346.2

176 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′-cyclopentane]-4- one 347.37 348.1

177 5-(3-(1H-benzo[d]imidazol-5-yl)- 1,2,4-oxadiazol-5-yl)-2-(allylamino)benzonitrile 346.36 343.1

178 2,2-diethyl-6-(5-(2- methoxyphenyl)-1,3,4-thiadiazol-2-yl)chroman-4-one 394.49 395.2

179 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)benzamide391.43 392.1

180 2-(5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-3-yl)phenol 321.34 322.1

181 N-(benzo[d]isoxazol-3-yl)-1- isopropyl-1H-benzo[d][1,2,3]triazole-5- carboxamide 321.34 322.1

182 1-(2,2-difIuoroethyl)-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 341.32 342.1

183 5-[4-(2-bromophenyl)-1,3-oxazol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 383.25 383

184 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxyphenyl)thiazole 350.44 351

185 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N-methylbenzamide 405.45 406.1

186 2,2-bis(methoxymethyl)-6-[3- (pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one 381.39 282.2

187 2,2-diethyl-6-[3-(2- hydroxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 364.40 365.1

188 2,2-dibutyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 405.50 406.2

189 2-(allylamino)-5-(3-(2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 359.35 360.1

190 5-[3-(2-bromophenvl)-1,2,4- oxadiazol-5-yl]-1H-1,2,3- benzotriazole342.16 342

192 1-cyclopentyl-5-[3-(5- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 351.43 352.1

193 5-{3-[3-fluoro-4- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-propyl-1H-1,2,3- benzotriazole 391.33 392.1

194 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methylpyridin-3-yl)-1,2,4- oxadiazole 320.36 321

195 2-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)acetic acid 400.19 400

196 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxyphenyl)-1,2,4-oxadiazole 361.41 362

197 1-cyclopentyl-5-{3-[4-methoxy-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 429.40 430.1

198 5-[3-(2-chloropyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-cyclopentyl-1H-1,2,3-benzotriazole 366.81 367.1

199 5-[3-(2-chloropyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(cyclopropylmethyl)-1H-1,2,3- benzotriazole 352.78 353.1

200 5-[5-(adamantan-1-yl)-1,2,4- oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 363.47 364

201 5-(5,6-dimethylpyridin-3-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 334.38 335.1

202 5-{3-[(2-methylphenyl)methyl]- 1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 333.40 334.1

203 1-cyclopentyl-5-[3-(3- methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 362.39 363.1

204 5-[3-(3,5-dimethylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 333.40 334.1

205 1-propyl-5-[3-(pyridin-4-yl)-1,2,4- oxadiazol-5-yl]-1H-1,2,3-benzotriazole 306.33 307.1

206 2-methyl-1-{5-[3-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan-2- ol 350.38 351.1

207 1-tert-butyl-5-[3-(2- methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 349.39 350.2

208 5-(3-(1H-indol-5-yl)-1,2,4- oxadiazol-5-yl)-2-(allylamino)benzonitrile 341.37 342.2

209 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 405.45 406.2

210 2-((cyclopropylmethyl)amino)-5- (3-(2-oxoindolin-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 371.40 372.1

211 6-(3-(1H-benzo[d]imidazol-5-yl)- 1,2,4-oxadiazol-5-yl)-2,2-diethylchroman-4-one 388.43 389.1

212 2,2-diethyl-6-(3-(3- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 379.42 380.2

213 5-[3-(2-methoxyphenyl)-1,2,4- thiadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 351.43 352

214 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,4′-oxane]-4-one 363.37 364.1

215 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(trifluoromethyl)phenyl)thiazole 388.41 389.2

216 2-(1-isopropylbenzotriazol-5-yl)-5- (o-tolyl)thiazole 334.44 335.1

217 4′,4′-difluoro-6-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′- cyclohexane]-4-one 397.38 398.2

218 2,2-dipropyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 377.44 378.2

219 5-{8H-indeno[1,2-d][1,3]oxazol-2- yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 316.36 317

220 5-(2-bromophenyl)-2-(1- isopropylbenzotriazol-5-yl)thiazole 399.31401

221 6-(3-(2-chlorophenyl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 382.84 383.1

222 2,2-diethyl-6-(5-(2- methoxyphenyl)-1,2,4-thiadiazol-3-yl)chroman-4-one 394.49 395.1

223 2,2-diethyl-6-(5-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,3,4- oxadiazol-2-yl)chroman-4-one 431.50432.2

224 2-(allylamino)-5-(3-(2-oxoindolin- 5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 357.37 358.1

225 2,2-diethyl-6-(3-(m-tolyl)-1,2,4- oxadiazol-5-yl)chroman-4-one362.43 363.1

226 2,2-diethyl-6-(3-(3-fluoropyridin-4- yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 367.38 368.1

227 2,2-diethyl-6-[3-(3- hydroxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 364.40 365.1

228 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methoxyphenyl)-1,2,4-oxadiazole 335.37 336

229 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(6-methylpyrazin-2-yl)-1,2,4- oxadiazole 321.34 322.1

230 3-(3,4-dimethoxyphenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 365.39 366

231 5-[3-(2-methoxyphenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 377.40 378.2

232 1-cyclopentyl-5-[3-(4- fluorophenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 349.37 350.2

233 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 426.27 426.1

234 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methylpyrazin-2-yl)-1,2,4- oxadiazole 321.34 322.1

235 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(p-tolyl)-1,2,4-oxadiazole 345.41 346

236 5-[3-(6-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 320.36 321.1

237 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-(methylthio)phenyl)-1,2,4- oxadiazole 377.47 378.1

238 2-(5-(5-(2-bromophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)ethanol 386.21 386

239 1-(cyclopropylmethyl)-5[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 337.40 338.2

240 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole 389.34 390

241 1-(propan-2-yl)-5-[3-(pyridin-2-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 306.33 307.2

242 1-propyl-5-{3-[3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 373.34 374.3

243 3-(2,6-dimethylphenyl)-5-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 333.40 334

244 1-(propan-2-yl)-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 306.33 307.1

245 1-cyclohexyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 359.43 360.2

246 5-(4-isopropoxy-3- (trifluoromethyl)phenyl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 431.42 432

247 5-(5-methyl-4-phenyl-1,3-oxazol-2- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole 318.38 319

248 5-([1,1′-biphenyl]-4-yl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 381.44 382.1

249 1-(propan-2-yl)-5-[3-(pyrimidin-5-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 307.32 308.1

250 5-[4-(4-methoxyphenyl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 334.38 335

251 3-(2,6-dimethoxyphenyl)-5-(1- isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole 365.39 366.1

252 5-(3-(1H-pyrazol-4-yl)-1,2,4- oxadiazol-5-yl)-2-(allylamino)benzonitrile 292.30 293.1

253 1-tert-butyl-5-[3-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 339.42 340.1

254 4′,4′-dimethyl-6[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′- cyclohexane]-4-one 389.46 390.2

255 5-(4-fluorophenyl)-3-(1- isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole 323.33 324.1

256 6-(3-(4-aminophenyl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 363.42 364.2

257 2,2-diethyl-6-(3-(2- methoxyphenyl)-1,2,4-thiadiazol-5-yl)chroman-4-one 394.49 395.1

258 2,2-diethyl-6-(3-(2-hydroxypyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 365.39 366.3

259 2-(isopropylamino)-5-(3-(2-oxo- 1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 373.42 374.1

260 3-(2-fluoro-6-methoxy-phenyl)-5- (1-isopropylbenzotriazol-5-yl)-1,2,4-oxadiazole 353.36 354.1

261 6-[3-(3-chlorophenyl)-1,2,4- oxadiazol-5-yl]-2,2-diethyl-chroman-4-one 382.84 383.1

262 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)phenyl)methanesulfonamide 441.50 442

263 2,2-diethyl-6-[3-(2-hydroxy-4- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 365.39 366.1

264 6-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 320.36 321.1

265 2,2-diethyl-6-(3-(3-methylthiophen- 2-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 368.45 369.1

266 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N-methylbenzenesulfonamide 441.50 442.1

267 2-(allylamino)-5-(3-(2- aminobenzo[d]thiazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 374.42 375.3

268 2,2-diethyl-6-[3-(2- methoxyphenyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 378.43 379.1

269 2,2-diethyl-6-[3-(p-tolyl)-1,2,4- oxadiazol-5-yl]chroman-4-one362.43 363.1

270 5-(3-phenyl-1,2,4-oxadiazol-5-yl)- 1-(prop-2-en-1-yl)-1H-1,2,3-benzotriazole 303.33

271 1-(3-methylbutyl)-5-(3-phenyl- 1,2,4-oxadiazol-5-yl)-1H-1,2,3-benzotriazole 333.40 334.2

272 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(5-methoxypyridin-3-yl)-1,2,4- oxadiazole 336.36 337.1

273 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(m-tolyl)-1,2,4-oxadiazole 345.41 346

274 2,2-dimethyl-6-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 321.34 322.1

275 3-(1-cyclopentyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole 391.43 392.1

276 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-(methylthio)phenyl)-1,2,4- oxadiazole 351.43 352.1

277 5-[4-(2-methoxyphenyl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 334.38 335

278 5-(5-cyclopentyl-1,2,4-oxadiazol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole5-(5-cyclopentyl- 1,2,4-oxadiazol-3-yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole 297.36 298

279 2-(3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 330.35 331

280 6-[3-(pyridin-4-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′-cyclohexane]-4- one 361.40 362.1

281 1-cyclopentyl-5-[3-(2- methoxypyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 362.39 363.1

282 5-[3-(2-bromophenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 384.24 384.2

283 5-(2-bromophenyl)-3-(1-(pyridin-3- ylmethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 433.27 434.9

284 1-cyclohexyl-5-{3-[4-methoxy-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 443.43 444.2

285 1-cyclopropyl-5-[3-(4- phenoxyphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 395.42 396.2

286 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole 335.37 356

287 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole 335.37 356

288 1-(cyclopropylmethyl)-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 331.38 332.2

289 5-[3-(2-chlorophenyl)-1,2,4- oxadiazol-5-yl]-1-(2-methylpropyl)-1H-1,2,3- benzotriazole 353.81 354.2

290 5-(4-cyclohexylphenyl)-3-(1- isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazole 387.49 388.1

291 2,2-dimethyl-6-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 321.34 322.1

292 1-cyclohexyl-5-(3-phenyl-1,2,4- oxadiazol-5-yl)-1H-1,2,3-benzotriazole 345.41 346.3

293 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 319.37 320.3

294 5-(4-phenyl-1,3-oxazol-2-yl)-1- (propan-2-yl)-1H-1,2,3-benzotriazole 304.35 305

295 1-cyclopropyl-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 304.31 305.2

296 5-{3-[4-(benzyloxy)-3- (trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-(propan-2-yl)- 1H-1,2,3-benzotriazole 479.46 480.2

297 5-{4H,5H-naphtho[2,1- d][1,3]oxazol-2-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 330.39 331

298 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl]-3,4-dihydrospiro[1-benzopyran-2,1′-cyclopentane]-4- one 347.37 348.1

299 3-(1-isopropylbenzotriazol-5-yl)-5- (3-methoxyphenyl)-1,2,4-oxadiazole 335.37 336.1

300 2,2-diethyl-6-(5-(2- methoxyphenyl)-1,3,4-oxadiazol-2-yl)chroman-4-one 378.43 379.3

301 2,2-diethyl-6-[3-(6-methoxy-3- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 379.42 380.3

302 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4- oxadiazol-5-yl)benzonitrile 385.43 386.2

303 2,2-diethyl-6-(3-(4- methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 379.42 380.3

304 3-chroman-8-yl-5-(1- isopropylbenzotriazol-5-yl)-1,2,4- oxadiazole361.41 362.1

305 2,2-diethyl-6-(3-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazol-5-yl)chroman-4-one 431.50432.2

306 1-cyclobutyl-5-[3-(2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 331.38 332.1

307 5-(2-fluorophenyl)-3-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4-oxadiazole 323.33 324

308 6-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 319.37 320.1

309 2,2-diethyl-6-(3-(pyridin-3-yl)- 1,2,4-thiadiazol-5-yl)chroman-4-one 365.45 366

310 2,2-diethyl-6-[3-(5-hydroxy-3- pyridyl)-1,2,4-oxadiazol-5-yl]chroman-4-one 365.39 366.1

311 2,2-diethyl-6-(3-(5- methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 379.42 380.1

312 2,2-diethyl-6-(3-(3-hydroxypyridin- 4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 365.39 366

313 2,2-diethyl-6-(3-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one 417.39 418

314 2,2-diethyl-6-(3-(2- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one 417.39 418

315 2,2-diethyl-6-(3-(2-methylpyridin- 4-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 363.42 364.1

316 N-(4-(5-(3-cyano-4- (isopropylamino)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 361.41 362.1

320 3-(2-chlorophenyl)-5-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole337.81 338

321 5-(1-isopropyl-1H-indol-5-yl)-3-(2- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole 387.36 388.1

322 3-(2-bromophenyl)-5-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole382.26 384

323 2-(5-(1-isopropyl-1H-indol-5-yl)- 1,2,4-oxadiazol-3-yl)phenol 319.36320.1

324 3-(2-isopropoxyphenyl)-5-(1- isopropyl-1H-indol-5-yl)-1,2,4-oxadiazole 361.45 362.1

325 3-(2,6-dimethoxyphenyl)-5-(1- isopropylindol-5-yl)-1,2,4- oxadiazole363.42 364.1

326 3-(benzo[d][1,3]dioxol-4-yl)-5-(1- isopropyl-1H-indol-5-yl)-1,2,4-oxadiazole 347.37 348.1

327 3-chroman-8-yl-5-(1- isopropylindol-5-yl)-1,2,4- oxadiazole 359.43360.1

328 3-(2-fluoro-6-methoxy-phenyl)-5- (1-isopropylindol-5-yl)-1,2,4-oxadiazole 351.38 352.1

329 5-(1-isopropyl-1H-indazol-5-yl)-3- (o-tolyl)-1,2,4-oxadiazole 318.38319.1

330 3-(2-chlorophenyl)-5-(1-isopropyl- 1H-indazol-5-yl)-1,2,4-oxadiazole338.80 339

331 5-(1-isopropyl-1H-indazol-5-yl)-3-(2-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole 388.35 389.1

332 3-(2-bromophenyl)-5-(1-isopropyl- 1H-indazol-5-yl)-1,2,4-oxadiazole383.25 385.1

333 2-(5-(1-isopropyl-1H-indazol-5-yl)- 1,2,4-oxadiazol-3-yl)phenol320.35 321.1

334 3-(2-isopropoxyphenyl)-5-(1- isopropyl-1H-indazol-5-yl)-1,2,4-oxadiazole 362.43 363.1

335 3-(2,6-dimethoxyphenyl)-5-(1- isopropylindazol-5-yl)-1,2,4-oxadiazole 364.41 365.1

336 3-(benzo[d][1,3]dioxol-4-yl)-5-(1- isopropyl-1H-indazol-5-yl)-1,2,4-oxadiazole 348.36 349.1

337 3-chroman-8-yl-5-(1- isopropylindazol-5-yl)-1,2,4- oxadiazole 360.42361.1

338 3-(2-fluoro-6-methoxy-phenyl)-5- (1-isopropylindazol-5-yl)-1,2,4-oxadiazole 352.37 353.1

339 5-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1,3-dihydro-2,1-benzoxazol-3-one 309.28 310.2

340 5-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1-methyl-1,3-dihydro-2,1-benzoxazol-3-one 323.31 324.1

341 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-1,2,3,4-tetrahydroquinolin-2-one 321.34 322.1

342 methyl N-({6-[5-(2- methoxyphenyl)-1,3,4-oxadiazol-2-yl]-2-oxo-2,3-dihydro-1,3- benzoxazol-3- yl}sulfonyl)carbamate 446.39447

343 2-[(2-fluoroethyl)amino]-5-[3-(2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5- yl]benzonitrile 377.38 378.1

344 2-[(2,2-difluoroethyl)amino]-5-[3-(2-oxo-1,2,3,4-tetrahydroquinolin- 6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile 395.37 396.1

345 2-amino-5-[3-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile 331.34 332.1

346 2-[(2-fluoroprop-2-en-1-yl)amino]- 5-[3-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4- oxadiazol-5-yl]benzonitrile 389.39 390.1

347 2-[(2,2-difluoropropyl)amino]-5-[3-(2-oxo-1,2,3,4-tetrahydroquinolin- 6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile 409.40 410.1

348 2-[(2-fluoropropyl)amino]-5-[3-(2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5- yl]benzonitrile 391.41 392.1

349 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-2,3-dihydro-1,3-benzoxazol-2-one 309.28 310

350 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one 323.31 324.1

351 5-[5-(1H-indazol-5-yl)-1,3,4- oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile 344.38 345.2

352 2-[(cyclopropylmethyl)amino]-5- [5-(1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 356.39 357.1

353 2-[(2-fluoroethyl)amino]-5-[5-(1H- indazol-5-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 348.34 349.1

354 2-[(2,2-difluoroethyl)amino]-5-[5-(1H-indazol-5-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 366.33 367.1

355 2-[(2,2-difluoropropyl)amino]-5-[5-(1H-indazol-5-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 380.36 381.1

356 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile 344.38 345.1

357 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(cyclopropylmethyl)amino] benzonitrile 356.39 357.1

358 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2-fluoroethyl)amino]benzonitrile 348.34 349.1

359 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2,2-difluoroethyl)amino]benzonitrile 366.33 367.1

360 5-(4-methyl-2-phenyl-1,3-oxazol-5- yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one 291.1  292.1

361 4-[5-(4-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1H-indole 307.08 308

362 5-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1,3-benzothiazole293.06 294.2

363 5-[3-(4-methoxyphenyl)-1,2,4- thiadiazol-5-yl]-1H-indole 307.08 308

364 5-[5-(3-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1H-indole 307.08 308

365 6-[3-(2-methylphenyl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2-one 305.12 306.1

366 5-[5-(3-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-indole 349.12 350

367 1-methyl-6-[3-(2-methylphenyl)- 1,2,4-oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2-one 319.13 320.2

368 5-(1H-indol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole 291.1  292

369 5-(1H-benzo[d]imidazol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole292.1  293.2

370 5-(1-isopropyl-1H-indazol-5-yl)-3- (2-methoxyphenyl)-1,2,4-oxadiazole 334.14 335.3

371 5-(1H-indazol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole 292.1 293.2

372 5-(1-isopropyl-1H-indol-5-yl)-3-(2- methoxyphenyl)-1,2,4-oxadiazole333.15 334.1

373 5-(1-isopropyl-1H- benzo[d]imidazol-5-yl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole 334.14 335.2

374 5-[3-(2-fluorophenyl)-1,2,4- thiadiazol-5-yl]-1(propan-2-yl)-1H-indole 337.1  338

375 5-[5-(2-methoxyphenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-indole 349.12 350

376 4-methyl-3-(5-{thieno[2,3- b]pyridin-6-yl}-1,2,4-oxadiazol-3-yl)pyridine 294.06 295

377 1-methyl-5-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-2,3-dihydro-1H-indol-2-one 292.1  293.1

378 8-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}cubane-1-carboxylate 389.15 390

379 8-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}cubane-1-carboxylic acid 375.13 376

380 5-[5-(2-fluorophenyl)-1,2,4- thiadiazol-3-yl]-1-(propan-2-yl)-1H-indole 337.1  338

381 5-[3-(2-methylphenyl)-1,2,4- thiadiazol-5-yl]-1-(propan-2-yl)-1H-indole 333.13 334

382 3-(2-methylphenyl)-5-[3-(propan-2- yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazole 320.14 321.2

383 3-(2-methoxyphenyl)-5-[3-(propan- 2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazole 336.13 337.1

384 1-methyl-6-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2-one 306.11 307.1

385 5-[4-(3-methoxyphenyl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 334.14 335

386 6-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1,2,3,4-tetrahydroquinolin-2- one 292.1  293.1

387 5-(2-fluorophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole321.13 322.3

388 5-(2-bromophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole381.05 382.2

389 3-(1-isopropyl-1H-indol-5-yl)-5-(o- tolyl)-1,2,4-oxadiazole 317.15318.3

390 3-(1-isopropyl-1H-indol-5-yl)-5-(2- (trifluoromethyl)phenyl)-1,2,4-oxadiazole 371.12 372.3

391 3-(1-isopropyl-1H-indol-5-yl)-5-(3- methoxypyridin-4-yl)-1,2,4-oxadiazole 334.14 335.3

392 3-(1-isopropyl-1H-indol-5-yl)-5-(3- methoxyphenyl)-1,2,4-oxadiazole333.15 334.3

393 3-(1-isopropyl-1H-indol-5-yl)-5-(4- methoxyphenyl)-1,2,4-oxadiazole333.15 334.2

394 5-(3-fluorophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole321.13 322.1

395 3-(1-isopropyl-1H-indol-5-yl)-5- (pyridin-4-yl)-1,2,4-oxadiazole304.13 305.1

396 3-(1-isopropyl-1H-indol-5-yl)-5- (pyridin-3-yl)-1,2,4-oxadiazole304.13 305.1

397 3-(1-isopropyl-1H-indol-5-yl)-5- (pyridin-2-yl)-1,2,4-oxadiazole304.13 305.1

398 3-(1-isopropyl-1H-indol-5-yl)-5-(2- methoxyphenyl)-1,2,4-oxadiazole333.15 334.2

399 5-(3-fluoropyridin-4-yl)-3-(1- isopropyl-1H-indol-5-yl)-1,2,4-oxadiazole 322.12 323

400 5-(4-fluorophenyl)-3-(1-isopropyl- 1H-indol-5-yl)-1,2,4-oxadiazole321.13 322.1

401 2-(1-isopropyl-1H-pyrrolo[2,3- b]pyridin-5-yl)-4-(2-methoxyphenyl)thiazole 349.12 350

402 4-(2-fluorophenyl)-2-(1-isopropyl- 1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole 337.1  338.1

403 4-(2-fluorophenyl)-2-(1- isopropylindol-5-yl)thiazole 336.11 337.1

404 2-(1-isopropylindol-5-yl)-4-[2- (trifluoromethyl)phenyl]thiazole386.11 387.1

405 2-(1-isopropylindol-5-yl)-4-(3- methoxyphenyl)thiazole 348.13 349.1

406 6-[5-(2-methoxyphenyl)-1,3,4- oxadiazol-2-yl]-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one 323.09 324.1

407 2-(1-isopropylpyrrolo[2,3- b]pyridin-5-yl)-4-(o-tolyl)thiazole333.13 334.1

408 2-(1-isopropylpyrrolo[2,3- (trifluoromethyl)phenyl]thiazole 387.1 388.1

409 2-(1-isopropylpyrrolo[3,2- b]pyridin-5-yl)-4-(o-tolyl)thiazole333.13 334.1

410 2-(1-isopropylpyrrolo[3,2- b]pyridin-5-yl)-4-(3-methoxyphenyl)thiazole 349.12 350.1

411 2-(1-isopropyl-1H-pyrrolo[3,2- b]pyridin-5-yl)-4-(2-methoxyphenyl)thiazole 349.12 350.1

412 4-(2-bromophenyl)-2-(1-isopropyl- 1H-pyrrolo[3,2-b]pyridin-5-yl)thiazole 397.02 400

413 3-(2-bromophenyl)-5- [3-(propan-2-yl)- 3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazole 384.03 385.1

414 4-methyl-3-{5-[3-(propan-2-yl)- 3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]-1,2,4-oxadiazol-3-yl}pyridine 321.13 322.1

415 6-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-3,4-dihydroquinolin-2(1H)-one 417.17 418.2

416 5-(5-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)indolin-2- one 403.15 404.1

417 1-cyclobutyl-5-[3-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazole 332.14 333.1

418 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methylbenzo[d]oxazole 292.13 293.1

419 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methylbenzo[d]oxazole 292.13 293.1

420 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methylbenzo[d]oxazole 292.13 293.1

421 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-7-methylbenzo[d]oxazole 292.13 293.1

422 2-(isopropylamino)-5-(3-(2-oxo- 2,3-dihydrobenzo[d]oxazol-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 361.12 362.1

423 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-1,2,4- oxadiazol-5-yl)benzonitrile 373.12374.2

424 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methoxybenzo[d]oxazole 308.13 309

425 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methoxybenzo[d]oxazole 308.13 309.1

426 2-(1-isopropyl-1H- benzo[d[[1,2,3]triazol-5-yl)-6-methoxybenzo[d]oxazole 308.13 309

427 4-chloro-2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole 312.08 313

428 4-bromo-2-(1- isopropylbenzotriazol-5-yl)-1,3- benzoxazole 356.03357

429 7-bromo-2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole 356.03 359

430 N-[(4Z)-2,2-diethyl-6-[3-(pyridin- 3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4- ylidene]hydroxylamine 364.15 365.1

431 N-[(4E)-2,2-diethyl-6-[3-(pyridin- 3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4- ylidene]hydroxylamine 364.15 365.1

432 1-(propan-2-yl)-5-{4-[2- (trifluoromethyl)phenyl]-1,3-oxazol-2-yl}-1H-1,2,3- benzotriazole 372.12 373

433 5-[4-(2-methylphenyl)-1,3-oxazol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 318.15 319

434 4-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-5-oxa-3-azatricyclo[8,4,0,0²,6]tetradeca- 1(14),2(6),3,10,12-pentaene 344.16 345

435 2-(isopropylamino)-5-(3-(2-oxo- 1,2,3,4-tetrahydroquinolin-7-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 373.15 374

436 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methoxy-4-methylbenzo[d]oxazole 322.14 323

437 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methylbenzo[d]oxazole 306.15 307.2

438 2-{2-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,3-oxazol-4-yl}aniline 319.14 320

439 5-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 362.15 363.1

440 5-(3-(2-aminobenzo[d]thiazol-5- yl)-1,2,4-oxadiazol-5-yl)-2-((cyclopropylmethyl)amino) benzonitrile 388.11 389

441 5-(3-(2-aminobenzo[d]thiazol-5- yl)-1,2,4-oxadiazol-5-yl)-2-(isopropylamino)benzonitrile 376.11 377

442 2-(isopropylamino)-5-(3-(1-oxo- 1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 373.15 374

443 5-(3-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-5-yl)-2-(isopropylamino)benzonitrile 430.2  431

444 2-((cyclopropylmethyl)amino)-5- (3-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-5- yl)benzonitrile 442.2  443.3

445 6-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)benzo[d]oxazol-2(3H)-one 405.13 406

446 6-(3-(2-aminobenzo[d]thiazol-5- yl)-1,2,4-oxadiazol-5-yl)-2,2-diethylchroman-4-one 420.13 421

447 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methylbenzo[d]oxazole 306.15 307

448 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methylbenzo[d]oxazole 306.15 307

449 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-7-methylbenzo[d]oxazole 306.15 307

450 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-methoxybenzo[d]oxazole 322.14 323

451 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-methoxybenzo[d]oxazole 322.14 323

452 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)-6-methoxybenzo[d]oxazole 322.14 323

453 4-chloro-2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole 326.09 326.9

454 7-bromo-2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole 370.04 371.1

455 1-(propan-2-yl)-5-{3-[3- (trifluoromethyl)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazole 374.11 375.1

456 4-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-5-oxa-10-thia-3-azatricyclo[7,3,0,0²,6]dodeca- 1(9),2(6),3,11-tetraene 336.1  337

457 4-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-5-oxa-10-thia-3-azatricyclo[7,3,0,0²,6]dodeca- 1(9),2(6),3,7,11-pentaene 334.09 335

458 N-(2-{2-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,3-oxazol-4-yl}phenyl)acetamide 361.15 362

459 1-(propan-2-yl)-5-[4-(thiophen-2- yl)-1,3-oxazol-2-yl]-1H-1,2,3-benzotriazole 310.09 311

460 2-methyl-1-(5-{3-[3- (trifluoromethyl)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-1H-1,2,3- benzotriazol-1-yl)propan-2-ol 404.12405.1

461 4-bromo-2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)benzo[d]oxazole 370.04 372.9

462 5-{4H-chromeno[4,3- d][1,3]oxazol-2-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole 332.13 333

463 5-[4-(3-chlorothiophen-2-yl)-1,3- oxazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 344.05 345

464 6-(3-(1H-pyrrol-2-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 337.14 338.2

465 2,2-diethyl-6-(3-(furan-2-yl)-1,2,4- oxadiazol-5-yl)chroman-4-one338.13 339.2

466 6-(3-(1H-imidazol-5-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 338.14 339.2

467 2,2-diethyl-6-(3-(thiophen-2-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 354.1  355.2

468 2,2-diethyl-6-(3-(thiophen-3-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 354.1  354.9

469 6-(3-(1H-pyrazol-4-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 338.14 339.1

470 6-(3-(1H-pyrazol-5-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 338.14 339.1

471 2-((cyclopropylmethyl)amino)-5- (3-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-1,2,4- oxadiazol-5-yl)benzonitrile 385.43

472 5-[3-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,2,4-oxadiazol-5-yl]-2-[(2,2,2- trifluoroethyl)amino]benzonitrile 413.11414.1

473 5-[5-(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 373.15 374.1

474 1-(propan-2-yl)-5-[4-(pyridin-2-yl)- 1,3-oxazol-2-yl]-1H-1,2,3-benzotriazole 305.13 306

475 2-[(cyclopropylmethyl)amino]-5- [5-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4- oxadiazol-2-yl]benzonitrile 385.15 386.1

476 2-[(2-fluoroethyl)amino]-5-[5-(2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 377.13 378.1

477 2-[(2,2-difluoroethyl)amino]-5-[5-(2-oxo-1,2,3,4-tetrahydroquinolin- 6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 395.12 396.1

478 2,2-bis(hydroxymethyl)-6-[3- (pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one 353.1  354.1

479 3-bromo-2,2-bis(hydroxymethyl)-6- [3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 431.01 432

480 2,2-dimethyl-5-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-2,3-dihydro-1-benzofuran-3-one 307.1  308.1

481 2,2-dimethyl-5-[3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-2,3-dihydro-1-benzofuran-3-one 307.1  308.1

482 2,2-bis(hydroxymethyl)-6-[3- (pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 353.1  354.1

483 3-bromo-2,2-bis(hydroxymethyl)-6- [3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 431.01 432

484 5-[5-(2-oxo-2,3-dihydro-1,3- benzoxazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 361.12 362.1

485 6-(3-(1H-pyrrol-3-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 337.14 338

486 2-[(cyclopropylmethyl)amino]-5- [5-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 373.12 374.1

487 2-[(2-fluoroethyl)amino]-5-[5-(2- oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 365.09 366.1

488 2-[(2,2-difluoroethyl)amino]-5[5- (2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 383.08 384

489 5-[3-(1H-1,3-benzodiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2,2,2-trifluoroethyl)amino]benzonitrile 384.09 385.2

490 5-[3-(2,5-dimethylfuran-3-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 323.14 324.1

491 5-[3-(2-methylfuran-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 309.12 310.1

492 2-methyl-1-{5-[3-(2-methylfuran-3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3- benzotriazol-1-yl}propan-2-ol 339.13340.1

493 1-{5-[3-(2,5-dimethylfuran-3-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methylpropan- 2-ol 353.15 354.1

494 2,2-bis(methoxymethyl)-6-[3- (pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran- 4-one 381.13 382.1

495 2,2-diethyl-6-(3-(furan-3-yl)-1,2,4- oxadiazol-5-yl)chroman-4-one338.13 339

496 2-(isopropylamino)-5-(3-(2- oxoindolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 359.14 360.2

497 2-((cyclopropylmethyl)amino)-5- (3-(2-oxoindolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 371.14 372.3

498 5-{5-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}-2,1,3-benzoxadiazole 347.11 348.1

499 5-[3-(2-chloropyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 340.08 341

500 6-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2,2-diethyl-3,4-dihydro-2H-1-benzopyran-4- one 390.13 391.1

501 1-{5-[3-(1H-1,3-benzodiazol-6-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methylpropan- 2-ol 375.14 376.1

502 6-(3-(5-aminopyridin-3-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 364.15 365.2

503 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)oxazolo[5,4-c]pyridine 279.11 280.2

504 2-(1-isobutyl-1H- benzo[d][1,2,3]triazol-5-yl)oxazolo[5,4-c]pyridine 293.13 294.3

505 2,2-dimethyl-3-(5-(5-(o-tolyl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 363.17 364.1

506 4-isopropoxy-4′-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)[1,1′-biphenyl]-3-carbonitrile 396.2  397.1

507 4′-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-4-(isopropylamino)-[1,1′-biphenyl]-3- carbonitrile 395.21 396.1

508 4-(allylamino)-4′-(1-isopropyl-1H-benzo[d][1,2,3]triazol-5-yl)[1,1′- biphenyl]-3-carbonitrile 393.2  394.1

509 2,2-diethyl-6-(5-(pyridin-3- yl)pyrimidin-2-yl)chroman-4-one 359.16360.3

510 2,2-diethyl-6-(5-(pyridin-4- yl)pyrimidin-2-yl)chroman-4-one 359.16360.3

511 5-[3-(1H-1,3-benzodiazol-6-yl)- 1,2,4-oxadiazol-5- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 345.13 346.1

512 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)acetamide 406.16 407.3

513 6-(3-(2-aminopyridin-4-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 364.15 365.4

514 2-(isopropylamino)-5-(3-(1-oxo- 1,2,3,4-tetrahydroisoquinolin-7-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 373.15 374.3

515 2-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-7-methoxybenzo[d]oxazole 308.13 309.2

516 5-[4-(2-methylphenyl)-1H-pyrrol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 316.17 317

517 5-[1-methyl-4-(2-methylphenyl)- 1H-pyrrol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 330.18 331

518 1-{5-[3-(1,4-dimethyl-1H-pyrazol- 3-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol 353.16 354.1

519 5-[3-(1,4-dimethyl-1H-pyrazol-3- yl)-1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole 323.15 324.1

520 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2,2-difluoropropyl)amino]benzonitrile 380.12 381.2

521 2,2-diethyl-6-(3-(quinolin-6-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 399.16 400.4

522 2,2-diethyl-6-(3-(isoquinolin-6-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 399.16 400.3

523 3-(5-(5-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2,2-dimethylpropan-1-ol 393.18394.3

524 2,2-dimethyl-3-(5-(5-(3- methylthiophen-2-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 369.13370.2

525 3-(5-(5-(2-methoxyphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2,2- dimethylpropan-1-ol 379.16 380

526 3-(5-(5-(2-chlorophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2,2- dimethylpropan-1-ol 383.11 384

527 3-(5-(5-(2-ethylphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2,2- dimethylpropan-1-ol 377.19 378.1

528 2,2-dimethyl-3-(5-(5-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 1-ol418.14 419

529 2,2-dimethyl-3-(5-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 1-ol418.14 419

530 2,2-diethyl-6-(5-(pyridin-2- yl)pyrimidin-2-yl)chroman-4-one 359.16360.3

531 N-{4-[5-(2,2-diethyl-4-oxo-3,4- dihydro-2H-1-benzopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3- methoxyphenyl}acetamide 435.18 436.2

532 N-(3-methoxy-4-{5-[1-(propan-2- yl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}phenyl) acetamide 392.16 393.1

533 N-{4-[5-(2,1,3-benzoxadiazol-5- yl)-1,2,4-oxadiazol-3-yl]-3-methoxyphenyl}acetamide 351.1 352

534 5-[1-(2-methoxyethyl)-4-(2- methylphenyl)-1H-pyrrol-2-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole 374.21 375

535 2-methyl-7-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 307.1  308

536 2-methyl-7-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 307.1  308.1

537 5-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)nicotinamide 392.15 393.2

538 N-(5-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-3-yl)acetamide 406.16 407.3

539 5-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d]imidazol-2(3H)-one 404.15 405

540 2,2-dimethyl-3-(5-(5-(3- methylpyrazin-2-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 365.16366.3

541 2,2-dimethyl-3-(5-(5-(4- methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 364.16 365

542 5-[4-(2-fluorophenyl)-1H-pyrrol-2- yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 320.14 321.2

543 5-(5-phenyl-1H-pyrrol-3-yl)-1- (propan-2-yl)-1H-1,2,3- benzotriazole302.15 303

544 5-(1-methyl-5-phenyl-1H-pyrrol-3- yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole 316.17 317

545 N-(5-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-3- yl)methanesulfonamide 442.13 443.3

546 2,2-diethyl-6-(3-(6-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one 367.13 368.3

547 2,2-diethyl-6-(3-(2-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one 367.13 368.2

548 2,2-diethyl-6-(3-(6- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one 417.13 418.2

549 2,2-diethyl-6-(3-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 363.16 364.3

550 2,2-diethyl-6-(3-(6-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 363.16 364.3

551 2,2-diethyl-6-(3-(5-fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman- 4-one 367.13 368.2

552 2,2-diethyl-6-(5-(2-hydroxypyridin-4-yl)pyrimidin-2-yl)chroman-4-one 375.16 376.3

553 2,2-diethyl-6-[3-(6- methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 379.15 380.1

554 2,2-diethyl-6-(3-(thiophen-3-yl)- 1,2,4-oxadiazol-5-yl)-2,3-dihydroquinolin-4(1H)-one 353.12 354.2

555 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)picolinamide 392.15 393

556 N-(4-(5-(2,2-diethyl-4- oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridin-2- yl)methanesulfonamide 442.13 443.3

557 2,2-diethyl-6-(3-(5- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one 417.13 418

558 2,2-diethyl-6-(3-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one 417.13 418

559 2,2-diethyl-6-(5-(pyridin-3-yl)- 1,2,4-oxadiazol-3-yl)chroman-4- one349.14 350

560 5-[5-(2-methyl-1H-1,3- benzodiazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 358.15 359.2

561 2-[(2,2-difluoroethyl)aminol-5[5- (2-methyl-1H-1,3-benzodiazol-5-yl)-1,3,4-oxadiazol-2-yl] benzonitrile 380.12 381.2

562 2,2-diethyl-6-(3-(2- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4- one 417.13 418

563 2,2-diethyl-6-(3-(5-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 363.16 364

564 2,2-diethyl-6-(3-(2-methylpyridin- 3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 363.16 364

565 1-isopropyl-5-(5-(2- methoxyphenyl)pyrimidin-2-yl)-1H-benzo[d][1,2,3]triazole 345.16 346.1

566 5-[4-(2-methoxyphenyl)-1H-pyrrol- 2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 332.16 333.2

567 2-methyl-1-{5-[3-(1-methyl-1H- imidazol-2-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1- yl}propan-2-ol 339.14 340.1

568 N-{4-[5-(2,2-diethyl-4-oxo-3,4- dihydro-2H-1-benzopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3- methoxyphenyl} methanesulfonamide 471.15 472.1

569 5-[3-(1-methyl-1H-imidazol-2-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 309.13 310.1

570 2-methyl-1-{5-[3-(1,3-oxazol-4-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan-2-ol 326.11 327

571 5-[5-(2-methyl-1H-1,3- benzodiazol-5-yl)-1,2,4-oxadiazol-3-yl]-1-(propan-2-yl)-1H-1,2,3- benzotriazole 359.15 360

572 5-[5-(1-methyl-1H-1,3- benzodiazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 358.15 359.1

573 2-[(2,2-difluoroethyl)amino]-5[5- (1-methyl-1H-1,3-benzodiazol-5-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 380.12 381.1

574 5-{5-[1-(2-hydroxyethyl)-1H-1,3- benzodiazol-5-yl]-1,3,4-oxadiazol-2-yl}-2-[(propan-2- yl)amino]benzonitrile 388.16 389.1

575 5-[2-(2-methoxyphenyl)-1,3- oxazol-4-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 334.14 335

576 2-{3[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}aniline 320.14 321.2

577 1-{5-[3-(1H-indol-7-yl)-1,2,4- oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methylpropan- 2-ol 374.15 375.2

578 2-[(2,2-difluoroethyl)amino]-5-{5- [1-(2-hydroxyethyl)-1H-1,3-benzodiazol-5-yl]-1,3,4-oxadiazol- 2-yl}benzonitrile 410.13 411.1

579 5-[5-(1-methyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 358.15 359.2

580 2-[(2,2-difluoroethyl)amino]-5-[5- (1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 380.12 381.1

581 [(4-{5-[1-(2-hydroxy-2- methylpropyl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol- 3-yl}phenyl)methyl]phosphonate485.18 486.2

582 N-{3-methoxy-4-[3-(pyridin-4-yl)- 1,2,4-oxadiazol-5-yl]phenyl}acetamide 310.11 311.2

583 diethyl [(4-{5-[1-(propan-2-yl)-1H- 1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-3- yl}phenyl)methyl]phosphonate 455.17 456.1

584 N-{4-[5-(2,2-diethyl-4-oxo-3,4- dihydro-2H-1-benzopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3- (trifluoromethoxy)phenyl} acetamide 489.15490.1

585 5-[5-(1H-1,3-benzodiazol-4-yl)- 1,3,4-oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile 344.14 345.1

586 5-[5-(1H-1,3-benzodiazol-4-yl)- 1,3,4-oxadiazol-2-yl]-2-[(2,2-difluoroethyl)amino]benzonitrile 366.1  367.1

587 N-methyl-2-{2-[1-(propan-2-yl)- 1H-1,2,3-benzotriazol-5-yl]-1,3-oxazol-4-yl}aniline 333.16 334

588 2-ethyl-7-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 321.11 322.1

589 2-ethyl-7-[3-(pyridin-4-yl)-1,2,4- oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 321.11 322.1

590 1-{5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methylpropan- 2-ol 377.12 378.1

591 2,2-diethyl-6-(3-(thiophen-2-yl)- 1,2,4-oxadiazol-5-yl)-2,3-dihydroquinolin-4(1H)-one 353.12 353.9

592 4-(5-(2,2-diethyl-4-oxochroman-6- yl)-1,2,4-oxadiazol-3-yl)-N-methylpicolinamide 406.16 407

593 2-methyl-1-(5-(5-(o-tolyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol 349.15 350

594 2,2-diethyl-6-(5-(2- methoxyphenyl)pyrimidin-2- yl)chroman-4-one388.18 389

595 2-isopropoxy-5-(5-(1-isopropyl- 1H-benzo[d][1,2,3]triazol-5-yl)pyrimidin-2-yl)benzonitrile 398.19 399.2

596 5-(5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)pyrimidin-2-yl)-2- (isopropylamino)benzonitrile 397.2  398.1

597 2-methyl-1-{5-[3-(3-methylpyridin- 4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan-2- ol 350.15 351.1

598 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-(cyclopropylamino)benzonitrile 342.12 343.1

599 N-methyl-2-{3-[1-(propan-2-yl)- 1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}aniline 334.15 335.2

600 5-[5-(1H-1,3-benzodiazol-5-yl)- 1,3,4-oxadiazol-2-yl]-2-[(1,3-difluoropropan-2- yl)amino]benzonitrile 380.12 381.1

601 5-[5-(2-methylphenyl)-1H-pyrrol- 3-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 316.17 317

602 2-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}pyridin-3-ol 322.12 323

603 5-(5-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridine-3- sulfonamide 428.12 428.9

604 2,2-diethyl-6-(3-(3- methoxythiophen-2-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one 384.11 385.2

605 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(4-methoxypyridin-3-yl)-1,2,4- oxadiazole 336.13 337.2

606 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxypyridin-4-yl)-1,2,4- oxadiazole 336.13 337.2

607 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(2-methoxypyridin-3-yl)-1,2,4- oxadiazole 336.13 337.2

608 4-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}-2,3-dihydro-1H-inden-1-one 359.14 360

609 2-methyl-2-(5-(5-(o-tolyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 349.15 350.1

610 2-(5-(5-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2-methylpropan-1-ol 379.16 380

611 2-methyl-2-(5-(5-(3- methylthiophen-2-yl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 355.11 355.9

612 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methoxypyridin-2-yl)-1,2,4- oxadiazole 336.13 337.2

613 7-[3-(4-methylpyridin-3-yl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin-2-one 307.11 307.1

614 7-[3-(2-methoxyphenyl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin-2-one 322.11 322.1

615 N,N-dimethyl-2-{3-[1-(propan-2- yl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}aniline 348.17 349.1

616 4-(5-(2,2-diethyl-4-oxochroman-6-yl)-1,2,4-oxadiazol-3-yl)pyridine-2- sulfonamide 428.12 428.9

617 2,2-diethyl-6-(3-(pyrazin-2-yl)- 1,2,4-oxadiazol-5-yl)chroman-4- one350.14 351.1

618 2-(5-(5-(2-chlorophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol 369.1  369.9

619 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-methoxypyridin-3-yl)-1,2,4- oxadiazole 336.13 337.2

620 2,2-diethyl-6-(3-(pyrimidin-5-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 350.14 351.1

621 2,2-diethyl-6-(3-(pyridazin-3-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 350.14 351.1

622 6-(3-(benzo[d]oxazol-6-yl)-1,2,4- oxadiazol-5-yl)-2,2-diethylchroman-4-one 389.14 390

623 2-(5-(5-(2-methoxyphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol 365.15 365.9

624 2-(5-(5-(2-ethylphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol 363.17 364.1

625 2-methyl-2-(5-(5-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 350.15 351.1

626 2-methyl-2-(5-(5-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 1-ol404.12 405.1

627 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methoxypyridin-2-yl)-1,2,4- oxadiazole 336.13 337.1

628 2-(isopropylamino)-5-(5-(2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)benzonitrile 370.15 371.1

629 7-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin- 2-one 293.09 292.1

630 2-propyl-7-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1- benzopyran-4-one 335.13 336.1

631 2,2-diethyl-6-[5-(5-fluoropyridin-3- yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one 367.13 368.1

632 2,2-diethyl-6-[5-(5-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one 363.16 364.1

633 2-butyl-7-[3-(pyridin-3-yl)-1,2,4- oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 349.14 350.1

634 2-[(1-hydroxy-2-methylpropan-2- yl)amino]-5-[5-(1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 388.16 389.2

635 2-[(2,2-difluoro-3- hydroxypropyl)amino]-5-[5-(1-methyl-1H-1,3-benzodiazol-6-yl)- 1,3,4-oxadiazol-2-yl]benzonitrile410.13 411.2

636 4-{3-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-5-yl}-2,3-dihydro-1H-inden-1-ol 361.15 362

637 5-[5-(2-oxo-2,3-dihydro-1,3- benzoxazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 361.12 362.2

638 5-[5-(1-oxo-1,2,3,4- tetrahydroisoquinolin-7-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]henzonitrile 373.15 374.2

639 2,2-diethyl-6-(3-(pyrimidin-4-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 350.14 351.1

640 2,2-diethyl-6-(3-(pyrimidin-2-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 350.14 351.1

641 2-methyl-2-(5-(5-(3-methylpyrazin- 2-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 1-ol 351.14 352.2

642 2-(5-(5-(1H-benzo[d]imidazol-6- yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-o 375.14 376.1

643 2-(5-(5-(2-fluoropyridin-3-yl)- 1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-1-ol 354.12 355.1

644 2-methyl-2-(5-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl) propan-1-ol404.12 405.2

645 7-[3-(1H-pyrazol-4-yl)-1,2,4- oxadiazol-5-yl]-1,2,3,4-tetrahydroquinoxalin-2-one 282.09 281.1

646 1-(propan-2-yl)-5-[3-(1H-pyrazol- 4-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazole 295.12 296.2

647 1-{5-[3-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol 379.16 380.1

648 2,2-diethyl-6-(3-(pyridazin-4-yl)- 1,2,4-oxadiazol-5-yl)chroman-4-one 350.14 351

649 2-(isopropylamino)-5-(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)benzonitrile 305.13 306.3

650 5-(3-(1-(1-hydroxy-2- methylpropan-2-yl)-1H-benzo[d][1,2,3]triazol-5-yl)-1,2,4- oxadiazol-5-yl)indolin-2-one 390.14391.1

651 2-[(2,2-difluoroethyl)amino]-5-[5- (2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 383.08 384

652 2-[(2,2-difluoroethyl)amino]-5-[5- (1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)-1,3,4- oxadiazol-2-yl}benzonitrile 395.12396.1

653 2-methyl-1-{6-[3-(1H-pyrazol-4- yl)-1,2,4-oxadiazol-5-yl]-3H-indazol-3-yl}propan-2-ol 324.13 326.2

654 1-(5-(5-(4-methoxy-2- methylphenyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2-methylpropan-2-ol 379.16 380.3

655 2-methyl-1-(5-(5-(3- methylthiophen-2-yl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol 355.11 356.2

656 1-(5-(5-(2-methoxyphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)- 2-methylpropan-2-ol 365.15 366.2

657 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methoxypyridin-4-yl)-1,2,4- oxadiazole 336.13 337.1

662 1-{5-[3-(2-methoxy-4- methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2- methylpropan-2-ol 379.16 380

663 2,2-diethyl-6-[5-(2-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one 363.16 364.1

664 2,2-diethyl-6-[5-(5-hydroxypyridin- 3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one 365.14 366.1

665 5-[5-(1-tert-butyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 400.2  401.3

666 2,2-diethyl-N-[(1E)- (hydroxyimino)[2- (trifluoromethyl)pyridin-3-yl]methyl]-4-oxo-3,4-dihydro-2H- 1-benzopyran-7-carboxamide 435.14 436.2

667 2-(isopropylamino)-5-(5-(pyridin- 4-yl)-1,3,4-oxadiazol-2-yl)benzonitrile 305.13 306.3

668 2-methyl-1-(5-(5-(3-methylpyrazin- 2-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol 351.14 352.2

669 1-(5-(5-(2-chlorophenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-2-ol 369.1  369.9

670 1-(5-(5-(2-ethylphenyl)-1,2,4- oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-2- methylpropan-2-ol 363.17 364

671 2-methyl-1-(5-(5-(4-methylpyridin- 3-yl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d][1,2,3]triazol-1-yl)propan- 2-ol 350.15 351.2

672 2-methyl-1-(5-(5-(3- (trifluoromethyl)pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 2-ol404.12 405.2

673 2-methyl-1-(5-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H- benzo[d][1,2,3]triazol-1-yl)propan- 2-ol404.12 405.2

675 1-{5-[3-(2,6-dimethylpyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}-2-methylpropan- 2-ol 364.16 365.1

676 5-[5-(1-tert-butyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(2,2- difluoroethyl)amino]benzonitrile 422.17 423.1

677 2,2-diethyl-6-[3-(1-methyl-1H- indol-3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4- one 401.17 402.1

678 5-[3-(1-methyl-1H-indol-3-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 358.15 359.1

679 5-[3-(2,6-dimethylpyridin-3-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 334.15 335.1

680 2-methyl-1-{5-[3-(4-methyl-1,3- oxazol-5-yl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-benzotriazol-1-yl}propan- 2-ol 340.13 341.1

681 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(4-methoxypyridin-3-yl)-1,2,4- oxadiazole 336.13 337.3

682 5-[3-(1-methyl-1H-indol-3-yl)- 1,2,4-oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile 357.16 358.2

683 5-[3-(4-methyl-1,3-oxazol-5-yl)- 1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole 310.12 311.1

684 2,2-diethyl-6-[3-(1-ethyl-1H-indol- 3-yl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-2H-1-benzopyran-4-one 415.19 416.2

685 5-[5-(1-methyl-1H-1,3- benzodiazol-4-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 358.15 359.2

686 2-[(2,2-difluoroethyl)amino]-5[5- (1-methyl-1H-1,3-benzodiazol-4-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 380.12 381.2

687 4-{5-[1-(propan-2-yl)-1H-1,2,3- benzotriazol-5-yl]-1,2,4-oxadiazol-3-yl}-2,3-dihydro-1H-inden-1-one 359.14 360

688 2-((2,2-difluoroethyl)amino)-5-(5- (pyridin-4-yl)-1,3,4-oxadiazol-2-yl)benzonitrile 327.09 328.3

689 5-(5-(1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)-2-(isopropylamino)benzonitrile 294.12 295.3

690 3-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-5-(3-methylpyridin-2-yl)-1,2,4- oxadiazole 320.14 321.3

691 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(2-methylpyridin-3-yl)-1,2,4- oxadiazole 320.14 321.2 321.2

692 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methylpyridin-4-yl)-1,2,4- oxadiazole 320.14 321.2

693 5-(1-isopropyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-methylpyridin-2-yl)-1,2,4- oxadiazole 320.14 321.1

694 5-{5-[1-(propan-2-yl)-1H-1,3- benzodiazol-6-yl]-1,3,4-oxadiazol-2-yl}-2-[(propan-2- yl)amino]benzonitrile 386.19 387.2

695 5-[5-(1-ethyl-1H-1,3-benzodiazol- 6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile 372.17 373.1

696 2,2-diethyl-6-[5-(2- methoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1- benzopyran-4-one 379.15 380.2

697 2,2-diethyl-6-{5-[4- (trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-3,4-dihydro- 2H-1-benzopyran-4-one 417.13 418.2

698 2,2-diethyl-6-[5-(2-fluoropyridin-3- yl)-1,2,4-oxadiazol-3-yl]-3,4-dihydro-2H-1-benzopyran-4-one 367.13 368.1

699 2,2-diethyl-6-{5-[2- (trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-3,4-dihydro- 2H-1-benzopyran-4-one 417.13 418.1

700 6-[5-(5-aminopyridin-3-yl)-1,2,4- oxadiazol-3-yl]-2,2-diethyl-3,4-dihydro-2H-1-benzopyran-4-one 364.15 365.1

701 2-[(2,2-difluoroethyl)amino]-5-{5- [1-(propan-2-yl)-1H-1,3-benzodiazol-6-yl]-1,3,4-oxadiazol- 2-yl}benzonitrile 408.15 409.1

702 2-[(2,2-difluoroethyl)amino]-5-[5-(1-ethyl-1H-1,3-benzodiazol-6-yl)- 1,3,4-oxadiazol-2-yl]benzonitrile394.14 395.1

703 5-[3-(1-ethyl-1H-indol-3-yl)-1,2,4- oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile 371.17 372.1

704 2-[(2-fluoroethyl)amino]-5-[5-(1- methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 362.13 363.1

705 5-[5-(1-methyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-1H-indazol-3-amine 331.12 332

706 2-[(2,2-difluoropropyl)aminol-5-[5- (1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 394.14 395.1

707 2-(cyclopropylamino)-5-[5-(1- methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 356.14 357.1

708 2-[(1,3-difluoropropan-2- yl)amino]-5-[5-(1-methyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 394.14 395.1

709 5-[3-(3-methoxypyridin-4-yl)- 1,2,4-oxadiazol-5-yl]-1-(oxan-4-yl)-1H-1,2,3-benzotriazole 378.14 379.1

710 5-[5-(1,2-dimethyl-1H-1,3- benzodiazol-6-yl)-1,3,4-oxadiazol-2-yl]-2-[(propan-2- yl)amino]benzonitrile 372.17 373.1 .

711 2-[(2,2-difluoroethyl)amino]-5-[5- (1,2-dimethyl-1H-1,3-benzodiazol-6-yl)-1,3,4-oxadiazol-2- yl]benzonitrile 394.14 395.1

712 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2,2,2-trifluoroethyl)amino]benzonitrile 386.07 387

713 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2-fluoroethyl)amino]benzonitrile 350.09 351

718 2,2-diethyl-6-(5-(2-methylpyridin- 3-yl)-1,3,4-oxadiazol-2-yl)chroman-4-one 363.16 364.4

719 2,2-diethyl-6-(5-(2-methylpyridin- 3-yl)-1,3,4-thiadiazol-2-yl)chroman-4-one 379.14 380.2

720 2,2-diethyl-6-(5-(2-fluoropyridin-3-yl)-1,3,4-thiadiazol-2-yl)chroman- 4-one 383.11 384.2

721 5-(5-(1H-indol-5-yl)-1,3,4- oxadiazol-2-yl)-2-(isopropylamino)benzonitrile 343.14 344.4

724 2,2-diethyl-6-(5-(5-methylpyridin- 3-yl)-1,3,4-thiadiazol-2-yl)chroman-4-one 379.14 380.3

725 2,2-diethyl-6-(5-(4- (trifluoromethyl)pyridin-3-yl)-1,3,4-thiadiazol-2-yl)chroman-4- one 433.11 434.3

726 2-(cyclopropylmethylamino)-5-[3- (2-oxo-3H-1,3-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]benzonitrile 373.12 374.1

727 2-((cyclopropylmethyl)amino)-5- (3-(1-oxoisoindolin-5-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 371.14 372.1

728 2-(isopropylamino)-5-(3-(2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1,2,4-oxadiazol-5- yl)benzonitrile 360.13 361.1

729 2-((cyclopropylmethyparnino)-5- (3-(2-oxo-2,3-dihydro-1H-benzo[d]]imidazol-5-yl)-1,2,4- oxadiazol-5-yl)benzonitrile 372.13 373.1

730 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile 346.12 347.1

730 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(propan-2-yl)amino]benzonitrile 346.12 347.1

731 N-[4-(5-{3-cyano-4-[(propan-2- yl)amino]phenyl}-1,2,4-oxadiazol-3-yl)-3-methoxyphenyl]acetamide 391.16 392.1

732 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(2,2-difluoroethyl)amino]benzonitrile 358.12 369

733 2-[(2,2-difluoroethyl)amino]-5-[5-(isoquinolin-6-yl)-1,3,4-oxadiazol- 2-yl]benzonitrile 377.11 378.1

734 5-[3-(2,1,3-benzoxadiazol-5-yl)- 1,2,4-oxadiazol-5-yl]-2-[(cyclopropylmethyl)amino] benzonitrile 368.08 359

735 5-[5-(isoquinolin-6-yl)-1,3,4- oxadiazol-2-yl]-2-[(propan-2-yl)amino]benzonitrile 355.14 356.1

736 2-[(propan-2-yl)amino]-5-[5- (quinolin-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 355.14 356.1

736 2-[(propan-2-yl)amino]-5-[5- (quinolin-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile 355.14 356.1

737 2-(isopropylamino)-5-(5-(pyridin- 3-yl)pyrimidin-2-yl)benzonitrile315.15 316

738 2-isopropoxy-5-(5-(pyridin-3- yl)pyrimidin-2-yl)benzonitrile 316.13317

739 2-(isopropylamino)-5-(5-(pyridin- 4-yl)pyrimidin-2-yl)benzonitrile315.15 316

740 2-isopropoxy-5-(5-(pyridin-4- yl)pyrimidin-2-yl)benzonitrile 316.13317

741 2-(isopropylamino)-5-(5-(pyridin- 2-yl)pyrimidin-2-yl)benzonitrile315.15 316

742 2-isopropoxy-5-(5-(pyridin-2- yl)pyrimidin-2-yl)benzonitrile 316.15317

743 5-(5-(2-hydroxypyridin-4- yl)pyrimidin-2-yl)-2-(isopropylamino)benzonitrile 331.14 332

744 5-(5-(2-hydroxypyridin-4- yl)pyrimidin-2-yl)-2-isopropoxybenzonitrile 332.13 333

745 2-isopropoxy-5-(5-(2- methoxyphenyl)pyrimidin-2- yl)benzonitrile345.15 346

746 5-(5-(2,2-diethyl-4-oxochroman-6- yl)pyrimidin-2-yl)-2-(isopropylamino)benzonitrile 440.22 441.4

747 2-(isopropylamino)-5-(5-(2- methoxyphenyl)pyrimidin-2-yl)benzonitrile 344.16 345.3

748 5-(5-(benzo[c][1,2,5]oxadiazol-5- yl)pyrimidin-2-yl)-2-isopropoxybenzonitrile 357.12 357.9

749 5-(5-(benzo[c][1,2,5]oxadiazol-5- yl)pyrimidin-2-yl)-2-(isopropylamino)benzonitrile 356.14 356.9

750 N-isopropyl-4-(5-(2- methoxyphenyl)pyrimidin-2-yl)-2-(trifluoromethyl)aniline 387.16 388

751 2-(4-isopropoxy-3- (trifluoromethyl)phenyl)-5-(2-methoxyphenyl)pyrimidine 388.14 389

752 2-(4-isopropoxy-3- (trifluoromethyl)phenyl)-5-(pyridin-4-yl)pyrimidine 359.13 360

General Procedure A:

Example 2

Synthesis of Intermediate 2-2: N,2-dihydroxypyridine-3-carboximidamide

To a mixture of 2-1 (2-hydroxypyridine-3-carbonitrile)(200 mg, 1.67mmol) in ethanol (10 mL) was added hydrochloride salt of hydroxylamine(174 mg, 2.50 mmol), diisopropylethylamine (430 mg, 3.33 mmol) at 20° C.The mixture was then heated to 90° C. and stirred for 16 hrs. Themixture was concentrated in vacuum to remove part of ethanol, theresulting mixture was filtered, and the solid was dried in vacuum whichwas used as the product in next step without further purification (185mg, 69% yield).

¹H NMR (400 MHz, DMSO-d₆) δ=12.06 (br, s, 1H), 9.50 (br, s, 1H), 7.95(dd, J=7.2, 2.4 Hz, 1H), 7.51 (dd, J=6.0, 2.0 Hz, 1H), 6.3-6.30 (m, 3H).

General Procedure B Synthesis of Intermediate 3-2:2,2-diethyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-carboxylic acid

Alternative Synthesis of Intermediate 4-4:2,2-diethyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-carboxylic acid

Synthesis of 4-2: 6-bromo-2,2-diethyl-3,4-dihydro-2H-1-benzopyran-4-one

To a solution of 1-(5-bromo-2-hydroxy-phenyl)ethanone (20 g, 93.0 mmol,1 eq) in methanol (400 mL) was added pyrrolidine (7.94 g, 112 mmol, 1.2eq) and pentan-3-one (9.61 g, 112 mmol, 1.2 eq). The mixture was stirredat 80° C. for 16 hr. The reaction mixture diluted with water (200 mL)and extracted with ethyl acetate (200 mL×2), the combined organic layerswere washed with brine (500 mL), dried over sodium sulfate, filtered andconcentrated under reduced pressure to give a residue which was purifiedby column chromatography to give the desired product 4-2 (12 g, 46%yield) as a yellow oil.

¹H NMR (400 MHz, CDCl₃) δ=7.93 (d, J=2.5 Hz, 1H), 7.52 (dd, J=8.8, 2.6Hz, 1H), 6.84 (d, J=8.8 Hz, 1H), 2.70 (s, 2H), 1.86-1.62 (m, 4H), 0.92(t, J=7.5 Hz, 6H).

Synthesis of Intermediate 4-3:2,2-diethyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-carbonitrile

To a solution of 6-bromo-2,2-diethyl-chroman-4-one (10 g, 35.3 mmol, 1eq) in DMF (100 mL) was added zinc cyanide (6.22 g, 53.0 mmol, 1.5 eq)and tetratriphenylphosphine palladium (4.08 g, 3.53 mmol, 0.1 eq). Themixture was stirred at 130° C. for 2 hr. The reaction mixture wasdiluted with water (100 mL) and extracted with ethyl acetate (100 mL×3).The combined organic layers were washed with brine (200 mL), dried oversodium sulfate, filtered and concentrated under reduced pressure to givea residue which was purified by flash silica gel chromatography(petroleum ether/ethyl acetate=100/1 to 1/1) to give the desired product4-3 (8 g, 99% yield).

¹H NMR (400 MHz, DMSO-d₆) δ=8.08 (d, J=1.9 Hz, 1H), 7.96 (dd, J=8.7, 2.0Hz, 1H), 7.20 (d, J=8.7 Hz, 1H), 2.88 (s, 2H), 1.86-1.59 (m, 4H), 0.86(br, t, J=7.4 Hz, 6H).

Scheme 7 Synthesis of Intermediate 4-4:2,2-diethyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-carboxylic acid

A suspension of 2,2-diethyl-4-oxo-chromane-6-carbonitrile (6.05 g, 26.4mmol, 1 eq) in acetic acid (60 mL) and concentrated hydrochloridesolution (60 mL) was stirred at 120° C. for 16 hr, The residue wastriturated with water (500 mL), filtered and dried under vacuum to givethe titled product 4-4 (5.8 g, 89% yield).

¹H NMR (400 MHz, DMSO-d₆) δ=8.27 (d, J=1.9 Hz, 1H), 8.06 (dd, J=8.7, 2.0Hz, 1H), 7.11 (d, J=8.7 Hz, 1H), 2.85 (s, 2H), 1.77-1.68 (m, 4H), 0.87(t, J=7.4 Hz, 6H).

General Procedure C:

Synthesis of Compound 9α-1:2,2-diethyl-6-(3-(2-hydroxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)chroman-4-one

To a mixture of 4-4 (268 mg, 1.08 mmol) in N,N-dimethylformamide (6 mL)was added HOBt (159 mg, 1.18 mmol, 1.2 eq), EDCI (225 mg, 1.18 mmol, 1.2eq) at 20° C. under nitrogen atmosphere. The mixture was stirred for 30min, then, 2-2 (150 mg, 980 umol, 1 eq) was added, and the resultantmixture was then heated to 120° C. and stirred for 2 hrs. The mixturewas diluted with water (20 mL), extracted with ethyl acetate (20 mL×3).The combined organic phase was washed by brine (50 mL), dried oversodium sulfate, concentrated in vacuum. The residue was purified byprep-HPLC (column: Phenomenex Gemini 150×25 mm×10 um; mobile phase:[water (0.05% ammonia hydroxide v/v)-ACN]; B %: 35%-65%, 12 min) to givethe product 9-1 as a white solid (20 mg, 6% yield). ¹H NMR (400 MHz,DMSO-d₆) δ=12.23 (br, s, 1H), 8.44 (d, J=2.0 Hz, 1H), 8.33 (dd, J=7.2,2.0 Hz, 1H), 8.28 (dd, J=8.8, 2.4 Hz, 1H), 7.68 (dd, J=6.0, 2.0 Hz, 1H),7.29 (d, J=8.8 Hz, 1H), 6.42 (t, J=6.8 Hz, 1H), 2.93 (s, 2H), 1.81-1.70(m, 4H), 0.90 (t, J=7.2 Hz, 6H).

Synthesis of Compound:2,2-diethyl-6-[3-(1H-pyrazol-4-yl)-1,2,4-oxadiazol-5-yl]-3H-1-benzopyran-4-one

To a solution of compound 4-4 (16.41 g, 66.08 mmol, 1 eq.) in DMF (50mL) was added EDCI (15.20 g, 79.29 mmol, 1.2 eq.) and HOBt (8.93 g,66.08 mmol, 1.0 eq.), stirred at 20° C. for 0.5 hour. Then compound 9b-1(10 g, 79.29 mmol, 1.2 eq.) was added. The mixture was stirred at 20° C.for 0.5 hour, then heated to 120° C. and stirred for 2 hours. Themixture was diluted with water (100 mL), extracted with EtOAc (150mL*3), dried with sodium sulfate, filtered and concentrated. The residuewas purified by silica gel column chromatography (PE:EA=3:1) to give9b-2 (7.2 g, yield: 30%) as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ=13.49 (br. s, 1H), 8.47 (s, 1H), 8.42 (d,J=2.3 Hz, 1H), 8.26 (dd, J=2.3, 8.8 Hz, 1H), 8.06 (s, 1H), 7.26 (d,J=8.7 Hz, 1H), 2.91 (s, 2H), 1.79-1.69 (m, 4H), 0.89 (t, J=7.4 Hz, 6H).

General Procedure D:

Synthesis of 11-1: 3-bromo-5-(3-methoxyphenyl)-1,2,4-thiadiazole

To a solution of (3-methoxyphenyl)boronic acid (247.25 mg, 1.63 mmol, 1eq) in DME (5 mL) was added Pd(dppf)Cl₂ (119.06 mg, 162.71 umol, 0.1eq), K₃PO₄ (1.04 g, 4.88 mmol, 3 eq) and10-1,3-bromo-5-chloro-1,2,4-thiadiazole (649.07 mg, 3.25 mmol, 2 eq).The mixture was stirred at 80° C. for 0.5 h. The reaction mixture wasdiluted with water (50 mL) and extracted with EA (50 mL×3). The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated underreduced pressure to give a residue. The residue was purified by flashsilica gel chromatography (PE/EA=10/1) to give 11-1(3-bromo-5-(3-methoxyphenyl)-1,2,4-thiadiazole) (200 mg, 737.64 umol,45% yield) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.23 (dd, J=1.6, 7.8 Hz, 1H), 7.78-7.57 (m,1H), 7.38 (d, J=8.4 Hz, 1H), 7.21 (t, J=7.6 Hz, 1H), 4.13 (s, 3H).

Synthesis of 12-1:2,2-diethyl-6-[5-(2-methoxyphenyl)-1,2,4-thiadiazol-3-yl]-3,4-ihydro-2H-1-benzopyran-4-one

To a solution of 3-bromo-5-(2-methoxyphenyl)-1,2,4-thiadiazole (100 mg,368.82 umol, 1 eq) and2,2-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-one(146.15 mg, 442.59 umol, 1.2 eq) in DMF (1 mL) and H₂O (0.5 mL) wasadded K₃PO₄ (234.87 mg, 1.11 mmol, 3 eq) and Pd(PPh₃)₄ (42.62 mg, 36.88umol, 0.1 eq) and stirred at 120° C. for 0.25 h. The residue waspurified by prep-HPLC (column: Phenomenex Synergi C18 150×25×10 um;mobile phase: [water(0.225% FA)-ACN]; B %: 70%-100%, 10 min) to give2,2-diethyl-6-[5-(2-methoxyphenyl)-1,2,4-thiadiazol-3-yl]chroman-4-one(34.5 mg, 87.46 umol, 23.71% yield, 100% purity) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.66 (d, J=2.1 Hz, 1H), 8.52-8.41 (m, 2H),7.71-7.62 (m, 1H), 7.39 (d, J=8.3 Hz, 1H), 7.26 (t, J=7.5 Hz, 1H), 7.19(d, J=8.7 Hz, 1H), 4.14 (s, 3H), 2.88 (s, 2H), 1.76 (quint, J=7.2, 14.4Hz, 4H), 0.90 (t, J=7.4 Hz, 6H).

Synthesis of 10-8:2,2-diethyl-6-(tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran-4-one

To a solution of 6-bromo-2,2-diethyl-chroman-4-one (1 g, 3.53 mmol, 1eq) in dioxane (10 mL) was added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(986.48 mg, 3.88 mmol, 1.1 eq), DPPF (195.78 mg, 353.16 umol, 0.1 eq),Pd(dppf)Cl₂ (258.41 mg, 353.16 umol, 0.1 eq) and KOAc (415.92 mg, 4.24mmol, 1.2 eq), the mixture was stirred at 100° C. for 4 h, The reactionmixture was diluted with water (100 mL) and extracted with (EA 100 mL x2). The combined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure to give a residue. The residue waspurified by flash silica gel chromatography (PE/EA=1/1) to give2,2-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-one(1 g, 3.03 mmol, 85.75% yield) as a white solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.26 (d, J=1.6 Hz, 1H), 7.86-7.75 (m,1H), 6.85 (d, J=8.3 Hz, 1H), 2.64 (s, 2H), 1.82-1.58 (m, 4H), 1.32-1.21(m, 12H), 0.85 (t, J=7.5 Hz, 6H).

Synthesis of 14-5:1-(propan-2-yl)-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-1,2,3-benzotriazole

Synthesis of 14-2: 4-bromo-2-nitro-N-(propan-2-yl)aniline

To a solution of 4-bromo-1-fluoro-2-nitro-benzene (5 g, 22.73 mmol, 2.79mL, 1.00 eq) and propan-2-amine (2.02 g, 34.09 mmol, 2.92 mL, 1.50 eq)in THF (250.00 mL) was added DIEA (7.34 g, 56.82 mmol, 9.90 mL, 2.50 eq)at 10° C. and stirred for 1 h, The reaction mixture was diluted withwater (500 mL) and extracted with EA (500 mL×2). The combined organiclayers were washed with NaHCO₃(500 mL), dried over Na₂SO₄, filtered andconcentrated under reduced pressure to give a residue. The residue waspurified by flash silica gel chromatography to give4-bromo-N-isopropyl-2-nitro-aniline (3.2 g, 12.35 mmol, 54.34% yield) asyellow oil.

¹H NMR (400 MHz, DMSO-d₆) δ=8.14 (d, J=2.4 Hz, 1H), 7.88 (br d, J=7.5Hz, 1H), 7.63 (dd, J=2.3, 9.3 Hz, 1H), 7.07 (d, J=9.4 Hz, 1H), 3.92(sxtd, J=6.5, 13.2 Hz, 1H), 1.25 (d, J=6.4 Hz, 6H).

Synthesis of 14-3: 4-bromo-1-N-(propan-2-yl)benzene-1,2-diamine

To a solution of 4-bromo-N-isopropyl-2-nitro-aniline (2 g, 7.72 mmol, 1eq) in EtOH (20 mL) was added SnCl₂.2H₂O (5.23 g, 23.16 mmol, 1.93 mL, 3eq) and stirred at 80° C. for 16 h. The reaction mixture was quenchedwith aqueous NaOH (4 M, 50 mL), and then diluted with water (50 mL) andextracted with EA (100 mL×2). The combined organic layers were driedover Na₂SO₄, filtered and concentrated under reduced pressure to give aresidue. The residue was purified by flash silica gel chromatography(PE/EA=100/1 to 1/1) to give 4-bromo-N-isopropyl-benzene-1,2-diamine(850 mg, 3.71 mmol, 48.06% yield) as a black-brown solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=6.82 (dd, J=2.1, 8.4 Hz, 1H), 6.76 (d,J=2.2 Hz, 1H), 6.44 (d, J=8.3 Hz, 1H), 3.56-3.40 (m, 1H), 1.14 (d, J=6.4Hz, 6H).

Synthesis of 14-4: 5-bromo-1-(propan-2-yl)-1H-1,2,3-benzotriazole

To a solution of 4-bromo-N-isopropyl-benzene-1,2-diamine (750 mg, 3.27mmol, 1.00 eq) in HCl (5 mL, 6 M) was added NaNO₂ (271.04 mg, 3.93 mmol,213.42 uL, 1.20 eq) in H₂O (2 mL) dropwise at 5° C. and stirred for 0.5h. The reaction mixture was diluted with water (200 mL) and extractedwith EA (200 mL×2). The combined organic layers were dried over Na₂SO₄,filtered and concentrated under reduced pressure to give a residue. Theresidue was purified by flash silica gel chromatography (1/1) to give5-bromo-1-isopropyl-benzotriazole (700 mg, 2.92 mmol, 89.06% yield)black-brown solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.32 (d, J=1.7 Hz, 1H), 7.94 (d, J=8.8 Hz,1H), 7.60-7.60 (m, 1H), 7.67 (dd, J=1.8, 8.9 Hz, 1H), 5.32-5.16 (m, 1H),1.62 (d, J=6.7 Hz, 6H).

Synthesis of 14-5:1-(propan-2-yl)-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-1,2,3-benzotriazole

To a solution of 5-bromo-1-isopropyl-benzotriazole (700 mg, 2.92 mmol, 1eq) in dioxane (10 mL) was added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(814.38 mg, 3.21 mmol, 1.1 eq), DPPF (161.63 mg, 291.55 umol, 0.1 eq),Pd(dppf)Cl₂ (213.33 mg, 291.55 umol, 0.1 eq) and KOAc (343.35 mg, 3.50mmol, 1.2 eq), The mixture was stirred at 100° C. for 1 h, the mixturewas diluted with water (100 mL) and extracted with (EA 100 mL x 2). Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure to give a residue. The residue waspurified by flash silica gel chromatography (PE EA=100/1 to 1/1) to give1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzotriazole(300 mg, 1.04 mmol, 35.83% yield) as a yellow solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.57 (s, 1H), 7.89 (dd, J=0.7, 8.3 Hz,1H), 7.55 (dd, J=0.8, 8.4 Hz, 1H), 5.11 (spt, J=6.8 Hz, 1H), 1.75 (d,J=6.8 Hz, 6H), 1.47-1.34 (m, 12H).

General Procedure E:

Synthesis of 19-6 and 19-7:2,2-diethyl-6-{5-[1-(propan-2-yl)-1H-1,2,3-benzotriazol-5-yl]-1,3,4-thiadiazol-2-yl}-3,4-dihydro-2H-1-benzopyran-4-one;2,2-diethyl-6-{5-[1-(propan-2-yl)-1H-1,2,3-benzotriazol-5-yl]-1,3,4-oxadiazol-2-yl}-3,4-dihydro-2H-1-benzopyran-4-one

Synthesis of 19-2: methyl1-(propan-2-yl)-1H-1,2,3-benzotriazole-5-carboxylate

A mixture of 1-isopropylbenzotriazole-5-carbonitrile (1 g, 5.37 mmol,eq. in HCl/MeOH (20 mL, 4 M) was stirred at 80° C. for 2 h. The mixturewas concentrated, diluted with water (20 mL), extracted with EA (20mL×2), dried over Na₂SO₄ and concentrated to dry. The crude productmethyl 1-isopropylbenzotriazole-5-carboxylate (0.9 g, 4.11 mmol, 76.44%yield) was used into the next step without further purification.

Synthesis of 19-3:1-(propan-2-yl)-1H-1,2,3-benzotriazole-5-carbohydrazide

A mixture of methyl 1-isopropylbenzotriazole-5-carboxylate (0.5 g, 2.28mmol, 1 eq.) and NH₂NH₂·H₂O (1.14 g, 22.81 mmol, 1.11 mL, 10 eq.) inEtOH (10 mL) was stirred at 80° C. for 2 h.

The mixture was concentrated to dry. The residue was purified by columnchromatography (SiO₂, Petroleum ether/Ethyl acetate=1:1) to give1-isopropyl Benzotriazole-5-carbohydrazide (0.38 g, 1.73 mmol, 76.00%yield) as a white solid.

Synthesis of 19-5:2,2-diethyl-4-oxo-N′-[1-(propan-2-yl)-1H-1,2,3-benzotriazole-5-carbonyl]-3,4-dihydro-2H-1-benzopyran-6-carbohydrazide

To a mixture of 2,2-diethyl-4-oxo-chromane-6-carboxylic acid (274.04 mg,1.10 mmol, 1.1 eq.) and 1-isopropylbenzotriazole-5-carbohydrazide (220mg, 1.00 mmol, 1 eq.) in THF (10 mL) was added HATU (419.70 mg, 1.10mmol, 1.1 eq.) and DIEA (142.66 mg, 1.10 mmol, 192.26 uL, 1.1 eq.), themixture was stirred at 15° C. for 2 hr. The mixture was diluted withwater (50 mL), extracted with EA (50 mL×2), dried over Na₂SO₄ andconcentrated in vacuum.N′-(2,2-diethyl-4-oxo-chromane-6-carbonyl)-1-isopropyl-benzotriazole-5-carbohydrazide(420 mg, 934.37 umol, 93.12% yield) was obtained as yellow solid withoutfurther purification.

Synthesis of 19-7:2,2-diethyl-6-{5-[1-(propan-2-yl)-1H-1,2,3-benzotriazol-5-yl]-1,3,4-thiadiazol-2-yl}-3,4-dihydro-2H-1-benzopyran-4-one

A mixture ofN′-(2,2-diethyl-4-oxo-chromane-6-carbonyl)-1-isopropyl-benzotriazole-5-carbohydrazide(200 mg, 444.94 umol, 1 eq.) and Lawesson's reagent (359.93 mg, 889.88umol, 2 eq.) in THF (2 mL) was stirred at 80° C. for 2 h. The mixturewas diluted with water (20 mL), extracted with EA (20 mL×2), dried overNa₂SO₄ and concentrated to dry. The residue was purified by prep-HPLC(column: Phenomenex Synergi C18 150×25×10 um; mobile phase: [water(0.1%TFA)-ACN]; B %: 62%-92%, 13 min) to give2,2-diethyl-6-[5-(1-isopropylbenzotriazol-5-yl)-1,3,4-thiadiazol-2-yl]chroman-4-one(61 mg, 29.99 umol, 6.74% yield, 22% purity) as a white solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.62 (d, J=0.6 Hz, 1H), 8.38-8.36 (m,1H), 8.36-8.33 (m, 1H), 8.33-8.30 (m, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.13(d, J=8.7 Hz, 1H), 5.22-5.11 (m, 1H), 2.82 (s, 2H), 1.95-1.83 (m, 4H),1.82-1.80 (m, 6H), 0.99 (t, J=7.5 Hz, 6H).

Synthesis of 19-7:2,2-diethyl-6-{5-[1-(propan-2-yl)-1H-1,2,3-benzotriazol-5-yl]-1,3,4-oxadiazol-2-yl}-3,4-dihydro-2H-1-benzopyran-4-one

A mixture ofN′-(2,2-diethyl-4-oxo-chromane-6-carbonyl)-1-isopropyl-benzotriazole-5-carbohydrazide(200 mg, 444.94 umol, 1 eq.) and Burgess reagent (530.17 mg, 2.22 mmol,5 eq.) in DCM (2 mL) was stirred at 15° C. for 2 h. The mixture wasdiluted with water (20 mL), extracted with EA (20 mL×2), dried overNa₂SO₄ and concentrated to dry. The residue was purified by prep-HPLC(column: Phenomenex Synergi C18 150×25×10 um; mobile phase: [water(0.1%TFA)-ACN]; B %: 55%-85%, 12 min) to give2,2-diethyl-6-[5-(1-isopropylbenzotriazol-5-yl)-1,3,4-oxadiazol-2-yl]chroman-4-one(56 mg, 129.78 umol, 29.17% yield, 100% purity) as a white solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.85 (s, 1H), 8.61 (d, J=2.3 Hz, 1H),8.35 (t, J=2.1 Hz, 1H), 8.33 (t, J=2.1 Hz, 1H), 7.75 (d, J=8.7 Hz, 1H),7.16 (d, J=8.8 Hz, 1H), 5.24-5.11 (m, 1H), 2.84 (s, 2H), 1.94-1.85 (m,2H), 1.82 (d, J=6.8 Hz, 5H), 1.80-1.75 (m, 2H), 1.00 (t, J=7.5 Hz, 6H)Synthesis of 25-2:5-[5-(1H-1,3-benzodiazol-5-yl)-1,3,4-oxadiazol-2-yl]-2-fluorobenzonitrile

A suspension of 1(N′-(1H-1,3-benzodiazole-5-carbonyl)-3-cyano-4-fluorobenzohydrazide, 541mg, 1.67 mmol) in phosphorus oxychloride (10 mL, excess) was heated at105° C. for 3 hours. The mixture was concentrated, and the residue wassuspended in water with sonication/stirring. The resulting solid wascollected, washed with sat'd NaHCO₃and water, then dried under N₂/vac inthe filter funnel. The tan solid was suspended in MeCN and concentratedtwice to remove residual water and dried under high vacuum to yield 25-2(0.55 g, 107%). MH+=306.1.

Synthesis of 26-2:6-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one

To a suspension of 3(6-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-2,3-dihydro-1,3-benzoxazol-2-onetrifluoroacetate, 13 mg, 0.031 mmol) in DMF (1 mL) was added potassiumcarbonate (8.6 mg, 0.062 mmol) followed by methyl iodide (5.2 mg, 0.037mmol) and the resulting white suspension heated to 100° C. for 45 min.The reaction was cooled to room temperature, filtered, and purified byreverse phase chromatography, 25%-75% MeCN/water/0.1% TFA. The productfractions lyophilized to yield 26-2 (1.6 mg, 12%). MH+=324.1. ¹H NMR(400 MHz, DMSO) 7.93-7.91 (3H, m), 7.59-7.54 (1H, m), 7.44-7.41 (1H, m),7.25-7.22 (1H, m), 7.11-7.07 (1H, m), 3.88 (3H, s); 3.45 (3H, s)

Synthesis of 27-3: methylN-({6-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}sulfonyl)carbamate

To a dry mixture of 27-1 (2-methoxyphenylhydrazide, 139 mg, 0.837 mmol),27-2 (benzoxazol-2-one-6-carboxylic acid, 150 mg, 0.837 mmol), and HATU(318 mg, 0.837 mmol) was added THF (10 mL) to yield a hazy reddishsolution. DIPEA (0.29 mL, 1.67 mmol) was added and the reaction wasstirred at rt for 2 hr. Burgess reagent (499 mg, 2.09 mmol) was addedone portion, and the reaction was heated to 60° C. overnight. Anadditional 499 mg Burgess reagent was added. and continued heating.After 4 hr, 2N KHSO₄ (10 mL) was added and the resulting oily mixturewas extracted 3×EtOAc. The combined organics were washed once withwater, once with brine, filtered through cotton and concentrated to anorange solid which was purified by reverse phase chromatography, 20%-60%MeCN/water/0.1% TFA to yield 67 mg 27-3(18%) MH+=447.0. ¹H NMR (400 MHz,DMSO) 8.02-7.97 (3H, m), 7.74 (1H, d, J=8.4 Hz), 7.64 (1H, t, J=8.2 Hz),7.30 (1H, d, J=8.4 Hz), 7.18 (1H, t, J=7.4 Hz), 3.95 (3H, s), 3.39 (3H,s).

Synthesis of 28-2:2-[(2-fluoropropyl)amino]-5-[5-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4-oxadiazol-2-yl]benzonitrile

To a nitrogen purged small Parr hydrogenation bottle was added 10% Pd/C(14 mg) and moistened with a small volume of EtOH. To 28-1(2-[(2-fluoroprop-2-en-1-yl)amino]-5-[5-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4-oxadiazol-2-yl]benzonitriletrifluoroacetate, 70 mg, 0.139 mmol) was added EtOH (10 mL) and EtOAc(90 mL) to yield a milky mixture which was added to the hydrogenationbottle. The mixture was hydrogenated under 50 psi H₂ for 24 hr. MeCN wasadded until the milky mixture clears, then filtered through Celite andconcentrated. The residue was heated in a small volume of DMF, cooled,filtered, and purified by reverse phase chromatography, 30%-75%MeCN/water/0.10% TFA. The product fractions were lyophilized to yield28-2 as a fluffy white solid (12.8 mg, 18%). MH+=392.1. ¹H NMR (400 MHz,DMSO) 10.40 (1H, s), 8.25 (1H, d, J=2.1 Hz), 8.11 (1H, dd, J=2.0, 9.2Hz), 7.92-7.81 (2H, m), 7.22 (1H, t, J=6.3 Hz), 7.11 (1H, d, J=9.2 Hz),7.11 (1H, d, J=9.4 Hz), 7.02 (1H, d, J=8.7 Hz), 7.04-7.00 (1H, m),5.00-4.80 (1H, m), 3.60-3.51 (2H, m), 3.01 (2H, t, J=7.4 Hz), 1.35 (3H,dd, J=6.2, 24.0 Hz).

Synthesis of 29-3:5-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,3-dihydro-2,1-benzoxazol-3-one

To a nitrogen purged hydrogenation bottle was added 10% Pd/C (12 mg),which was moistened with EtOH. A suspension of 29-1 (methyl5-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-2-nitrobenzoate, preparedaccording to Wuxi 1,3,4-oxadiazole experimental, 112 mg, 0.281) in EtOH(25 mL) and EtOAc (20 mL) was hydrogenated at 48 psi H₂. After 30minutes the reaction was filtered and concentrated to solid 29-2 (113mg, 105%), which was used without further purification. MH+=342.1.

To a solution of 29-2 (47 mg, 0.132 mmol) in DMF (2 mL) was addedtriethylamine (0.1 mL) then water (0.2 mL) and the resulting solutionstirred at rt for 60 hr. The reaction mixture was purified directly byreverse phase chromatography, 20%-65% MeCN/water/0.1% TFA to yield 8 mg29-3 (14%). MH+=310.1. ¹H NMR (400 MHz, DMSO) 12.52 (1H, s), 8.42-8.38(2H, m), 8.03 (1H, d, J=6.9 Hz), 7.65 (1H, t, J=8.3 Hz), 7.57 (1H, d,J=7.6 Hz), 7.32 (1H, d, J=8.3 Hz), 7.17 (1H, t, J=6.9 Hz), 3.96 (3H, s).

Synthesis of 30-1:5-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1-methyl-1,3-dihydro-2,1-benzoxazol-3-one

To a solution of 29-2 (8 mg, 0.019 mmol) in DMF (0.5 mL) was addedpotassium carbonate (2.6 mg, 0.019 mmol) followed by methyl iodide (4.0mg, 0.028 mmol) and the resulting solution heated to 100° C. for 15minutes. The reaction was cooled to rt, filtered, and purified directlyby reverse phase chromatography, 25%-75% MeCN/water/0.1% TFA to yield5.3 mg 30-1 (64%) as a white solid. MH+=324.1. ¹H NMR (400 MHz, DMSO)8.40 (1H, d, J=8.7 Hz), 8.32 (1H, s), 7.97 (1H, d, J=8.0 Hz), 7.73 (1H,d, J=8.7 Hz), 7.58 (1H, t, J=8.3 Hz), 7.25 (1H, d, J=8.0 Hz), 7.10 (1H,t, J=7.7 Hz), 3.89 (3H, s), 3.49 (3H, s).

General Procedure F:

Synthesis of 32-2:N-hydroxy-2-oxo-2,3-dihydro-1H-indole-5-carboximidamide

To a mixture of 2-oxoindoline-5-carbonitrile (200 mg, 1.26 mmol, 1 eq)in ethanol (5 mL) was added hydrochloride salt of hydroxylamine (176 mg,2.53 mmol, 2.0 eq), diisopropylethylamine (327 mg, 2.53 mmol, 2.0 eq) at20° C. under nitrogen atmosphere. The mixture was then heated to 90° C.and stirred for 16 hrs. The mixture was concentrated in vacuum, and awhite solid was precipitated out. The suspension was filtered, and thewhite solid was dried in vacuum to give the product 32-2 (210 mg, 83%yield).

¹H NMR (400 MHz, DMSO-d₆) δ=10.46 (br, s, 1H), 9.45 (br, s, 1H), 7.51(s, 1H), 7.50 (d, J=10.8 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H), 5.70 (br, s,2H), 3.49 (s, 2H).

Synthesis of 33-1:2-[(cyclopropylmethyl)amino]-5-[3-(2-oxo-2,3-dihydro-1H-indol-5-yl)-1,2,4-oxadiazol-5-yl]benzonitrile

To a mixture of 3-cyano-4-(cyclopropylmethylamino)benzoic acid (107 mg,496 umol, 1.2 eq) in N,N-dimethylformamide (1 mL) was added HOBt (67.0mg, 496 umol, 1.2 eq), EDCI (95.1 mg, 496 umol, 1.2 eq) at 20° C. Themixture was stirred for 30 min, thenN-hydroxy-2-oxo-indoline-5-carboxamidine (79 mg, 413 umol, 1 eq) wasadded, and the resultant mixture then heated to 150° C. and stirred for1 hour. The cooled reaction mixture was directly purified by prep-HPLC(column: Boston Green ODS 150×30 5 u; mobile phase: [water(0.225%FA)-ACN]; B %: 47%-77%, 10 min) to give the product 33-1 (20 mg, 12%yield).

¹H NMR (400 MHz, DMSO-d₆) δ=10.73 (br, s, 1H), 8.23 (d, J=2.4 Hz, 1H),8.11 (dd, J=9.2, 2.0 Hz, 1H), 7.93 (d, J=8.0 Hz, 1H), 7.89 (s, 1H), 7.17(t, J=6.4 Hz, 1H), 7.07 (d, J=9.2 Hz, 1H), 7.00 (d, J=8.0 Hz, 1H), 3.61(s, 2H), 3.20 (t, J=6.4 Hz, 2H), 1.16-1.13 (m, 1H), 0.52-0.47 (m, 2H),0.33-0.29 (m, 2H).

General Procedure G:

Synthesis of 35-2: 3-cyano-4-[(cyclopropylmethyl)amino]benzoic acid

To a mixture of 3-cyano-4-fluoro-benzoic acid (5 g, 30.3 mmol, 1 eq) andcyclopropylmethanamine (5.38 g, 75.7 mmol, 2.5 eq) in dimethylsulfoxide(30 mL) was added potassium carbonate (12.6 g, 90.8 mmol, 3 eq) at 20°C. The mixture was then heated to 100° C. and stirred for 16 hours. Themixture was filtered, and the filtrate was diluted with water (50 mL),acidified by hydrochloride solution (2N) to pH=4-5. A yellow solid wasprecipitated out, the suspension was filtered, and the solid was washedby water (50 mL×3). The solid was dried in vacuum to give the desiredproduct 35-2 (5 g, 73% yield). 1H NMR (400 MHz, DMSO-d₆) δ=7.95 (d,J=1.2 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 6.88 (d, J=9.2 Hz, 1H), 6.85-6.82(m, 1H), 3.13 (t, J=6.0, 2H), 1.16-1.06 (m, 1H), 0.49-0.44 (m, 2H),0.29-0.25 (m, 2H).

Synthesis of 36-2:5-[3-(1H-indol-5-yl)-1,2,4-oxadiazol-5-yl]-2-[(prop-2-en-1-yl)amino]benzonitrile

To a mixture of tert-butyl5-[5-[4-(allylamino)-3-cyano-phenyl]-1,2,4-oxadiazol-3-yl]indole-1-carboxylate(60.0 mg, 136 umol, 1.00 eq) in dichloromethane (10.0 mL) was addedtrifluoroacetic acid (770 mg, 6.75 mmol, 50 eq) at 20° C. under nitrogenatmosphere. The mixture was stirred at 20° C. for 16 h. The mixture wasconcentrated in vacuum and the residue was purified by prep-HPLC(column: Gemini 150×25 5 u; mobile phase: [water (0.05% ammoniahydroxide v/v)-ACN]; B %: 47%-77%, 12 min) to give the product 36-2 (15mg, 30% yield) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.33 (s, 1H), 8.27 (d, J=2.0 Hz, 1H), 8.14(dd, J=8.8, 2.0 Hz, 1H), 7.80 (dd, J=8.4, 1.2 Hz, 1H), 7.56 (d, J=8.8Hz, 1H), 7.48 (t, J=2.4 Hz, 1H), 7.39 (t, J=5.6 Hz, 1H), 6.91 (d, J=8.8Hz, 1H), 6.61 (s, 1H), 5.94-5.85 (m, 1H), 5.24-5.16 (m, 2H), 3.97 (s,1H).

General Procedure H:

Synthesis of 38-4:1-cyclopentyl-N-hydroxy-1H-1,2,3-benzotriazole-5-carboximidamide

Synthesis of 38-1: 4-(cyclopentylamino)-3-nitrobenzonitrile

Preparation of 1: To a solution of 4-fluoro-3-nitro-benzonitrile (1.00g, 6.02 mmol, 1.00 eq) and cyclopentanamine (767 mg, 9.03 mmol, 1.50 eq)in THF (20.00 mL) was added DIEA (1.95 g, 15.05 mmol, 2.63 mL, 2.50 eq)and the mixture was stirred at 10° C. for 16 hour. The mixture wasevaporated to dry and diluted with H₂O (50 mL), extracted with DCM (50mL×2), dried over Na₂SO₄, filtered and concentrated to dry. Compound4-(cyclopentylamino)-3-nitrobenzonitrile (1.36 g, 5.91 mmol, 98.10%yield) was obtained as a yellow solid which was used directly in nextstep.

Synthesis of 38-2: 3-amino-4-(cyclopentylamino)benzonitrile

Preparation of 2: To a solution of4-(cyclopentylamino)-3-nitro-benzonitrile (5.00 g, 21.62 mmol, 1.00 eq)in MeOH (150.00 mL) was added Pd/C (1.00 g, 4.32 mmol, 10% purity, 0.20eq). Then the mixture was stirred for 12 hours at 20° C. under H₂ (50psi). The mixture was filtered and the filtrate was concentrated to dryto get 3-amino-4-(cyclopentylamino)benzonitrile (4.20 g, 20.87 mmol,96.52% yield) as black solid, which was used directly in the next step.¹H NMR (400 MHz, DMSO-d6) δ=8.77 (s, 1H), 8.12 (d, J=8.7 Hz, 1H), 7.91(d, J=8.7 Hz, 1H), 5.43 (m, 1H), 2.37-2.21 (m, 2H), 2.18-2.06 (m, 2H),1.99-1.85 (m, 2H), 1.81-1.67 (m, 2H).

Synthesis of 38-4:1-cyclopentyl-N-hydroxy-1H-1,2,3-benzotriazole-5-carboximidamide

Preparation of 3: To a solution of1-cyclopentylbenzotriazole-5-carbonitrile (1.50 g, 7.07 mmol) in ethanol(15.00 mL) was added hydroxylamine hydrochloride (736.64 mg, 10.60 mmol)and DIPEA (2.01 g, 15.55 mmol, 2.72 mL). Then the mixture was stirred at70° C. for 4 hours. The mixture was filtered to get1-cyclopentyl-N-hydroxy-benzotriazole-5-carboxamidine (1.20 g, 4.89mmol, 69.20% yield) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ=9.77 (s, 1H), 8.31 (s, 1H), 7.97-7.89 (m,1H), 7.87-7.79 (m, 1H), 5.98 (s, 2H), 5.34 (q, J=7.0 Hz, 1H), 2.36-2.21(m, 2H), 2.19-2.07 (m, 2H), 1.99-1.84 (m, 2H), 1.81-1.67 (m, 2H).

General Procedure I:

Synthesis of 42-2:5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]-1-cyclopentyl-1H-1,2,3-benzotriazole

To a solution of 3-methylbenzoic acid (66.61 mg, 489.24 umol) in DMF(4.00 mL) was added EDCI (93.79 mg, 489.24 umol) and HOBt (66.11 mg,489.24 umol). The mixture was stirred at 20° C. for 1 hour and1-cyclopentyl-N-hydroxy-benzotriazole-5-carboxamidine (100.00 mg, 407.70umol) was added to the mixture. Then the mixture was stirred at 120° C.for 12 hours under N₂. The mixture was quenched with water (30 mL) andextracted with ethyl acetate (30 mL×2). The organic layers were washedwith brine (40 mL), dried over Na₂SO₄ and concentrated to dryness. Theresidue was purified by prep-HPLC (TFA) to get t3-(1-cyclopentylbenzotriazol-5-yl)-5-(m-tolyl)-1,2,4-oxadiazole (96.00mg, 277.94 umol, 68.17% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃)δ=8.93 (s, 1H), 8.30 (dd, J=1.3, 8.7 Hz, 1H), 8.08 (s, 1H), 8.06 (br d,J=6.8 Hz, 1H), 7.68 (d, J=8.8 Hz, 1H), 7.51-7.42 (m, 2H), 5.22 (quin,J=7.0 Hz, 1H), 2.50 (s, 3H), 2.43-2.32 (m, 4H), 2.15-2.01 (m, 2H),1.92-1.81 (m, 2H).

Synthesis of 44-2:2-{5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]-1H-1,2,3-benzotriazol-1-yl}aceticacid

To a solution of methyl2-[5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]benzotriazol-1-yl] acetate(40.00 mg, 96.57 umol, 1.00 eq) in dioxane (2.00 mL) and H₂O (2.00 mL)was added NaOH (15.45 mg, 386.28 umol, 4.00 eq). Then the mixture wasstirred at 20° C. for 12 hours. The mixture was adjust to pH=2-3 withHCl (1N) and extracted with ethyl acetate (15 mL×2). The organic layerswere dried over Na₂SO₄ and concentrated to give2-[5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]benzotriazol-1-yl]aceticacid(17.30 mg, 43.23 umol, 44.76% yield) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.70 (s, 1H), 8.26 (m, 3H), 7.93 (m, 2H),7.66 (m, 2H), 5.24 (br s, 2H)

Synthesis of 45-1:2-{5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]-1H-1,2,3-benzotriazol-1-yl}ethan-1-ol

To a solution of methyl2-[5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]benzotriazol-1-yl] acetate(50.00 mg, 120.71 umol, 1.00 eq) in THF (1.00 mL) was added LiBH₄ (5.26mg, 241.42 umol, 2.00 eq) and stirred at 10° C. for 16 h. The mixturewas diluted with H₂O (20 mL) and extracted with EA (30 mL×2), thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated to dry. The residue was purified by prep-HPLC (TFAcondition) to give2-[5-[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]benzotriazol-1-yl]ethanol(10.00 mg, 25.89 umol, 21.45% yield) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.74 (s, 1H), 8.43 (br s, 1H), 8.25 (dd,J=1.1, 8.8 Hz, 1H), 8.17 (dd, J=1.9, 7.4 Hz, 1H), 8.12 (d, J=8.7 Hz,1H), 8.01-7.92 (m, 1H), 7.74-7.60 (m, 2H), 4.84 (t, J=5.1 Hz, 2H), 3.93(t, J=5.1 Hz, 2H).

General Procedure J:

Synthesis of 46-1:3-(2-isopropoxyphenyl)-5-(1-isopropylindol-5-yl)-1,2,4-oxadiazole

To a solution of N-hydroxy-2-isopropoxy-benzamidine (90.00 mg, 393.86umol, 1.00 eq) in DMF (2.00 mL) was added 1-isopropylindole-5-carboxylicacid (80.05 mg, 393.86 umol, 1.00 eq), HOBt (63.86 mg, 472.63 umol, 1.20eq) and EDCI (90.60 mg, 472.63 umol, 1.20 eq), the reaction was stirredat 120° C. for 12 h. The mixture was filtered and concentrated. Theresidue was purified by prep-HPLC to give3-(2-isopropoxyphenyl)-5-(1-isopropylindol-5-yl)-1,2,4-oxadiazole (26.00mg, 71.93 umol, 18.26% yield, 98.9% purity) as a yellow oil.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.56 (d, J=1.1 Hz, 1H), 8.10 (dt,J=1.7, 8.6 Hz, 2H), 7.53-7.43 (m, 2H), 7.35 (d, J=3.3 Hz, 1H), 7.14-7.07(m, 2H), 6.69 (d, J=3.3 Hz, 1H), 4.81-4.65 (m, 2H), 1.60 (d, J=6.7 Hz,7H), 1.46 (d, J=6.1 Hz, 6H).

Synthesis of 48-2:5-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole

To a solution of 1-isopropylbenzotriazole-5-carboxylic acid (100.00 mg,487.31 umol, 1.00 eq) in DMF (1.00 mL) was added HOBt (79.01 mg, 584.77umol, 1.20 eq) and EDCI (112.10 mg, 584.77 umol, 1.20 eq). The mixturewas stirred at 10° C. for 0.5 h, then N-hydroxy-2-methoxy-benzamidine(80.98 mg, 487.31 umol, 1.00 eq) was added and stirred at 120° C. for 12h. The mixture was diluted with H₂O (20 mL) and extracted with EA (30mL×2), the combined organic layers were dried over Na₂SO₄, filtered andconcentrated to dry. The residue was purified by prep-HPLC (column:Welch Ultimate AQ-C18 150×30 mm×5 um; mobile phase: [water(0.1%TFA)-ACN]; B %: 50%-80%, 13 min) to give5-(1-isopropylbenzotriazol-5-yl)-3-(2-methoxyphenyl)-1,2,4-oxadiazole(110.00 mg, 328.01 umol, 67.31% yield) as a white solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.99 (s, 1H), 8.36 (dd, J=1.2, 8.7 Hz,1H), 8.17 (dd, J=1.6, 7.7 Hz, 1H), 7.74 (d, J=8.7 Hz, 1H), 7.59-7.48 (m,1H), 7.20-7.05 (m, 2H), 5.16 (spt, J=6.8 Hz, 1H), 4.03 (s, 3H), 1.81 (d,J=6.8 Hz, 6H).

General Procedure K:

Synthesis of 49-1:1-(propan-2-yl)-1H-1,2,3-benzotriazole-5-carbothioamide

To a solution of 1-isopropylbenzotriazole-5-carbonitrile (2 g, 10.74mmol, 1 eq) in HCl/dioxane (100 mL, 4 M) was added thioacetamide (1.61g, 21.48 mmol, 2 eq) and stirred at 110° C. for 2 h. The reactionmixture was concentrated under reduced pressure and purified by flashsilica gel chromatography (PE/EA=2/1 to 1/1) to give1-isopropylbenzotriazole-5-carbothioamide (2.1 g, 9.53 mmol, 88.76%yield) as a yellow solid.

Synthesis of 51-2:5-{5-[2-(methyl-λ³-oxy)phenyl]-1,3-thiazol-2-yl}-1-(propan-2-yl)-1H-1,2,3-benzotriazole

To a solution of 1-isopropylbenzotriazole-5-carbothioamide (300 mg, 1.36mmol, 1 eq) in DMF (3 mL) was added Cs₂CO₃ (443.71 mg, 1.36 mmol, 1.00eq) and 2-bromo-1-(2-methoxyphenyl)ethanone (311.95 mg, 1.36 mmol, 1eq). The mixture was stirred at 100° C. for 12 h. The residue waspurified by prep-HPLC (column: Waters Xbridge 150×25 5 u; mobile phase:[water(10 mM NH₄HCO3)-ACN]; B %: 60%-90%, 10 min) to give2-(1-isopropylbenzotriazol-5-yl)-5-(2-methoxyphenyl)thiazole (190 mg,509.65 umol, 37.42% yield, 94% purity) as a yellow solid.

¹H NMR (400 MHz, CHLOROFORM-d) 6=8.60 (s, 1H), 8.37 (dd, J=1.7, 7.8 Hz,1H), 8.22 (dd, J=1.1, 8.8 Hz, 1H), 7.91 (s, 1H), 7.55 (d, J=8.8 Hz, 1H),7.31-7.23 (m, 1H), 7.05 (t, J=7.5 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.04(spt, J=6.8 Hz, 1H), 3.92 (s, 3H), 1.70 (d, J=6.7 Hz, 6H).

General Procedure L:

Synthesis of 52-1: 1-(propan-2-yl)-1H-1,2,3-benzotriazole-5-carboxamide

To a solution of 46-1 (1.0 g, 5.4 mmol) in HOAc (10 mL) was added H₂SO₄(0.5 mL) and reaction heated in MW 90 min at 120° C. Let cool overnight.Reaction mixture poured onto ice, neutralized and extracted with EtOAc.Solvent evaporated to give a dark solid. Silica gel chromatography(10-50% acetone in hexane) gave a residue which was triturated with asmall amount of acetone and an off-white solid was collected byfiltration to give the title compound (52-1) (0.5 g, 45%).

Synthesis of 52-3:5-(4-phenyl-1,3-oxazol-2-yl)-1-(propan-2-yl)-1H-1,2,3-benzotriazole

To a mixture of 52-1 (50 mg, 0.25 mmol), 52-2 (51 mg, 0.25 mmol) wasadded AgSbF6 (86 0.25 mmol) and the mixture was heated to 90° C. forabout 3 hrs then cool to rt. Reaction worked up with NaHCO3and CH2Cl2.Organic layer separated and evaporated to give a dark oil. Residue waschromatographed (0 to 5% MeOH in CH2Cl2) to give a residue which wasfurther purified by reverse phase HPLC. Appropriate fractions combinedand lyophilized to give the title compound as an off-white solid. (7 mg,10%).

General Procedure M

Synthesis of 5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-amine 53-2

To a solution of 53-1 (1.9 g, 10.0 mmol) in CH2Cl2 (50 mL) was added DMF(0.2 mL) followed by portion wise addition of oxalyl chloride (1.7 mL,20.0 mmol) and the solution was stirred overnight at rt. Reactionmixture was evaporated in vacuum. To residue was added thiosemicarbazide(1.1 g, 15 mmol) followed by POCl3 (2.8 mL, 30 mmol) and the reactionmixture was heated to 90° C. After about 45 min to 1 hr, heat was turnedoff and allowed to cool overnight. Quench with ice and worked up withK2CO3 and EtOAc. Organic layer washed with sat'd NaHCO3and dried overNa2SO4. Filtered and evaporated to give a yellow residue which wastriturated with CH2Cl2 and the title compound was collected as a beigesolid (0.9 g, 43%). This material was used directly in the next step.

Synthesis of 2-bromo-5-(2-methoxyphenyl)-1,3,4-thiadiazole 53-3

A mixture of t-Bu-nitrite (0.9 mL, 9.6 mmol) and CuBr2 (2.2 g, 9.6 mmol)in MeCN (30 mL) was stirred for 10 min and then 53-2 (0.9 g, 1.76 mmol)was added in 2 portions. Stirred ˜1 hr and then solvent removed invacuum. Residue was suspended in EtOAc, washed 2× with 1 N HCl, thenbrine and dried over Na2SO4. Filtered and evaporated to give the titlecompound as a yellow-orange solid (1 g, 86%).

Synthesis of5-[5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-1-(propan-2-yl)-1H-1,2,3-benzotriazole53-4

Combined 52-3 (95 mg, 0.25 mmol), 14-5 (45 mg, 0.3 mmol), K3PO4 (132 mg,0.625 mmol) and Pd(Ph3P)₄ (58 mg, 0.05 mmol) in a mixture of DMF (4 mL)and water (1 mL). Heated to 120° C. for 30 min in MW. Evap sol to give aresidue which was chromatographed on silica (0 to 30% EtOAc in hex).Appropriate fraction were combined and solvent evaporated. This residuewas further purified by reverse phase HPLC to give the title compound(30 mg, 20%) as an off-white solid.

Synthesis of2-{3-[1-(propan-2-yl)-1H-1,2,3-benzotriazol-5-yl]-1,2,4-thiadiazol-5-yl}phenol53-5: 53-4

(40 mg, 0.11 mmol) was dissolved in HR and heated to 120° C. After ˜ 48hrs starting material was gone. Neutralize with NaHCO₃. Residue purifiedby reverse phase HPLC to give the title compound (10 mg, 22%).[M+H]⁺:338.0

General Procedure N

Synthesis of 54-3:4-amino-3-(3-ethyl-3-hydroxypent-1-yn-1-yl)benzonitrile

To a solution of compound 54-1 (1 g, 5.08 mmol, 1 eq.) in DMF (7 mL) andTEA (2.18 g, 21.55 mmol, 3 mL, 4.25 eq.) was added compound 54-2 (683.15mg, 6.09 mmol, 783.43 uL, 1.2 eq.), CuI (48.33 mg, 253.77 umol, 0.05eq.) and Pd(PPh₃)₂Cl₂ (178.12 mg, 253.77 umol, 0.05 eq.). The mixturewas stirred at 90° C. under nitrogen atmosphere for 3 hours. TLC showeda new one spot formed. The reaction mixture was diluted with water (20mL), extracted with EtOAc (20 mL×2), washed with brine (20 mL), driedwith sodium sulfate, filtered and concentrated. The residue was purifiedby flash silica gel column chromatography (PE:EA=5:1) to give compound 3(1 g, yield: 86%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ=7.52 (d,J=1.6 Hz, 1H), 7.34 (dd, J=8.6, 1.8 Hz, 1H), 6.68 (d, J=8.4 Hz, 1H),4.76 (s, 2H), 2.95 (s, 1H), 2.88 (s, 1H), 2.32 (s, 1H), 1.85-1.70 (m,4H), 1.10 (t, J=7.4 Hz, 6H).

Synthesis of 54-4: 2,2-diethyl-4-oxo-1,3-dihydroquinoline-6-carboxylicacid

A mixture of compound 54-3 (300 mg, 1.31 mmol) in concentratedhydrochloric acid solution (1 mL) and acetic acid (1 mL) was stirred at115° C. for 3 hours. The mixture was basified with 1 N sodium hydroxidesolution to pH=10, washed with EtOAc (20 mL×3), the aqueous phase wasacidized with 1 N hydrochloric acid solution to pH=3, filtered, thefiltrate cake was washed with water (10 mL), dried under vacuum to givecompound 54-4 (35 mg, yield: 11%) as white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=12.08 (br. s, 1H), 7.90 (d, J=2.0 Hz, 1H), 7.52 (dd, J=2.0,8.7 Hz, 1H), 7.14 (s, 1H), 6.58 (d, J=8.7 Hz, 1H), 1.73 (s, 1H),1.36-1.19 (m, 4H), 0.58 (t, J=7.4 Hz, 6H).

Synthesis of 55-1:2,2-diethyl-6-[3-(thiophen-3-yl)-1,2,4-oxadiazol-5-yl]-1,3-dihydroquinolin-4-one

To a solution of compound 54-4 (100 mg, 404.39 umol, 1 eq.) in DMF (1mL) was added HOBt (65.57 mg, 485.26 umol, 1.2 eq.) and EDCI (93.02 mg,485.26 umol, 1.2 eq.). After stirring at 20° C. for 30 mins, compound55-2 (63.24 mg, 444.82 umol, 1.1 eq.) was added, and stirred for another30 mins. Then the mixture was heated to 120° C. and stirred for 2 hours.The mixture was triturated with EA (20 mL), filtered, washed with EA (10mL), the residue was purified by prep-HPLC (column: Phenomenex SynergiC18 150×25×10 um; mobile phase: [water(0.1% TFA)-ACN]; B %: 50%-80%, 13min) to give 55-1 (45 mg, yield: 29%) as orange solid. ¹H NMR (400 MHz,DMSO-d₆) δ=8.36-8.27 (m, 2H), 7.96 (dd, J=2.0, 8.8 Hz, 1H), 7.79 (dd,J=3.0, 5.0 Hz, 1H), 7.71 (s, 1H), 7.62 (d, J=5.0 Hz, 1H), 6.99 (d, J=8.9Hz, 1H), 2.59 (s, 2H), 1.67-1.48 (m 4H), 0.86 (t, J=7.3 Hz, 6H).

General Procedure O

Synthesis of 57-3:5-(4-methoxy-1,3-benzoxazol-2-yl)-1-(2-methylpropyl)-1,2,3-benzotriazole

Synthesis of 57-2:N-(2-hydroxy-6-methoxyphenyl)-1-(2-methylpropyl)-1,2,3-benzotriazole-5-carboxamide

To a solution of compound 57-1 (100 mg, 487.30 umol, 1 eq.) in DMF (3mL) was added HOBt (65.85 mg, 487.30 umol, 1 eq.) and EDCI (112.10 mg,584.76 umol, 1.2 eq.). After addition, the mixture was stirred at 20° C.for 0.5 hour, then compound 57-4 (81.37 mg, 584.76 umol, 1.2 eq.) wasadded, the mixture was stirred at 20° C. for further 12 hours. LCMSshowed compound 57-1 consumed, and a major peak with desired MSdetected. The mixture was diluted with water (20 mL), extracted withEtOAc (15 mL*2), washed with brine (20 mL), dried with sodium sulfate,filtered and concentrated, to give compound 57-2 (159 mg, crude) asbrown oil, which was used in next step directly without furtherpurification. LCMS: 327.2[M+1]

Synthesis of 57-3:5-(4-methoxy-1,3-benzoxazol-2-yl)-1-(2-methylpropyl)-1,2,3-benzotriazole

To a solution of compound 57-2 (159 mg, crude) in xylene (10 mL) wasadded TsOH-H₂O (370.70 mg, 1.95 mmol, 4 eq.). After addition, themixture was stirred at 120° C. for 2 hours. LCMS showed compound 57-2consumed, and a major peak with desired Ms detected. The mixture wasconcentrated, diluted with saturated sodium bicarbonate solution (20mL), extracted with EtOAc (20 mL*2), dried with sodium sulfate, filteredand concentrated. The residue was purified by prep-HPLC (column:Phenomenex Synergi C18 150*25*10 um; mobile phase: [water(0.1%TFA)-ACN]; B %: 42%-72%, 10 min) to give 57-3 (53 mg, yield: 35%) asgrey solids.

¹H NMR (400 MHz, CDCl₃) δ=8.95 (s, 1H), 8.51 (dd, J=1.1, 8.8 Hz, 1H),7.69 (d, J=8.8 Hz, 1H), 7.37-7.31 (m, 1H), 7.28-7.27 (m, 1H), 6.85 (d,J=7.9 Hz, 1H), 5.18-5.08 (m, 1H), 4.10 (s, 3H), 1.80 (s, 3H), 1.78 (s,3H)

Synthesis of 58-3:1-isopropyl-5-(7-methoxy-1,3-benzoxazol-2-yl)-1,2,3-benzotriazole

Synthesis of 58-2:N-(2-bromo-3-methoxyphenyl)-1-isopropyl-1,2,3-benzotriazole-5-carboxamide

A mixture of compound 58-1 (200 mg, 989.86 umol, 1 eq.), compound 58-1(243.76 mg, 1.19 mmol, 1.2 eq.) and EDCI (284.64 mg, 1.48 mmol, 1.5 eq.)in pyridine (3 mL) was stirred at 20° C. for 12 hours. The mixture wasdiluted with EtOAc (30 mL), washed with 1 N hydrochloric acid solution(20 mL*3), dried with sodium sulfate, filtered and concentrated. Theresidue was purified by prep-TLC (PE:EA=3:1) to give compound 58-2 (150mg, yield: 38%) as brown oil. LCMS: 391.1 [M+1]

Synthesis of 58-3:1-isopropyl-5-(7-methoxy-1,3-benzoxazol-2-yl)-1,2,3-benzotriazole

A mixture of compound 58-2 (50 mg, 128.45 umol, 1 eq.),1,10-phenanthroline (2.31 mg, 12.85 umol, 0.1 eq.), Cs₂CO₃ (62.78 mg,192.68 umol, 1.5 eq.) and CuI (1.22 mg, 6.42 umol, 0.05 eq.) in DME (2mL) was heated to 85° C. and stirred for 12 hours under nitrogenatmosphere. The mixture was diluted with EtOAc (20 mL), washed withwater (10 mL), dried with sodium sulfate, filtered and concentrated. Theresidue was purified by prep-HPLC (column: Phenomenex Synergi C18150*25*10 um; mobile phase: [water(0.1% TFA)-ACN]; B %: 45%-75%, 12 min)to give 58-3 (8 mg, yield: 19%) as gray solid.

¹H NMR (400 MHz, DMSO-d₆) δ=8.76 (s, 1H), 8.32 (dd, J=1.3, 8.8 Hz, 1H),8.13 (d, J=8.7 Hz, 1H), 7.44-7.28 (m, 2H), 7.07 (d, J=7.8 Hz, 1H), 5.29(spt, J=6.7 Hz, 1H), 4.02 (s, 3H), 1.66 (d, J=6.6 Hz, 6H).

Synthesis of 59-3:1-isopropyl-5-(6-methoxy-4-methyl-1,3-benzoxazol-2-yl)-1,2,3-benzotriazole

Synthesis of 59-3:1-isopropyl-5-(6-methoxy-4-methyl-1,3-benzoxazol-2-yl)-1,2,3-benzotriazole

To a solution of compound 59-2(1-isopropyl-N-(4-methoxy-2-methylphenyl)-1,2,3-benzotriazole-5-carboxamide)prepared according to the procedure to prepare 58-2, (50 mg, 154.14umol, 1 eq.) in o-xylene (2 mL) was added Cu(OTf)₂ (11.12 mg, 30.83umol, 0.2 eq.). The reaction was stirred at 130° C. under oxygenatmosphere for 16 hours. The mixture was diluted with water (20 mL),extracted with EtOAc (30 mL*3), dried with sodium sulfate, filtered andconcentrated. The residue was purified by prep-TLC (PE:EA=4:1) to give59-3 (1.1 mg, yield: 2%) as yellow solid.

¹H NMR (400 MHz, CDCl₃) δ=8.80 (s, 1H), 8.33 (dd, J=1.4, 8.7 Hz, 1H),7.59 (d, J=8.8 Hz, 1H), 6.91 (d, J=2.2 Hz, 1H), 6.72 (d, J=1.5 Hz, 1H),5.16-4.93 (m, 1H), 3.81 (s, 3H), 2.58 (s, 3H), 1.72 (d, J=6.8 Hz, 6H)

Example 2: In Vitro Activity of Compounds

Stable clonal Chinese hamster ovary K1 (CHO-K1) cells co-expressingEA-β-arrestin2 and the human sphingosine-1-phosphate receptor 1(NM_001400, S1P₁) with a C-terminal Prolink™ tag were purchased fromDiscoverX corporation (Cat #: 93-0207C2).

Cell Culturing and Assay Plating

Cell lines were cultured in AssayComplete™ Media 6 (DiscoverXCorporation, Cat #: 920018GF2) at 37° C. and 5% CO₂ in a humidified CO₂and temperature-controlled incubator. To begin assay plating, cells werewashed with dulbecco's phosphate buffered saline (CellGro, Cat #:21-031-CV) and lifted from the culturing flask by incubation (37° C., 5min) with CellStripper (Cellgro, Cat #: 25-056-CI). Lifted cells wereresuspended to 250,000 cells per milliliter in AssayComplete™ CellPlating 11 Reagent (DiscoverX Corporation, Cat #: 93-0563R11B) andplated at 5,000 cells per well in white-opaque 384 well plates (GreinerBio-One Item #: 20-784080). Plated cells were incubated overnight at 37°C. and 5% CO₂ in a humidified CO₂ and temperature-controlled incubator.

Detecting Inhibition of cAMP Production

Agonist-promoted G-protein responses were determined by measuringchanges in intracellular cAMP using the HTRF® cAMP HiRange kit (CisBio,Cat #: 62AM6PEJ) based on time-resolved fluorescence resonance energytransfer (TR-FRET) technology. AssayComplete™ Cell Plating 11 Reagentwas removed and replaced with Ham's F-12 (CellGro, Cat #: 10-080-CM)containing isobutyl-methyl-xanthine (IBMX; 500 μM; Tocris Bioscience,Cat #: 2845), and NKH-477 (1.5 μM; Tocris Bioscience, Cat #: 1603) alongwith test or control compounds at the desired concentrations. Followinga 30-minute incubation at 37° C. and 5% CO₂ in a humidified CO₂ andtemperature-controlled incubator, the components of the cAMP HiRange kitwere added as per the manufacturer's instructions. After an hourincubation at room temperature, plates were analyzed by a BMG PheraStarmicroplate reader. Responses were measured as the ratio of fluorescenceemission at 665 nm to fluorescence emission at 620 nm.

β-Arrestin2 Recruitment Assay

Agonist-promoted 0-arrestin2 recruitment to the sphingosine-1-phosphate1 receptor was determined using the β-arrestin PathHunter®) Detectionkit (DiscoverX Corporation, Cat #: 93-0001). In this system, 0-arrestin2is fused to an N-terminal deletion mutant of β-galactosidase (termed theenzyme acceptor or EA) and the C-terminus of the GPCR of interest isfused to a smaller (42 amino acids), weakly-complementing fragment 15termed ProLink™. In cells that stably express these fusion proteins,stimulation with a cognate agonist results in the interaction ofβ-arrestin2 and the Prolink™-tagged GPCR. This allows thecomplementation of the two β-galactosidase fragments and results in theformation of a functional enzyme with β-galactosidase activity.AssayComplete™ Cell Plating 11 Reagent was removed and replaced withHam's F-12 containing IBMX (500 μM), and NKH-477 (1.5 μM) along withtest or control compounds at the desired concentrations. Following a 60minute incubation at 37° C. and 5% CO₂ in a humidified CO₂ andtemperature-controlled incubator, the components of the β-arrestinPathHunter® Detection kit were added as per the manufacturer'sinstructions. After an hour incubation at room temperature, plates wereanalyzed by a BMG PheraStar microplate reader.

Activity Table

The compounds as indicated herein were able to modulate the activities(inhibition of cAMP production and β-arrestin2 recruitment) of thesphingosine-1-phosphate 1 receptor as indicated herein. The tables belowinclude the efficacy of the compound as compared to a positive control,referred to as “SPAN”. These values are normalized to fingolimod, aknown agonist of the sphingosine-1-phosphate 1 receptor. The tables alsoinclude potency values (pEC50) for modulating discrete receptor-mediatedactivities (inhibition of cAMP production and β-arrestin2 recruitment).This value represents the estimated concentration to promote half of themaximal efficacy (or SPAN) observed for each compound.

hS1P1 hS1P1 hS1P1 hS1P1 Compound cAMP cAMP B-arrestin2 B-arrestin2Number pEC₅₀ SPAN pEC₅₀ SPAN   1 <6.5 <75 <5 <75   2 <6.5 >75 >5 <75  3 >6.5 >75 >5 >75   4 <6.5 <75 <5 <75   5 <6.5 <75 <5 <75   6 <6.5 <75<5 <75   7 <6.5 >75 <5 >75   8 <6.5 <75 <5 <75   9 <6.5 <75 <5 <75  10<6.5 <75 <5 <75  11 <6.5 <75 <5 <75  12 <6.5 <75 <5 <75  13 >6.5 <75 >5<75  14 >6.5 <75 >5 <75  15 <6.5 >75 <5 <75  16 <6.5 <75 >5 >75 17 >6.5 >75 >5 >75  18 <6.5 <75 <5 <75  19 <6.5 <75 >5 <75 20 >6.5 >75 >5 >75  21 <6.5 >75 <5 >75  22 >6.5 >75 >5 >75  23 <6.5 <75<5 <75  24 <6.5 >75 <5 <75  25 <6.5 <75 <5 <75  26 >6.5 >75 >5 >75 26 >6.5 >75 >5 <75  27 <6.5 >75 >5 <75  28 <6.5 >75 <5 >75  29 <6.5 <75<5 <75  30 <6.5 <75 <5 <75  31 >6.5 >75 >5 >75  32 >6.5 >75 >5 <75 33 >6.5 >75 >5 >75  34 <6.5 >75 >5 <75  35 <6.5 >75 <5 >75  36 <6.5 <75<5 <75  37 <6.5 <75 <5 <75  38 <6.5 <75 <5 >75  39 <6.5 <75 <5 <75 40 >6.5 >75 >5 >75  41 <6.5 <75 <5 <75  41 <6.5 <75 <5 <75  42 <6.5 >75<5 >75  43 >6.5 >75 >5 >75  44 <6.5 <75 <5 <75  45 <6.5 <75 <5 <75 46 >6.5 >75 >5 >75  47 <6.5 <75 <5 <75  48 <6.5 <75 <5 <75  49 <6.5 <75<5 <75  50 <6.5 <75 <5 <75  51 <6.5 <75 <5 <75  52 <6.5 <75 <5 <75  53<6.5 <75 <5 <75  54 <6.5 <75 <5 >75  55 >6.5 >75 >5 >75  56 <6.5 <75 <5<75  57 <6.5 <75 <5 <75  58 <6.5 <75 <5 <75  59 >6.5 >75 >5 >75  60 <6.5<75 <5 <75  61 >6.5 >75 >5 >75  62 <6.5 >75 <5 >75  63 >6.5 <75 <5 <75 64 >6.5 >75 <5 >75  65 <6.5 <75 <5 <75  66 >6.5 >75 >5 >75  67<6.5 >75 >5 <75  68 <6.5 <75 <5 <75  69 <6.5 <75 >5 <75  70 >6.5 <75 >5<75  71 <6.5 >75 <5 <75  72 >6.5 >75 >5 >75  73 <6.5 <75 >5 <75  74 <6.5<75 <5 <75  75 >6.5 <75 >5 >75  76 <6.5 <75 <5 <75  77 <6.5 <75 <5 <75 78 <6.5 <75 <5 <75  79 >6.5 >75 >5 >75  80 >6.5 <75 <5 <75  81 <6.5 >75<5 <75  82 <6.5 <75 <5 <75  83 >6.5 >75 >5 >75  84 <6.5 <75 >5 >75  85<6.5 <75 <5 <75  86 <6.5 <75 <5 >75  87 <6.5 <75 <5 <75  88 <6.5 <75 <5<75  89 <6.5 <75 <5 <75  90 <6.5 >75 >5 >75  91 <6.5 <75 <5 <75  92 <6.5<75 <5 <75  93 <6.5 <75 <5 >75  94 <6.5 >75 <5 >75  95 <6.5 <75 <5 <75 96 >6.5 >75 >5 >75  97 <6.5 <75 <5 <75  98 <6.5 >75 >5 >75 99 >6.5 >75 >5 >75 100 <6.5 <75 <5 <75 101 >6.5 >75 >5 >75 102 <6.5 <75<5 <75 103 >6.5 >75 >5 >75 103 >6.5 >75 >5 >75 103 >6.5 >75 >5 >75104 >6.5 >75 <5 >75 105 <6.5 <75 <5 <75 106 >6.5 >75 >5 >75107 >6.5 >75 >5 >75 108 >6.5 <75 <5 <75 109 <6.5 <75 >5 <75 110 <6.5 <75<5 <75 111 <6.5 >75 <5 >75 112 >6.5 >75 >5 >75 113 <6.5 <75 <5 <75 114<6.5 <75 <5 <75 115 >6.5 >75 >5 >75 116 <6.5 <75 <5 <75 117 <6.5 <75 <5<75 118 <6.5 <75 <5 <75 119 <6.5 <75 <5 <75 120 >6.5 >75 >5 >75 121 <6.5<75 <5 <75 122 <6.5 <75 <5 <75 123 >6.5 >75 >5 >75 124 <6.5 <75 <5 <75125 <6.5 <75 <5 <75 126 <6.5 <75 <5 <75 127 <6.5 <75 <5 <75 128 <6.5 <75<5 <75 129 <6.5 <75 <5 <75 130 <6.5 <75 <5 <75 131 <6.5 <75 <5 <75132 >6.5 >75 >5 >75 133 <6.5 <75 <5 <75 134 <6.5 <75 <5 <75 135 <6.5 <75<5 <75 136 <6.5 <75 <5 <75 137 >6.5 >75 <5 >75 138 >6.5 >75 >5 >75139 >6.5 >75 >5 >75 140 >6.5 >75 >5 >75 141 >6.5 >75 >5 >75142 >6.5 >75 >5 >75 143 <6.5 <75 <5 <75 144 <6.5 >75 >5 <75145 >6.5 >75 >5 <75 146 >6.5 >75 >5 <75 147 >6.5 >75 >5 >75 148 <6.5 <75<5 <75 149 >6.5 >75 >5 >75 150 >6.5 >75 >5 >75 151 <6.5 >75 <5 >75 152<6.5 >75 >5 >75 153 <6.5 >75 >5 <75 154 <6.5 <75 <5 <75 155 <6.5 <75 <5<75 156 >6.5 >75 >5 >75 157 <6.5 <75 <5 <75 158 <6.5 <75 <5 <75 159 <6.5<75 <5 <75 160 <6.5 <75 <5 <75 161 <6.5 <75 <5 >75 162 <6.5 >75 >5 >75163 >6.5 >75 >5 >75 164 <6.5 <75 <5 <75 165 <6.5 >75 <5 >75 166 <6.5 <75<5 >75 167 <6.5 <75 <5 <75 168 <6.5 <75 <5 <75 169 >6.5 >75 >5 >75 170<6.5 <75 <5 <75 171 >6.5 >75 >5 >75 172 <6.5 <75 <5 <75173 >6.5 >75 >5 >75 174 >6.5 >75 <5 >75 175 >6.5 >75 >5 >75 176 <6.5 >75<5 <75 177 >6.5 >75 >5 >75 178 <6.5 >75 >5 <75 179 >6.5 >75 >5 >75 180<6.5 >75 <5 >75 181 <6.5 >75 <5 >75 182 >6.5 >75 >5 <75183 >6.5 >75 >5 >75 184 <6.5 >75 <5 <75 185 >6.5 >75 >5 >75 186 <6.5 <75<5 <75 187 <6.5 <75 <5 >75 188 <6.5 <75 <5 <75 189 >6.5 >75 >5 >75 190<6.5 <75 <5 <75 192 <6.5 <75 <5 <75 193 <6.5 <75 <5 <75 194 <6.5 <75 <5<75 195 <6.5 <75 <5 <75 196 <6.5 <75 <5 <75 197 <6.5 <75 <5 <75198 >6.5 >75 >5 <75 199 <6.5 <75 <5 <75 200 <6.5 <75 <5 <75 201 <6.5 <75<5 >75 202 <6.5 <75 <5 <75 203 <6.5 <75 <5 >75 204 <6.5 >75 >5 >75 205<6.5 >75 <5 <75 206 <6.5 >75 <5 <75 207 >6.5 >75 >5 >75208 >6.5 >75 >5 >75 209 >6.5 >75 >5 >75 210 >6.5 >75 >5 >75 211 <6.5<75 >5 >75 212 >6.5 >75 >5 <75 213 <6.5 >75 <5 >75 214 <6.5 <75 <5 <75215 <6.5 <75 <5 <75 216 <6.5 <75 <5 <75 217 <6.5 <75 <5 <75 218 <6.5 >75<5 >75 219 >6.5 <75 >5 >75 220 <6.5 <75 <5 <75 221 >6.5 >75 >5 >75 222<6.5 >75 >5 <75 223 <6.5 <75 <5 <75 224 >6.5 >75 >5 >75 225 <6.5 >75 >5<75 226 <6.5 >75 <5 >75 227 >6.5 <75 <5 >75 228 <6.5 <75 <5 <75 229 <6.5<75 >5 <75 230 <6.5 <75 <5 <75 231 <6.5 <75 <5 <75 232 <6.5 <75 <5 <75233 <6.5 <75 <5 <75 234 <6.5 <75 <5 <75 235 <6.5 <75 <5 <75 236 <6.5 <75<5 >75 237 <6.5 <75 <5 <75 238 <6.5 <75 <5 <75 239 <6.5 <75 <5 <75 240<6.5 >75 <5 >75 241 <6.5 >75 <5 >75 242 <6.5 <75 <5 <75 243 <6.5 >75<5 >75 244 >6.5 >75 >5 >75 245 <6.5 >75 >5 >75 246 >6.5 >75 >5 >75 247<6.5 <75 <5 <75 248 <6.5 <75 <5 <75 249 <6.5 >75 <5 <75 250 <6.5 <75 <5<75 251 <6.5 <75 <5 <75 252 >6.5 >75 >5 >75 253 >6.5 >75 >5 >75 254 >6.5<75 <5 <75 255 <6.5 <75 <5 <75 256 >6.5 >75 >5 >75 257 <6.5 >75 <5 <75258 <6.5 <75 <5 <75 259 >6.5 >75 >5 <75 260 <6.5 >75 <5 >75 261<6.5 >75 >5 <75 262 >6.5 >75 >5 >75 263 >6.5 >75 >5 >75 264 <6.5 <75 <5<75 265 >6.5 >75 >5 <75 266 <6.5 >75 >5 >75 267 >6.5 <75 >5 <75268 >6.5 >75 >5 >75 269 <6.5 <75 <5 <75 270 <6.5 <75 <5 <75 271 <6.5 <75<5 <75 272 <6.5 <75 <5 <75 273 <6.5 <75 <5 <75 274 <6.5 >75 >5 <75 275<6.5 <75 <5 <75 276 >6.5 >75 >5 >75 277 >6.5 >75 >5 >75 278 <6.5 <75 <5<75 279 <6.5 >75 <5 >75 280 <6.5 <75 <5 <75 281 <6.5 <75 <5 <75282 >6.5 >75 >5 >75 283 <6.5 <75 <5 <75 284 <6.5 <75 <5 <75 285 <6.5 <75<5 <75 286 >6.5 >75 >5 >75 287 >6.5 >75 >5 >75 288 <6.5 <75 <5 <75 289<6.5 <75 <5 <75 290 <6.5 <75 <5 <75 291 <6.5 <75 <5 <75 292 <6.5 <75 <5<75 293 >6.5 >75 >5 >75 294 <6.5 <75 <5 >75 295 <6.5 >75 <5 <75 296 <6.5<75 <5 <75 297 <6.5 >75 <5 >75 298 <6.5 >75 >5 <75 299 <6.5 <75 <5 >75300 <6.5 >75 <5 >75 301 <6.5 <75 <5 <75 302 >6.5 >75 >5 >75 303 <6.5 >75<5 >75 304 >6.5 <75 >5 >75 305 <6.5 >75 <5 <75 306 >6.5 >75 >5 <75307 >6.5 >75 >5 >75 308 <6.5 <75 <5 <75 309 <6.5 >75 <5 >75310 >6.5 >75 >5 >75 311 <6.5 >75 <5 >75 312 <6.5 >75 <5 >75 313 >6.5 >75<5 >75 314 <6.5 <75 <5 <75 315 >6.5 >75 >5 <75 316 >6.5 >75 <5 <75320 >6.5 >75 >5 >75 321 <6.5 >75 >5 <75 322 >6.5 >75 >5 >75 323 <6.5 >75<5 >75 324 <6.5 <75 <5 <75 325 <6.5 <75 <5 <75 326 <6.5 >75 >5 >75 327<6.5 <75 >5 >75 328 <6.5 >75 >5 >75 329 >6.5 >75 >5 >75330 >6.5 >75 >5 >75 331 >6.5 >75 >5 >75 332 >6.5 >75 >5 >75 333 >6.5 >75<5 >75 334 <6.5 >75 <5 >75 335 <6.5 <75 <5 <75 336 >6.5 >75 >5 <75337 >6.5 >75 >5 >75 338 <6.5 >75 <5 >75 339 <6.5 <75 <5 <75 340 <6.5 <75<5 <75 341 <6.5 <75 <5 <75 342 <6.5 <75 <5 <75 343 >6.5 >75 >5 >75344 >6.5 >75 >5 >75 345 <6.5 <75 <5 <75 346 >6.5 >75 >5 >75347 >6.5 >75 >5 >75 348 >6.5 >75 >5 >75 349 >6.5 <75 <5 <75 350 <6.5 <75<5 <75 351 >6.5 >75 >5 >75 352 >6.5 >75 >5 >75 353 >6.5 >75 >5 >75354 >6.5 >75 >5 >75 355 >6.5 >75 >5 >75 356 >6.5 >75 >5 >75357 >6.5 >75 >5 >75 358 >6.5 >75 >5 >75 359 >6.5 >75 >5 >75 360 <6.5 <75<5 <75 361 <6.5 <75 <5 <75 362 <6.5 <75 <5 <75 363 <6.5 <75 <5 <75 364<6.5 >75 <5 <75 365 <6.5 >75 >5 <75 366 <6.5 <75 <5 <75 367 <6.5 <75 <5<75 368 <6.5 <75 <5 <75 369 <6.5 <75 <5 <75 370 >6.5 >75 >5 >75 371 <6.5<75 <5 <75 372 >6.5 >75 >5 >75 373 <6.5 >75 <5 >75 374 <6.5 <75 <5 <75375 >6.5 >75 >5 <75 376 <6.5 <75 <5 <75 377 <6.5 <75 <5 <75 378 <6.5 <75<5 <75 379 <6.5 <75 <5 <75 380 <6.5 <75 <5 <75 381 <6.5 <75 >5 <75382 >6.5 >75 >5 >75 383 >6.5 >75 >5 >75 384 <6.5 >75 <5 <75 385 <6.5 <75<5 >75 386 <6.5 >75 <5 <75 387 <6.5 >75 >5 >75 388 >6.5 >75 >5 >75389 >6.5 >75 >5 >75 390 >6.5 >75 >5 <75 391 >6.5 >75 >5 >75 392 <6.5 <75<5 <75 393 <6.5 <75 <5 <75 394 <6.5 <75 >5 <75 395 >6.5 <75 >5 >75 396<6.5 <75 <5 >75 397 <6.5 <75 <5 >75 398 >6.5 >75 >5 >75 399 >6.5 >75 >5<75 400 <6.5 <75 <5 <75 401 <6.5 <75 <5 <75 402 >6.5 <75 <5 <75 403 <6.5<75 <5 <75 404 <6.5 >75 <5 <75 405 <6.5 <75 <5 <75 406 >6.5 >75 >5 >75407 <6.5 >75 <5 <75 408 <6.5 >75 <5 <75 409 <6.5 >75 <5 <75 410 <6.5 <75<5 <75 411 <6.5 <75 <5 <75 412 <6.5 >75 <5 <75 413 >6.5 <75 >5 >75414 >6.5 <75 <5 >75 415 >6.5 <75 <5 >75 416 >6.5 >75 >5 >75417 >6.5 >75 >5 >75 418 >6.5 >75 >5 >75 419 >6.5 >75 >5 <75 420 >6.5 >75<5 >75 421 <6.5 >75 <5 <75 422 >6.5 >75 >5 >75 423 >6.5 >75 >5 >75424 >6.5 >75 <5 >75 425 >6.5 >75 >5 >75 426 >6.5 >75 <5 >75 427 <6.5 >75<5 >75 428 <6.5 >75 <5 >75 429 <6.5 >75 <5 >75 430 <6.5 >75 <5 >75 431<6.5 >75 <5 >75 432 >6.5 >75 >5 >75 433 >6.5 >75 >5 >75 434 <6.5 <75<5 >75 435 >6.5 >75 >5 >75 436 >6.5 >75 <5 >75 437 >6.5 >75 >5 <75438 >6.5 >75 >5 >75 439 <6.5 >75 <5 >75 440 >6.5 >75 >5 >75441 >6.5 >75 >5 >75 442 >6.5 >75 >5 >75 443 >6.5 >75 >5 <75 444 <6.5<75 >5 <75 445 >6.5 >75 >5 >75 446 <6.5 <75 <5 <75 447 >6.5 >75 >5 <75448 <6.5 >75 <5 <75 449 <6.5 >75 <5 >75 450 >6.5 >75 >5 >75 451 >6.5<75 >5 <75 452 <6.5 >75 >5 <75 453 >6.5 >75 >5 <75 454 >6.5 >75 >5 >75455 >6.5 >75 >5 >75 456 >6.5 >75 <5 >75 457 >6.5 >75 <5 >75 458 <6.5 <75<5 <75 459 <6.5 >75 <5 >75 460 <6.5 >75 <5 >75 461 <6.5 >75 <5 >75462 >6.5 >75 <5 >75 463 >6.5 >75 >5 >75 464 >6.5 <75 <5 <75465 >6.5 >75 >5 >75 466 <6.5 >75 <5 >75 467 >6.5 >75 >5 >75468 >6.5 >75 >5 >75 469 >6.5 >75 >5 >75 470 <6.5 >75 <5 >75471 >6.5 >75 >5 >75 472 >6.5 >75 >5 >75 473 >6.5 >75 >5 >75 474 <6.5 >75<5 >75 475 >6.5 >75 >5 <75 476 >6.5 >75 >5 <75 477 >6.5 >75 >5 <75 478<6.5 <75 <5 <75 479 <6.5 <75 <5 <75 480 <6.5 >75 <5 <75 481 <6.5 >75 >5<75 482 <6.5 <75 <5 >75 483 <6.5 >75 <5 <75 484 >6.5 >75 >5 >75485 >6.5 >75 <5 >75 486 >6.5 <75 <5 >75 487 <6.5 >75 >5 >75 488 >6.5<75 >5 >75 489 >6.5 >75 >5 >75 490 >6.5 >75 >5 >75 491 >6.5 >75 >5 >75492 <6.5 >75 <5 >75 493 <6.5 >75 <5 >75 494 <6.5 <75 >5 <75495 >6.5 >75 >5 >75 496 >6.5 >75 >5 >75 497 >6.5 >75 >5 >75 498 >6.5 >75<5 <75 499 >6.5 >75 >5 >75 500 <6.5 <75 <5 <75 501 <6.5 <75 <5 >75502 >6.5 >75 >5 >75 503 <6.5 >75 <5 >75 504 <6.5 >75 <5 <75 505 <6.5 <75<5 >75 506 >6.5 <75 >5 <75 507 >6.5 <75 <5 <75 508 <6.5 >75 <5 <75 509<6.5 <75 <5 >75 510 >6.5 <75 >5 >75 511 >6.5 <75 >5 >75 512 >6.5 >75 >5<75 513 >6.5 >75 >5 >75 514 >6.5 >75 >5 <75 515 >6.5 >75 >5 >75 516 <6.5<75 >5 <75 517 <6.5 <75 >5 <75 518 <6.5 >75 <5 <75 519 >6.5 >75 >5 >75520 >6.5 >75 >5 >75 521 <6.5 <75 <5 <75 522 <6.5 >75 <5 >75 523 <6.5 >75<5 >75 524 >6.5 >75 >5 <75 525 <6.5 >75 <5 >75 526 <6.5 >75 <5 >75 527<6.5 >75 <5 >75 528 <6.5 >75 <5 <75 529 <6.5 >75 >5 <75 530 <6.5 >75<5 >75 531 >6.5 >75 >5 >75 532 >6.5 >75 >5 <75 533 <6.5 <75 <5 <75 534<6.5 <75 <5 <75 535 <6.5 <75 >5 <75 536 <6.5 <75 >5 <75 537 >6.5 >75 >5<75 538 >6.5 <75 >5 <75 539 >6.5 <75 >5 <75 540 <6.5 <75 <5 <75 541 <6.5<75 <5 <75 542 <6.5 <75 >5 <75 543 >6.5 <75 <5 <75 544 <6.5 <75 >5 <75545 >6.5 >75 >5 >75 546 <6.5 <75 <5 <75 547 >6.5 >75 >5 >75 548 <6.5 <75<5 <75 549 >6.5 >75 >5 >75 550 <6.5 >75 >5 <75 551 >6.5 >75 >5 <75 552<6.5 <75 <5 <75 553 <6.5 >75 >5 <75 554 >6.5 >75 >5 >75 555 >6.5 <75 >5<75 556 >6.5 >75 >5 <75 557 <6.5 >75 >5 <75 558 >6.5 >75 >5 >75559 >6.5 >75 >5 >75 560 >6.5 >75 >5 >75 561 >6.5 >75 >5 <75562 >6.5 >75 >5 >75 563 >6.5 >75 >5 <75 564 >6.5 >75 >5 >75565 >6.5 >75 >5 >75 566 <6.5 <75 <5 <75 567 <6.5 >75 <5 <75568 >6.5 >75 >5 >75 569 <6.5 >75 <5 <75 570 <6.5 <75 <5 <75571 >6.5 >75 >5 <75 572 <6.5 <75 <5 >75 573 <6.5 <75 <5 <75 574 <6.5 >75<5 >75 575 >6.5 >75 >5 >75 576 >6.5 >75 >5 <75 577 <6.5 <75 >5 <75 578<6.5 >75 <5 <75 579 >6.5 >75 >5 >75 580 >6.5 >75 >5 >75 581 <6.5 >75 <5<75 582 <6.5 >75 <5 <75 583 <6.5 <75 <5 <75 584 >6.5 >75 >5 >75585 >6.5 >75 >5 >75 586 >6.5 >75 >5 >75 587 <6.5 <75 <5 <75 588 <6.5 <75<5 <75 589 <6.5 <75 <5 >75 590 <6.5 <75 <5 <75 591 >6.5 <75 >5 >75 592<6.5 <75 <5 >75 593 >6.5 >75 >5 >75 594 >6.5 >75 >5 >75595 >6.5 >75 >5 >75 596 >6.5 <75 >5 >75 597 >6.5 >75 >5 >75598 >6.5 >75 >5 >75 599 >6.5 <75 >5 >75 600 >6.5 >75 >5 >75 601<6.5 >75 >5 <75 602 <6.5 <75 <5 >75 603 >6.5 >75 >5 >75604 >6.5 >75 >5 >75 605 >6.5 >75 >5 >75 606 >6.5 >75 >5 >75607 >6.5 >75 >5 >75 608 >6.5 >75 >5 >75 609 >6.5 <75 <5 <75 610 <6.5 <75<5 >75 611 >6.5 <75 >5 <75 612 >6.5 <75 >5 >75 613 <6.5 <75 <5 <75 614<6.5 >75 <5 <75 615 >6.5 >75 >5 >75 616 >6.5 >75 >5 >75 617 <6.5 <75<5 >75 618 <6.5 <75 >5 <75 619 >6.5 >75 >5 >75 620 >6.5 <75 >5 >75 621<6.5 >75 <5 >75 622 >6.5 >75 <5 <75 623 <6.5 >75 <5 >75 624 <6.5 <75<5 >75 625 <6.5 <75 <5 <75 626 <6.5 <75 <5 <75 627 <6.5 >75 <5 >75628 >6.5 >75 >5 <75 629 <6.5 >75 <5 <75 630 <6.5 <75 <5 <75 633 <6.5 <75<5 <75 634 <6.5 <75 <5 <75 635 >6.5 <75 >5 <75 636 >6.5 >75 >5 >75637 >6.5 >75 >5 >75 638 >6.5 <75 <5 <75 639 <6.5 <75 <5 >75 640 <6.5 >75<5 <75 641 <6.5 <75 <5 <75 642 <6.5 <75 <5 <75 643 <6.5 >75 <5 <75 644<6.5 >75 <5 >75 645 <6.5 >75 <5 <75 646 <6.5 <75 <5 >75 647 >6.5 >75 >5>75

Example 3: S₁P₁ Receptor are Effective to Treat Chemotherapeutic InducedPeripheral Neuropathy

Compounds were tested for efficacy in mouse models of chemotherapyinduced peripheral neuropathy. The intraperitoneal (i.p.) injection ofchemotherapeutics in rodents has been shown to induce sensory impairmentand pain, similar to what is seen in humans where these sensations beginwithin days and last for several weeks. For these studies c57bl/6 miceare habituated to the test environment and baseline measurements of painsensitivity are assessed. To determine mechanical responses, thethreshold for responses to punctate mechanical stimuli (mechanicalhyperalgesia) was tested according to the frequency method. In brief,the plantar surface of the animal hindpaw was stimulated with a singlevon Frey monofilament (0.4 g) for approximately 1-2 seconds. If therewas a withdrawal response, it was recorded as a positive response. Aresponse was defined as a lifting or shaking of the paw uponstimulation. This was repeated ten times for each mouse. The finalmeasurement for each mouse is the % non-response to stimulation for theten trials. The % non-response to stimulation is converted to a % MPE.For paclitaxel induced peripheral neuropathy, a series of injections ofPAC (6 mg/kg, i.p.) on days 1, 3, 5 and 7 is used to induce peripheralneuropathy. After approximately 14 days from the initiation of PACinjections, animals are re-assessed for mechanical sensitivity. Animalsthat exhibit a 50% response rate and lower can be included in studieswith test compounds. On test day animals are dosed with compounds eithersubcutaneously or orally and tested for mechanical response by thefrequency method either 30 min (s.c.) or 60 min (p.o.) after drugadministration. Data is presented as a % MPE. For oxaliplatin inducedperipheral neuropathy, a series of injections of OXA (4 mg/kg, i.p.) ondays 1-5 is used to induce peripheral neuropathy. After approximately 14days from the initiation of PAC injections, animals are re-assessed formechanical sensitivity. Animals that exhibit a 50% response rate andlower can be included in studies with test compounds. On test dayanimals are dosed with compounds subcutaneously and tested formechanical response by the frequency method 30 min after drugadministration. Data is presented as a % MPE. One or more of thecompounds show reversal of chemotherapeutic induced peripheralneuropathy.

A compound was tested for the ability to prevent the development of OXAinduced peripheral neuropathy. A concurrent with the OXA injections onDay 1-5, a compound was dosed (3 mg/kg, sc) every day for 15 days. OnDay 16 animals were tested for mechanical allodynia. Animals treatedwith a test compound did not exhibit peripheral neuropathy. The data forexemplary compounds is provided below.

Reversal of Allodynia Induced by Oxaliplatin in Mice

Screen @ Compound 3 mg/kg sc Number (% MPE) 142 >50 287 >50  55 >50 169>50

Reversal of Allodynia Induced by Paclitaxel in Mice (s.c.)

Screen @ Compound 1 mg/kg sc Number (% MPE) 293 >50 287 <50  99 >50  55<50 142 >50   8 <50 169 >50  96 >50 277 >50 142 >50 103 >50 177 >50  26<50 252 <50 304 >50 221 <50  33 <50 149 <50 263 >50 147 >50 212 >50267 >50 262 >50 305 >50 224 >50 179 >50 185 >50 106 <50 306 <50 259 <50107 <50 210 <50

Reversal of Allodynia Induced by Paclitaxel in Mice (p.o.)

Screen @ Compound 3 mg/kg po Number (% MPE)  26 <50  99 >50 103 >50142 >50 179 >50 262 >50 263 >50 348 >50 354 >50 355 >50 356 >50 358 >50359 >50 415 <50 423 >50 435 >50 442 >50 455 >50 469 >50 471 <50 472 >50489 >50 497 <50 502 >50 513 <50 514 >50 519 <50 520 >50 531 >50 547 >50558 >50 560 >50 562 >50 563 <50 564 >50 568 <50 579 >50 580 >50 584 >50585 <50 586 <50 598 <50 600 <50 606 >50 607 >50 608 <50 615 >50 636 <50637 >50 726 >50 727 >50 728 >50 729 >50 730 >50 731 >50 732 >50 733 >50734 >50 735 <50 736 >50

Example 4: The S₁P₁ Receptor Compounds can be Used to Treat Inflammationand Pain

Assessment of Tactile Allodynia Produced by Intraplantar Freund'sComplete Adjuvant in Rats:

Animals were acclimated to the vivarium for at least 48 hr prior tobehavioral testing. Inflammation was induced with the administration ofan intraplantar (subcutaneous injection into the plantar surface of thehind paw, i.pl.) injection of 0.10 ml Freund's Complete Adjuvant (FCA).

The experiments were conducted 24 hours after CFA administration. Ratsare tested for mechanical allodynia in a Randall-Selitto apparatus. Theinflamed paw is put on a pedestal and a pointed force of increasingintensity (0 to 250 grams) is applied to the paw. When the animalstruggles to withdraw from the force the test is stopped and the forceto induce that struggle is recorded. Data is presented as mean grams offorce to withdrawal or a percentage of the maximum possible effect.

Exemplary compounds in the CFA model are shown below.

Active Doses, Compound mg/kg sc Number (>50% MPE) 103 ≥0.03 293 ≥0.1 142≥0.1  26 ≥0.1 212 ≥0.1 469 ≥0.01

Example 5: Compounds Selective for S1P1 Receptor In Vitro SelectivityAssays

Stable clonal Chinese hamster ovary K1 (CHO-K1) cells co-expressingEA-β-arrestin2 and the human sphingosine-1-phosphate receptor 2 (NM004230.3, S1P₂), human sphingosine-1-phosphate receptor 3 (NM_005226,S1P₃) and sphingosine-1-phosphate receptor 5 (NM_001166215.1, S1P₅) witha C-terminal Prolink™ tag were purchased from DiscoverX corporation(S1P₂: Cat #93-0256C2, S1P₃: Cat #93-0217C2, S1P₅: Cat #93-0583C2).

Cell Culturing and Assay Plating

Cell lines were cultured in AssayComplete™ Media 6 (DiscoverXCorporation, Cat #: 920018GF2) at 37° C. and 5% CO₂ in a humidified CO₂and temperature-controlled incubator. To begin assay plating, cells werewashed with dulbecco's phosphate buffered saline (CellGro, Cat #:21-031-CV) and lifted from the culturing flask by incubation (37° C., 5min) with CellStripper (Cellgro, Cat #: 25-056-CI). Lifted cells wereresuspended to 250,000 cells per milliliter in either AssayComplete™Cell Plating 11 Reagent (S1P5 cell line) (DiscoverX Corporation, Cat #:93-0563R11B) or AssayComplete™ Cell Plating 2 Reagent (S1P₂ and S1P₃cell line) (DiscoverX Corporation, Cat #: 93-0563R2B) and plated at 5000cells per well (S1P₃ cell line) or 7500 cells per well (S1P₂ and S1P₅cell line) in white-opaque 384 well plates (Greiner Bio-One Item #:20-784080). Plated cells were incubated overnight at 37° C. and 5% CO₂in a humidified CO₂ and temperature-controlled incubator.

Detecting Inhibition of cAMP Production

S1P3 and S1P5 Agonist-promoted G-protein responses were determined bymeasuring changes in intracellular cAMP using the HTRF® cAMP HiRange kit(CisBio, Cat #: 62AM6PEJ) based on time-resolved fluorescence resonanceenergy transfer (TR-FRET) technology. AssayComplete™ Cell Plating 11Reagent was removed and replaced with Ham's F-12 (CellGro, Cat #:10-080-CM) containing isobutyl-methyl-xanthine (IBMX; 500 μM; TocrisBioscience, Cat #: 2845), and NKH-477 (1.5 μM; Tocris Bioscience, Cat #:1603) along with test or control compounds at the desiredconcentrations. Following a 30-minute room temperature incubation thecomponents of the cAMP HiRange kit were added as per the manufacturer'sinstructions. After an hour incubation at room temperature, plates wereanalyzed by a BMG PheraStar microplate reader. Responses were measuredas the ratio of signal over background, fluorescence emission at 665 nmto fluorescence emission at 620 nm.

Detecting Inositol Monophosphate Production

S1P2 Agonist-promoted G-protein responses were determined by measuringchanges in intracellular inositol monophosphate using the IP-one TB kit(CisBio, Cat #: 62IPAPEJ) based on time-resolved fluorescence resonanceenergy transfer (TR-FRET) technology. AssayComplete™ Cell Plating 2Reagent was removed and replaced with 1×IP-one stimulation buffer (asper manufacturer's instructions) along with test or control compounds atthe desired concentrations. Following a 60-minute incubation at 37° C.and 5% CO₂ in a humidified CO₂ and temperature-controlled incubator, thecomponents of the IP-one TB kit were added as per the manufacturer'sinstructions. After an hour incubation at room temperature, plates wereanalyzed by a BMG PheraStar microplate reader. Responses were measuredas the ratio of signal over background, fluorescence emission at 665 nmto fluorescence emission at 620 nm.

Activity Table

The compounds were able to modulate the activities (inhibition of cAMPproduction or accumulation of inositol monophosphate) of thesphingosine-1-phosphate 2, sphingosine-1-phosphate 3,sphingosine-1-phosphate 5 receptor as indicated herein. The tables belowinclude the efficacy of the compound as compared to a positive control,referred to as “SPAN”. These values are normalized to fingolimod, aknown agonist of the sphingosine-1-phosphate 3 and 5 receptor orCYM5520, a known agonist of the sphingosine-1-phosphate 2 receptor. Thetables also include potency values (pEC50) for modulating discretereceptor-mediated activities (inhibition of cAMP production or inositolmonophosphate accumulation). This value represents the estimatedconcentration to promote half of the maximal efficacy (or SPAN) observedfor each compound. Exemplary compounds that were found to be selectiveare shown below.

hS1P2 hS1P2 hS1P3 hS1P3 hS1P5 hS1P5 Compound IP-one IP-one cAMP cAMPcAMP cAMP number pEC₅₀ SPAN pEC₅₀ SPAN pEC₅₀ SPAN 22 >5.0 <50 <5.0<50 >5.0 <50 26 <5.0 <50 <5.0 <50 <5.0 <50 32 <5.0 <50 <5.0 <50 <5.0 <5099 <5.0 <50 <5.0 <50 <5.0 >50 103 <5.0 <50 <5.0 <50 <5.0 <50 141 <5.0<50 >5.0 >50 >5.0 >50 147 <5.0 <50 <5.0 <50 >5.0 <50 149 <5.0<50 >5.0 >50 >5.0 >50 152 <5.0 <50 <5.0 <50 <5.0 <50 177 <5.0<50 >5.0 >50 >5.0 >50 185 <5.0 <50 <5.0 <50 <5.0 >50 212 <5.0 <50 <5.0<50 <5.0 <50 219 >5.0 <50 <5.0 <50 <5.0 <50 221 <5.0 <50 >5.0 <50 >5.0<50 252 >5.0 <50 >5.0 <50 >5.0 >50 259 <5.0 <50 <5.0 <50 <5.0 <50 262<5.0 >50 <5.0 <50 <5.0 <50 263 <5.0 <50 <5.0 <50 <5.0 <50 267 <5.0 <50<5.0 <50 <5.0 <50 277 <5.0 >50 <5.0 <50 <5.0 <50 287 <5.0 <50 <5.0 <50<5.0 <50 293 <5.0 <50 <5.0 <50 <5.0 >50 304 <5.0 <50 >5.0 <50 <5.0 <50391 >5.0 <50 >5.0 >50 >5.0 <50 398 <5.0 <50 <5.0 <50 <5.0 <50 406 <5.0<50 <5.0 <50 <5.0 <50 417 >5.0 <50 <5.0 <50 <5.0 <50 422 >5.0 <50 >5.0<50 423 >5.0 <50 >5.0 <50 445 >5.0 <50 <5.0 <50 455 <5.0 <50 <5.0 <50496 <5.0 <50 <5.0 <50Thus, the compounds were found to be sufficiently selective for S1P1.

Example 6: The S₁P₁ Receptor Compounds can be Used to Treat DiabeticNeuropathy

Assessment of Tactile Allodynia and Thermal Hyperalgesia in a RodentModel of Diabetic Neuropathy—Streptozotocin-Induced (STZ)

A cohort of 48 male Sprague Dawley rats, weighing 225-250 g at arrival,was group housed under constant temperature, humidity and a 12-hourlight-dark cycle. Following acclimation to the animal colony, theanimals were tested for baseline withdrawal responses to mechanicalallodynia and thermal hyperalgesia using the methods described below inChaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. and Yaksh, T.L. Quantitative assessment of tactile allodynia in the rat paw. J.Neurosci. Methods 53: 55-63, 1994; Joris, J. L., Dubner, R. andHargreaves, K. M. Opioid analgesia at Peripheral Sites: a Target forOpioids Released during Stress and Inflammation? Anesthesia andAnalgesia 66(12), 1277-81, 1987; and Morrow, T. J. Animal Models ofPainful Diabetic Neuropathy: The STZ rat model. Current Protocols inNeuroscience, November; Chapter 9, Unit 9.18, 2004.

A diabetic-like state was induced with a single intraperitoneal (IP)injection of streptozotocin STZ (50 mg/kg) freshly dissolved in 10 mMcitric acid buffer was injected intraperitoneally (IP) on Day 1. Twodays later (on Day 3), hyperglycermia was confirmed by existence ofblood glucose >350 mg/dL as measured by glucometer, and the animalhealth was monitored biweekly for 12 days.

For measures of mechanical allodynia, rats were preselected forexperimentation only if the pain threshold 7-14 days after STZ injection(pre-treatment) was reduced by 10 grams of force relative to theresponse of the individual paw before STZ challenge (pre-induction),namely, with clear presence of allodynia. The rats were randomized basedon pre-dose mechanical allodynia scores to balanced treatment groups.The animals were tested prior to study inclusion for mechanicalallodynia by the manual von Frey test on Day 20 (Chaplan up/down methodusing von Frey filaments on the plantar surface of the paw). The manualvon Frey test was repeated at 0.5 or 1 hr following administrations oftest articles, vehicle, and reference compound via the specifiedroute(s) and on Day 21 post-surgery.

For measures of thermal hyperalgesia, rats were pre-selected forexperimentation only if the pain threshold 7-14 days after STZ injection(pre-treatment) was reduced by 75% relative to the response of theindividual paw before STZ challenge (pre-induction), namely, with clearpresence of hyperalgesia. The rats were randomized based on pre-dosethermal hyperalgesia scores to balanced treatment groups. Rats werepreselected (with clear presence of thermal hyperalgesia) on Day 20.Thermal hyperalgesia was measured at 1 or 1.5 hr after dosing of testarticles, vehicle, and reference compound via the specified route(s) onDay 21. Each rat was placed within a plastic box atop a glass floor for20 to 30 minutes. A light beam under the floor was aimed at the plantarsurface of the left hind paw. The time was measured automatically whenthe paw was withdrawn away from the thermal stimulus. A cut-off latencyof 23 sec was imposed. The latency to withdrawal was obtained for eachrat and defined as the heat pain threshold.

Mean thresholds and withdrawal latencies were analyzed via Two Way ANOVAfollowed by Dunnett's Multiple Comparison tests to STZ+VEH group withdifferences considered significant at p<0.05.

Exemplary compounds, but not limited to these, that were effective inthis animal model are described below. For example, compounds 103 and293 were tested and found to have active doses between 50 and 100 mg/kgin both mechanical allodynia and thermal hyperalgesia.

Active Doses in STZ Active Doses in STZ Diabetic Neuropathy DiabeticNeuropathy Model (mg/kg, po) Model (mg/kg, po) (p < 0.05 compared to (p< 0.05 compared to STZ + VEH treated STZ + VEH treated Compound mice)mice) # MECHANICAL THERMAL 103 <100 <100 293 <100 <100 469 <100 <100

Example 7: The S₁P₁ Receptor Compounds can be Used to Treat PeripheralNeuropathy

Assessment of Tactile Allodynia and Thermal Hyperalgesia in a RodentModel of Peripheral Neuropathy—Spinal Nerve Ligation (SNL)

A cohort of 48 male Sprague Dawley rats, weighing 225-250 g at arrival,was group housed under constant temperature, humidity and a 12-hourlight-dark cycle. Following acclimation to the animal colony, theanimals were tested for baseline withdrawal responses to mechanicalallodynia and thermal hyperalgesia using the methods described in.Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. and Yaksh, T.L. Quantitative assessment of tactile allodynia in the rat paw. J.Neurosci. Methods 53: 55-63, 1994; Joris, J. L., Dubner, R. andHargreaves, K. M. Opioid analgesia at Peripheral Sites: a Target forOpioids Released during Stress and Inflammation? Anesthesia andAnalgesia 66(12), 1277-81, 1987; and Kim, S. H. and Chung, J. M. Anexperimental model of peripheral neuropathy produced by segmental spinalnerve ligation in the rat. Pain 50: 335-63, 1992.

Animals (n=40) were anesthetized with an intraperitoneal (IP) injectionof Pentobarbital (50 mg/kg). Spinal nerve ligation (SNL) was performedby first separating the left paraspinal muscles from the spinousprocesses (L4-S2). The L6-S1 facet joint was nipped. The transverseprocess of L6 was removed to identify the locations of the L5 and L6spinal nerve. The left L5 and L6 spinal nerves were isolated and tightlyligated with 6.0 silk sutures. Another 8 animals were underwent shamsurgery only (anesthesia, surgical opening and skin suture).

For measures of mechanical allodynia, rats were preselected forexperimentation only if the pain threshold 7-14 days after SNL surgery(pre-treatment) was reduced by 10 grams of force relative to theresponse of the individual paw before surgery (pre-induction), namely,with clear presence of allodynia. The rats were randomized based onpre-dose mechanical allodynia scores to balanced treatment groups. Theanimals were tested prior to study inclusion for mechanical allodynia bythe manual von Frey test on Day 20 (Chaplan up/down method using vonFrey filaments on the plantar surface of the paw). The manual von Freytest was repeated at 0.5 or 1 hr following administrations of testarticles, vehicle, and reference compound via the specified route(s) andon Day 21 post-surgery.

For measures of thermal hyperalgesia, rats were pre-selected forexperimentation only if the pain threshold 7-14 days after spinalsurgery (pre-treatment) was reduced by 75% relative to the response ofthe individual paw before surgery (pre-induction), namely, with clearpresence of hyperalgesia. The rats were randomized based on pre-dosethermal hyperalgesia scores to balanced treatment groups. Rats werepreselected (with clear presence of thermal hyperalgesia) on Day 20.Thermal hyperalgesia was measured at 1 or 1.5 hr after dosing of testarticles, vehicle, and reference compound via the specified route(s) onDay 21. Each rat was placed within a plastic box atop a glass floor for20 to 30 minutes. A light beam under the floor was aimed at the plantarsurface of the left hind paw. The time was measured automatically whenthe paw was withdrawn away from the thermal stimulus. A cut-off latencyof 23 sec was imposed. The latency to withdrawal was obtained for eachrat and defined as the heat pain threshold.

Mean thresholds and withdrawal latencies were analyzed via Two Way ANOVAfollowed by Dunnett's Multiple Comparison tests to SNL+VEH group withdifferences considered significant at p<0.05.

Exemplary compounds, but not limited to these, that were effective inthis animal model are described below. For example, compound 103 wastested and found to have active doses between 50 and 100 mg/kg.

Active Doses in SNL Active Doses in SNL Neuropathy Model NeuropathyModel (mg/kg) (mg/kg) (p < 0.05 compared to (p < 0.05 compared to SNL +VEH treated SNL + VEH treated Compound mice) mice) # MECHANICAL THERMAL103 <100 <100

Example 8: Compounds do not Inhibit hERG Channel Activity

The standard Automated Qpatch patch-clamp assay have been used and theselective hERG inhibitor E4031, serves as a positive control.

Compound IC₅₀ number (μM) E4031 0.013  26 >10 304 >10 469 >10 497 >10520 >10 730 >10 738 >10 742 >10 743 >10 744 >10

Example 9: Compounds do not Cause Lymphopenia

Compounds were tested for changes in peripheral blood lymphocytes inc57bl/6 mice. In acute studies, animals (n=5/group) were dosedsubcutaneously with test compound at a dose of 3 mg/kg. Animals weresacrificed at specific time points and 500 μl of whole blood wascollected in EDTA (K2) Eppendorf tubes. Blood was stored on ice andshipped immediately overnight delivery to Charles River Laboratories foranalysis. CRL ran samples through their WBC/differential panel on anAdvia 120 instrument. We received peripheral lymphocyte counts (10³cells/μl) for each blood sample. Treatment group means were compared toa vehicle treatment group for statistical significance. In chronicstudies, animals (n=6-8/group) were dosed subcutaneously with testcompound either in a dose response paradigm (highest dose of 3 mg/kg) orin a screening paradigm at 6 mg/kg for seven days. On the seventh day,animals were sacrificed 45 minutes after the final dose. Whole blood wascollected and analyzed as described for acute studies. None of thecompounds showed statistically significant decreases in peripheral bloodlymphocytes in acute or chronic studies. Non-limiting exemplary data isprovided below.

Lymphopenia—c57bl/6 Mice

Compound Number Effect and Doses, mg/kg, sc   8 no change: 6 mg/kg, 7days  19 no change: 6 mg/kg, 7 days  22 no change: 3 mg/kg, 7 days  32no change: 6 mg/kg, 7 days  55 no change: 6 mg/kg, 7 days  59 no change:6 mg/kg, 7 days  96 no change: 6 mg/kg, 7 days  99 no change: 6 mg/kg, 7days 103 no change: 6 mg/kg, 7 days 142 no change: 6 mg/kg, 7 days 147no change: 6 mg/kg, 7 days 169 no change: 6 mg/kg, 7 days 234 no change:6 mg/kg, 7 days 287 no change: 6 mg/kg, 7 days 293 no change: 6 mg/kg, 7days 304 no change: 6 mg/kg, 7 days 355 no change: 6 mg/kg, 7 days 356no change: 6 mg/kg, 7 days 384 no change: 3 mg/kg; 45 min and 2 hr 423no change: 6 mg/kg, 7 days 455 no change: 6 mg/kg, 7 days 469 −28% notstat sig: 6 mg/kg, 7 days 520 no change: 6 mg/kg, 7 days 531 no change:6 mg/kg, 7 days 730 no change: 6 mg/kg, 7 days 731 −78% stat sig: 6mg/kg, 7 days 737 −40% not stat sig: 6 mg/kg, 7 days

Example 10: Compounds Inhibit Tumor Growth and Prolong Survival in TumorModel

Female athymic nude mice (Crl:NU(NCr)-Foxn1nu, Charles RiverLaboratories) were implanted with A2780 human ovarian carcinoma cells toinitiate tumor growth.

Each mouse received 1×10₇ cells (0.1 mL cell suspension) subcutaneouslyin the right flank, and tumors were monitored as their volumesapproached the target range of 100 to 150 mm3. Fourteen days later,designated as Day 1 of the study, mice were sorted into six groups often each. The individual tumor volumes ranged from 108 to 196 mm3 andgroup mean tumor volumes were 148 mm3. Tumors were measured twice weeklyfor the study duration.

Paclitaxel dosing solutions were prepared in 5% ethanol, 5% Cremophor ELin D5W (Vehicle 1). Ozanimod and Compound 103 dosing solutions wereprepared in 10% dimethylacetamide, 10% Cremophor EL, 80% sterile waterwith 10% β-cyclodextrin (Vehicle 2). Starting on Day 1 of the study, sixgroups (n=10) of female athymic nude mice with established A2780 tumorswere treated according to the following plan. Treatments wereadministered either by intravenous injection (i.v.) or oral gavage(p.o.) and were adjusted to the body weight of the individual animal.Group 1 received Vehicle 1, i.v., once every other day for five doses(qod×5) and Vehicle 2, p.o., once daily to the end of the study (qd toend), and served as the control group for efficacy analysis. Group 2,the paclitaxel monotherapy group, received paclitaxel i.v., qod×5 plusVehicle 2, p.o., qd to end. Group 3, the ozanimod monotherapy group,received ozanimod p.o., qd to end plus Vehicle 1, i.v., qod×5.Combination Group 4 received ozanimod p.o., qd to end plus paclitaxeli.v., qod×5. Group 5, the Compound 103 monotherapy group, receivedCompound 103 p.o., qd to end plus Vehicle 1, i.v., qod×5. CombinationGroup 6 received Compound 103 p.o., qd to end plus paclitaxel i.v.,qod×5.

Animals were monitored individually, and each mouse was euthanized whenits tumor reached the endpoint volume of 2000 mm3 or on the final day,whichever came first. The time to endpoint (TTE) was calculated for eachmouse. Treatment outcome was determined from percent tumor growth delay(% TGD), defined as the percent increase in median TTE for treatedversus control mice, with differences in TTE values between groupsdeemed statistically significant at P<0.05 using logrank survivalanalysis. Mice were also monitored for complete regression (CR) andpartial regression (PR) responses. An animal with a CR at the end of thestudy was additionally classified as a tumor-free survivor (TFS).Treatment tolerability was assessed by body weight measurements andfrequent observation for clinical signs of treatment-related sideeffects.

All regimens were acceptably-tolerated based. Control tumors exhibitedprogressive growth, attaining the 2000 mm3 endpoint in a median 9.8days, establishing a maximum possible TGD of 50.2 days (512%) for the60-day study. Paclitaxel as monotherapy provided significant (P<0.001)survival benefit (128% TGD) compared to controls, whereas the ozanimodand Compound 103 monotherapy regimens were associated withnon-significant (P>0.05) TGD of 31% and 15%, respectively, compared withthe control. One animal receiving Compound 103 monotherapy survived thestudy with a sub-endpoint tumor. The combination of paclitaxel andozanimod was associated with 185% TGD, providing statisticallysignificant survival benefit over either of the correspondingmonotherapies, and one study survivor with a CR/TFS tumor regressionresponse. The combination of paclitaxel and Compound 103 provided 193%TGD, a significant result compared with paclitaxel monotherapy, but notstatistically different (P>0.05) from the result for ozanimodmonotherapy.

SUMMARY

The present example evaluated test agents ozanimod and Compound 103 eachin combination with paclitaxel for efficacy in the A2780 human ovariancarcinoma model in female athymic mice. All regimens wereacceptably-tolerated. Control tumors exhibited progressive growth,attaining the 2000 mm3 endpoint in a median 9.8 days, establishing amaximum possible TGD of 50.2 days (512%) for the 60-day study.Paclitaxel as monotherapy provided significant (P≤0.05) survival benefit(128% TGD) compared to controls, whereas the ozanimod and Compound 103monotherapy regimens were associated with non-significant (P>0.05) TGDof 31% and 15%, respectively, compared with the control. One animalreceiving Compound 103 monotherapy survived the study with asub-endpoint tumor. The combination of paclitaxel and ozanimod wasassociated with 185% TGD, providing statistically significant survivalbenefit over either of the corresponding monotherapies, and one studysurvivor with a CR/TFS tumor regression response. The combination ofpaclitaxel and Compound 103 provided 193% TGD, a significant resultcompared with paclitaxel monotherapy and more than additive as comparedwith the corresponding monotherapies.

Thus, these results demonstrate that the compounds provided herein canbe used to treat cancers, such as breast or ovarian cancer.

The examples and data provided herein demonstrate the unexpectedproperties and advantages of the compounds and pharmaceuticalcompositions provided herein. These properties could not have beenpredicted.

1-124. (canceled)
 125. A compound having Formula I, or apharmaceutically acceptable salt thereof:

wherein: AA is

W is O, S, or NR₁; X is O, S, or NR₄; Z is CHR₄₂ or NR₄₃; n is 0, 1, 2,3, or 4; B₁ and D₁ together have a formula of

B₂, B₃, and B₄ are independently CR₃₈ or N; D₁ is H, OH, NH₂, NO₂,optionally substituted carbocycle, optionally substituted heterocycle,optionally substituted heteroaryl, optionally substituted aryl group,branched or unbranched alkyl alcohol, halo, branched or unbranchedalkyl, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, oralkylsulfanyl; R₂ and R₃ are independently H, optionally substitutedC₁-C₆ alkyl, optionally substituted C₁-C₆ hydroxyalkyl, optionallysubstituted C₁-C₆ alkoxy, optionally substituted cycloalkyl, oroptionally substituted cycloheteroalkyl; or R₂ and R₃ are togetheroptionally substituted cycloalkyl, or together form

R₁, R₄, R₃₈, and R₄₃ are independently H, OH, NH₂, optionallysubstituted C₁-C₆ alkyl, optionally substituted C₁-C₆ hydroxyalkyl,optionally substituted C₁-C₆ alkoxy, optionally substituted cycloalkyl,or optionally substituted cycloheteroalkyl. R₄₂ is independently Br, Cl,F, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆hydroxyalkyl, optionally substituted C₁-C₆ alkoxy, optionallysubstituted cycloalkyl, or optionally substituted cycloheteroalkyl. 126.The compound of claim 125, or a pharmaceutically acceptable saltthereof, wherein AA is


127. The compound of claim 126, or a pharmaceutically acceptable saltthereof, wherein AA is


128. The compound of claim 127, or a pharmaceutically acceptable saltthereof, wherein both R₂ and R₃ are Et.
 129. The compound of claim 126,or a pharmaceutically acceptable salt thereof, wherein D₁ is

wherein: Z₆ is O, S, NR₄₀, or CHR₃₇; Z₇, Z₈, Z₉ and Z₁₀ areindependently N or CR₄₁; R₂₄, R₂₅, and R₂₆ are each independently H, OH,NH₂, NO₂, carbocycle, heterocycle, heteroaryl, aryl, branched orunbranched alkyl alcohol, halo, branched or unbranched alkyl, amide,cyano, alkoxy, haloalkyl, alkylsulfonyl, nitrite, alkylsulfanyl; or twoof R₂₄, R₂₅, and R₂₆ together form a carbocycle, heterocycle, aryl,heteroaryl that is attached to one or more of the atoms of D₁; and R₃₅,R₃₆, R₃₇, R₄₀, and R₄₁ are each independently H, OH, NH₂, carbocycle,heterocycle, aryl, heteroaryl, branched or unbranched alkyl alcohol,halo, branched or unbranched alkyl, amide, cyano, alkoxy, haloalkyl,aklylsulfonyl, nitrite, or alkylsulfanyl; or R₃₅ and R₃₆ together form acarbocycle, heterocycle, aryl, or heteroaryl that is attached to one ormore of the atoms of D₁.
 130. The compound of claim 129, or apharmaceutically acceptable salt thereof, wherein D₁ is


131. The compound of claim 126, or a pharmaceutically acceptable saltthereof, wherein D₁ is

wherein R²¹, R²², R²³ are each independently optionally substitutedC₁-C₆ alkyl or H, OH, NH₂, NO₂, carbocycle, heterocycle, aryl,heteroaryl, branched or unbranched alkyl alcohol, halo, branched orunbranched alkyl, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl,nitrite, or alkylsulfanyl; or two of R₂₁, R₂₂, and R₂₃ together form acarbocycle, heterocycle, aryl, or heteroaryl that is attached to one ormore of the atoms of D₁.
 132. The compound of claim 131, or apharmaceutically acceptable salt thereof, wherein D₁ is


133. The compound of claim 129, or a pharmaceutically acceptable saltthereof, wherein D₁ is

wherein: Z₆ is O, S, NR₄₀, or CHR₃₇; Z₇, Z₈, Z₉, and Z₁₀ areindependently N or CR₄₁; R₃₅, R₃₆, R₃₇, R₄₀, and R₄₁ are eachindependently H, OH, NH₂, carbocycle, heterocycle, heteroaryl, aryl,branched or unbranched alkyl alcohol, halo, branched or unbranchedalkyl, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, oralkylsulfanyl; or R₃₅ and R₃₆ together form an aryl, carbocycle,heterocycle, or heteroaryl that is attached to one or more of the atomsof D₁.
 134. The compound of claim 129, or a pharmaceutically acceptablesalt thereof, wherein D₁ is


135. The compound of claim 125 having the formula of:

or a pharmaceutically acceptable salt thereof.
 136. A pharmaceuticalcomposition comprising a compound of claim 125, or a pharmaceuticallyacceptable salt thereof.
 137. A method of treating or preventingneuropathy, pain, inflammatory pain, cancer pain, bone cancer pain,tumor pain, pain or neuropathy resulting from disorders of the centralor peripheral nervous system, neuropathic pain, pain associated withdysesthesia, allodynia or hypersensitivity, chemotherapy inducedneuropathic pain, chemotherapy induced peripheral neuropathy, diabeticneuropathy or pain associated with diabetic neuropathy, post herpeticneuralgia or pain associated with post herpetic neuralgia, HIV-relatedneuropathy or pain associated with HIV-related neuropathy, pain orneuropathy resulting from spinal chord injury, nerve lesions, tissueinjury, MS, stroke, nutritional deficiencies, or toxins, fibromyalgia orpain associated with fibromyalgia, phantom limb pain, complex regionpain syndrome, carpal tunnel syndrome, sciatica, pudendal neuralgia,back or neck pain, including those resulting from degenerative diskdisease, trigeminal neuralgia, headache disorders including, but notlimited to migraine and cluster headache, orofacial pain, odontalgia,temporomandibular joint pain, endometrial pain, osteoarthritis,rheumatoid arthritis, atypical odontalgia, interstitial cystitis,uveitis, or any combination thereof in a subject comprisingadministering to the subject a compound of any one of claim 125, or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.
 138. A method of treating or preventing neuropathy,chemotherapy induced neuropathic pain, chemotherapy induced peripheralneuropathy, diabetic neuropathy or pain associated with diabeticneuropathy in a subject in need thereof, the method comprisingadministering to the subject a compound of claim 125 or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.
 139. A method of treating or preventingchemotherapy induced neuropathic pain in a subject in need thereof, themethod comprising administering to the subject a compound of claim 125or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition thereof.
 140. A method of treating or preventing cancer in asubject, the method comprising administering to the subject a compoundof claim 125, or a pharmaceutically acceptable salt thereof, or apharmaceutical composition thereof.
 141. The method of claim 140,wherein the cancer is ovarian, breast, lung, brain, colon, prostate,esophageal, pancreatic, brain, glioblastoma, leukemia, multiple myeloma,lymphoma, skin cancer, acute Lymphoblastic Leukemia, acute myeloidleukemia, basal cell cancer, bile duct cancer, bladder cancer, bonecancer (Ewing sarcoma, osteosarcoma), CLL, CML, uterine cancer, cervicalcancer, hairy cell leukemia, melanoma, thyroid cancer, rectal cancer,renal cell cancer, small cell lung cancer, non-small cell lung cancer,or stomach cancer.